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Abstract 
 
Nosocomial infection is an increasing problem worldwide associated with significant 
morbidity and mortality in addition to heightened healthcare costs. The problem is even 
greater on the intensive care unit (ICU) where up to 20 of patients develop a secondary 
infection during their admission. In an era of increasing antibiotic resistance alternative 
strategies to prevent nosocomial infection must be sought. 
The intensive care population are recognised to be at high risk of developing immune 
dysfunction during their critical illness and this has been shown to be associated with an 
increased risk of the development of ICU acquired infection (ICUAI). The neutrophil, in 
particular, is key in terms of the host response to bacterial and fungal infections and 
impairments in neutrophil function have been demonstrated in critically ill patients.  
Granulocyte-macrophage colony-stimulating factor has been shown to improve the 
phagocytic function of impaired neutrophils ex-vivo and has previously been demonstrated to 
restore immune competent levels of monocyte HLA-DR expression in critically ill patients.  
If GM-CSF were demonstrated to restore neutrophil phagocytic function in critically ill 
patients in whom its known to be impaired it may have a role in preventing the development 
of ICUAI. 
Our initial study sought to validate neutrophil CD88 expression as a surrogate marker for 
phagocytic function. The dose finding study which followed aimed to determine the optimum 
dose and duration of GM-CSF to be carried forward to a randomised controlled trial. Finally, 
the randomised controlled trial sought to investigate the hypothesis that GM-CSF could 
restore effective neutrophil function in critically ill patients. 
While no significant difference was seen in our primary endpoint of neutrophil phagocytic 
capacity, on day 2 following administration of GM-CSF, we believe a small but true biological 
effect was observed suggesting further study is warranted to investigate whether GM-CSF 
could reduce the risk of ICUAI. 
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Chapter One: Introduction 
 
1.1 Thesis Outline 
Nosocomial infection is a major healthcare problem, particularly on the intensive 
care unit (ICU) where it can affect 20-40% of all admissions. Nosocomial 
infection has been shown to be associated with increased morbidity, mortality and 
health care costs. Despite multiple different strategies being introduced to tackle 
this problem nosocomial infection rates remain high. 
There is increasing evidence for the development of immunosuppression during 
critical illness and studies have shown that the development of such acquired 
defects in the innate immune system is associated with increased risk of developing 
nosocomial infection. 
This study focuses on neutrophil impairment during critical illness, and aimed to 
investigate whether impaired neutrophil phagocytosis may be restored with 
administration of, the immunostimulatory drug, granulocyte-macrophage colony 
stimulating factor (GM-CSF). If GM-CSF were able to restore neutrophil function it 
may have a role in preventing nosocomial infection in the ICU. 
Chapter 1, the introduction to the thesis, will outline the background to the study 
reviewing: the evidence for the the impact of nosocomial infection, the 
pathogenesis of sepsis and the systemic inflammatory response; the 
pathophysiology of immune dysfunction in sepsis and critical illness in relation to 
neutrophil, monocyte and T lymphocyte dysfunction in particular; the recognition and 
development in the understanding of GM-CSF and its therapeutic effects in treating 
illness and disease.  
Chapter 2 of the thesis will outline the materials and methods used in developing 
and completing the study including the necessary regulatory approvals, the design 
of each phase of the study and the clinical and laboratory procedures undertaken. 
Chapter 3 will describe the results of the preliminary phase of the study, an assay 
confirmation study, designed to locally validate the use of a surrogate biomarker for 
neutrophil phagocytic dysfunction. It will discuss the results and how they impacted 
on the design of the subsequent dose finding study and randomised controlled trial. 
Chapter 4 will outline the results of the dose finding study, undertaken to ensure a 
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safe and effective dose would be carried through to the randomised controlled trial. 
Finally, chapter 5 will outline the results and conclusions of the randomised 
controlled trial and suggest future areas of study. 
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1.2 Background 
1.2.1 Nosocomial infection 
Hospital-acquired infection (HAI), also known as nosocomial infection, affects up to 
10% of hospital inpatients at any one time (Vincent et al., 1995; Vincent et al., 2009; 
Health Protection Agency., 2001; Pratt et al 2001). Nosocomial infections are defined 
as those which are not present or incubating prior to admission to a healthcare 
setting. Infections occurring after the first 48 hours of admission are generally 
considered to be nosocomial (World Health Organization, 2002). Rates of 
nosocomial infection among critically ill patients on the intensive care unit (ICU) are 
considerably higher than in the rest of the hospital population with 3-5 times as many 
patients (20 - 40% of all ICU admissions) developing at least one secondary 
infection during their stay (Health Protection Agency., 2001; Sanchez-Velazquez et 
al., 2006; Donowitz et al., 1982). 
The development of such infections places a significant burden on both individual 
patients and the health care system as a whole with increased morbidity, mortality 
and health care costs having been shown to be directly attributable (Ylipalosaari et 
l.,2006; Sanchez-Velazquez et al., 2006; Olachea et al.,1995; Digiovine et al., 
1999). Nosocomial infection accounts for approximately 5000 deaths annually 
within the UK (Inweregbu et al., 2005) and estimates of total annual cost to the NHS 
of care related to such infections are in the region of £1 billion (Health Protection 
Agency., 2011). Large scale studies have shown that up to 1/3 of nosocomial 
infections are avoidable (Haley et al., 1985) and strategies for preventing hospital-
acquired infections have been the focus of government health policy makers in 
recent years. Within the UK each hospital Trust is required to have a dedicated 
infection control team responsible for ensuring compliance with infection control 
guidelines and meeting set targets in relation to HAI (Department of Health, 2008, 
2015).  
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1.2.2 Nosocomial infection within the intensive care unit 
There are several reasons why critically ill patients in intensive care are particularly 
vulnerable to nosocomial infection. The EPIC study, published in 1995, was a large 
scale Europe-wide point prevalence study involving more than 4,500 patients on 
intensive care. It set out to establish not only the prevalence of ICU- acquired 
infections, but also the risk factors contributing to the development of such 
infections and the associated consequences. Several factors were found to 
increase the risk of nosocomial infection and could be broadly divided into 4 distinct 
groups; underlying health status, the acute disease process, invasive procedures 
and treatments (Vincent et al.,1995). Patients on ICU have greater levels of 
underlying chronic diseases, for example diabetes, chronic lung disease and 
ischaemic heart disease, many of which contribute to relative immunosuppression 
(Sreeramoju et al., 2008, Lola et al., 2011). The nature of the acute disease process 
resulting in admission to ICU can also affect the risk of developing a nosocomial 
infection with patients presenting with sepsis, burns, trauma or those requiring 
surgery having increased risk (Vincent et al., 1995, Sreeramoju et al., 2008). 
Invasive procedures breach the body’s natural protective mechanisms and 
indwelling catheters at any site provide passageways and reservoirs for infection. 
The EPIC study revealed increased rates of infection in the presence of 
endotracheal tubes, central venous catheters, nasogastric tubes and urinary 
catheters (Vincent et al., 1995). 64% of all blood stream infections recorded in UK 
point prevalence data were associated with some form of vascular access device in 
the previous 48 hours.(Health Protection Agency., 2011) Finally, many of the 
treatments administered to ICU patients are associated with increased rates of 
nosocomial infection including blood transfusion (Hill et al., 2003), 
immunosuppressive drugs, stress ulcer prophylaxis and in particular repeated 
antibiotics. A significant proportion of such patients will have received multiple 
antibiotics during their hospital stay, leading to the development of resistant 
organisms and making such infections more difficult to treat. One study found that 
70% of ICU-acquired infections (ICUAI) were due to organisms resistant to one or 
more antibiotic,(Burke et al., 2003) with another retrospective analysis of eight years 
of Gram negative blood stream infections showing 30-50% resistance to one or 
more antibiotic (Sligl et al., 2015). 
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1.2.3 Prevention of Nosocomial Infection 
Large scale surveillance programmes including the Hospitals in Europe Link for 
Infection Control through Surveillance (HELICS) programme and the UK 
Nosocomial Infection National Surveillance Service have been established to 
monitor the incidence of HAI and identify intervention targets for reducing rates and 
improving patient care. The establishment of infection control teams, development 
of care bundles and improvements in hand hygiene and sterile technique have 
delivered some success and as a consequence rates of nosocomial infection have 
fallen over the last 10 years, with prevalence falling from 9.2% in 1980 to 6.4% in 
2011. (Health Protection Agency., 2011 (see Table 1); Pratt et al., 2001) 
 
Prevalence study Total number of 
patients 
No of patients 
w i th HAI 
Prevalence % 95% confidence 
interval 
1980 UK 18163 1671 9.2 8.8 - 9.6 
1993/4 UK 37111 3353 9.0 8.8 – 9.3 
2006 England 58775 4812 8.2 8.0 – 8.4 
2011 England 52443 3360 6.4 4.7 – 8.7 
 
Table 1. Hospital-acquired infection prevalence surveys in England and UK (Adapted 
from Health Protection Agency English National Point Prevalence Survey on Healthcare-
associated Infections and Anti-Microbial Use 2011). 
 
Despite this, however, there is still an unacceptably high rate of nosocomial 
infections occurring nationally and worldwide and other possible mechanisms 
need to be explored in an attempt to eliminate this problem. 
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1.2.4 Immune dysfunction and nosocomial infection 
Bacterial pathogens are responsible for the majority of HAIs, although, over the last 
20 years fungi have been identified as contributing to an increasing proportion of 
infections (Monneret et al., 2011; Martin et al., 2003). Within a healthy functioning 
immune system, the neutrophil is one of the key cells in ensuring the rapid 
detection and clearance of pathogenic bacteria and fungi. Over recent years 
increasing interest has been generated in the area of immune dysfunction in 
sepsis and critical illness with strengthening evidence for an association between 
such acquired abnormalities of immune function and an increased risk of 
nosocomial infection (Monneret et al., 2011; Angele et al., 2002; Conway Morris et 
al.,2013). Several studies have demonstrated significantly increased rates of 
nosocomial infection in patients with evidence of immunoparesis raising the 
question of whether stimulation of the immune system may have a role in the 
prevention of nosocomial infection and potential strategies for addressing this 
have been explored (Monneret et al., 2011; Conway Morris et al., 2011, Meisel et 
al., 2009). Currently however there remains insufficient evidence to recommend 
any of these immune modulating treatments and a recent Cochrane meta-analysis 
suggested further trials were necessary (Bo et al., 2011). 
The role of immune dysfunction in critical illness and in particular acquired 
impairment of neutrophil phagocytosis, will be the focus of this work. 
 
1.3 Critical illness, sepsis and the systemic inflammatory response 
Critical illness, generally accepted to mean a life-threatening illness, is usually 
accompanied by a marked systemic inflammatory response syndrome (SIRS). 
Sepsis (SIRS with infection), severe sepsis and septic shock form a continuum of a 
hyper-inflammatory state resulting in hypoperfusion, impairment in oxygen delivery 
and ultimately organ dysfunction and failure. The understanding of the 
pathophysiology of the systemic inflammatory response and sepsis has evolved 
over many years. 
In 1991 The American College of Chest Physicians (ACCP) and the Society of 
Critical Care Medicine (SCCM) held a consensus conference with the purpose of 
producing a framework which would help to define sepsis and the systemic 
inflammatory response. (Members of the ACCP/SCCM Consensus Conference 
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Committee, 1992) They drew up a set of criteria with which to define the systemic 
inflammatory response and the stages of sepsis. The guidance published in 1992 
was widely accepted and has been used throughout the world to aid clinical 
decision making and as a tool to define eligibility for research studies.  
The systemic inflammatory response is considered to be present when two or more 
of the following parameters are clinically evident: 
i. temperature greater than 38°C or less than 36°C 
ii. white cell count less than 4 or greater than 12x109/L 
iii. heart rate greater than 90 beats per minute 
iv. respiratory rate greater than 20 breaths per minute or PaCO2 less than 32mmHg 
It is recognised that the systemic inflammatory response is not specific for sepsis 
but also occurs in the context of non-septic inflammation such as acute 
pancreatitis, trauma and thermal injury. 
A second consensus conference, The International Sepsis Definitions Conference, 
was held in 2001 as there were concerns regarding the lack of specificity of the 
SIRS criteria. After 10 years of further research into sepsis, with the discovery of 
novel biomarkers and increased understanding of the multiple mediators implicated 
in the pathophysiology of sepsis, it was felt that the definitions should be updated to 
include such advances in knowledge. Following extensive review of the literature 
and subsequent expert debate it was concluded that despite extensive research no 
definitive evidence existed to allow such parameters to be incorporated into 
guidelines, however, additional clinical features were added to more clearly define 
the real clinical situations encountered (Levy et al., 2003). 
As will be discussed, the systemic inflammatory response arising in sepsis and 
critical illness is responsible for the acquired immune dysfunction seen. 
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1.3.1 Epidemiology of sepsis 
Sepsis causes significant health problems world wide and is a leading cause of 
death in critically ill patients (Mayr et al.,2014). With an increasingly ageing 
population affected by co-morbid disease and impaired immunity as a result of 
immunosenescence (progressive deterioration of the immune system with ageing 
(Berrut G et al., 2015)) the incidence of sepsis has been increasing over the last 
few decades. A secondary analysis of data gathered between 1996 and 2004 on 
the Intensive Care National Audit and Research Centre (ICNARC) Case Mix 
Programme Database revealed that of the 343,860 admissions to 172 ICUs in 
England, Wales and Northern Ireland 92,672 (27%) met the criteria for severe 
sepsis within the first 24 hours of admission. The number and percentage of 
admissions with severe sepsis rose over the course of the study from 46 per 
100,000 of the adult population (23.1% of admissions), in 1996 to 66 per 100,000 of 
the adult population (28.7% of admissions), in 2004 (Harrison et al., 2006). 
Although there was a reduction in the mortality rate among patients with severe 
sepsis, from 48.3% in 1996 to 44.7% in 2004, as a result of improvements in care, 
overall number of deaths increased due to the increased patient numbers (Harrison 
et al., 2006). With advances in treatment protocols, increasing numbers of patients 
survive the early pro-inflammatory phase with the majority of deaths occurring late 
in the course of sepsis as a result of acquired immunosuppression leading to 
secondary nosocomial infection (Otto et al., 2011). 
 
1.3.2 Pathophysiology of sepsis and the systemic inflammatory response 
Traditionally sepsis was believed to be characterised by overwhelming pro-
inflammatory cytokine release, often termed a 'cytokine storm' following recognition 
of foreign pathogens and activation of the innate immune system. It was understood 
that this resulted in recognised clinical signs and symptoms such as fever, 
tachycardia and hypotension. This theory was supported by studies in animals 
using large doses of lipopolysaccharide (LPS) or bacteria where very high levels 
of circulating cytokines were recorded and death occurred quickly as a result of an 
overwhelming response. In these studies, improvements in mortality could be 
seen when such inflammatory mediators were blocked calming the cytokine 
storm. (Riedemann et al., 2003; Deitch, 1998) 
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Multiple pro-inflammatory mediators were subsequently identified as components of 
the systemic inflammatory response (e.g.tumour necrosis factor alpha (TNFα), 
interleukin 1 beta, (IL-1β), interleukin 6 (IL-6),interleukin 8 (IL-8), inteferon gamma 
IFN-g) and became the targets of research into sepsis prevention and control. Many 
trials set out to investigate the role of anti-inflammatory agents in combating sepsis 
(see table 2) but while targeting specific pro-inflammatory mediators had been 
shown to be of benefit in animal models, trials in humans failed, with some resulting 
in worse outcomes. (Zeni et al., 1997; Natanson et al., 1994;). It became apparent 
that targeting the blockade of a single inflammatory agent would not be effective in 
controlling the host response. 
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Table 2: Trials targeting pro-inflammatory mediators of sepsis. aFisher et al., 1994; 
bOpal et al., 1997; cAbraham et al., 2001; dPanacek et al., 2004; eRice et al., 2006; fBone et 
al; gOpal et al 2013. 
Target 
Year (ref) 
Intervention Population Primary 
Outcome  
Result 
IL-1 
1994a 
Recombinant 
human IL-1 receptor 
antagonist 
893 patients 
sepsis 
syndrome 
28 day all 
cause 
mortality 
No significant difference in 
survival 
(? Increased survival if >1 organ 
dysfunction – secondary 
analysis) 
IL-1 
1997b 
IL-1 receptor 
antagonist 
696 patients 
severe 
sepsis / 
septic shock 
28 day all 
cause 
mortality 
No significant difference 
TNF – α 
2001c 
Lenercept – TNF – 
α receptor fusion 
protein 
1342 
patients 
73% severe 
sepsis 
27% septic 
shock 
28 day all 
cause 
mortality 
No significant difference 
TNF – α 
2004d 
Monocloncal TNF – 
α antibody 
2634 
patients 
severe 
sepsis (998 
­ IL-6 levels) 
28 day all 
cause 
mortality 
Overall no difference in 
mortality, mortality reduced in 
sub-group with increased IL-6 
TNF – α 
2006e 
Affinity purified anti 
TNF – α fAb 
81 patients 
septic shock 
/2 organ 
dysfunction 
Reduction in 
TNF – α and 
IL-6 levels 
¯ plasma TNF- α and IL-6. 
No difference in shock free 
days, 
28 day mortality 37% placebo vs 
26% FAb 
Multiple 
1987f 
High dose 
methylprednisolone 
382 patients 
with sepsis 
Reduction in 
shock / 
mortality 
No significant difference 
TLR4 
2013g 
Eritoran MD2-TLR4 
Lipid A antagonist 
1961 
patients with 
severe 
sepsis 
28 day all 
cause 
mortality 
No significant difference in 
survival 
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1.3.3 Immune dysfunction in sepsis 
As early as the 1970s it was noted that in addition to the inflammatory response 
patients with sepsis and trauma frequently displayed features of immune 
impairment, initially demonstrated by a loss of delayed type hypersensitivity 
response to common antigens (Meakins et al.,1977).  Further studies showed that 
whole blood and isolated immune cells from septic patients had a lower capacity for 
producing inflammatory mediators (Hotchkiss et al., 2013). It was also seen that 
mortality rates were worse in patients where anti-inflammatory cytokines 
predominated (Van Dissel et al., 1998). Gradually there was increased recognition of 
the importance of the fact that that the exaggerated inflammatory response was very 
often accompanied by an anti-inflammatory response with certain patients who 
displayed marked anti-inflammatory response having poor outcomes (Boomer et al., 
2011; Schefold et al., 2008). Similar patterns were also recognised in patients with 
other non-infective forms of critical illness including burns, trauma, pancreatitis and 
massive transfusion (Schwacha et al., 2002; Hazeldine et al.,2014; Angele et al., 
2002; Cata et al., 2013, Hill et al., 2003). This became known as the compensatory 
anti-inflammatory response. 
 
1.3.4 Compensatory anti-inflammatory response syndrome 
Bone first described the phenomenon of the Compensatory Anti-inflammatory 
Response Syndrome (CARS), in the mid 1990s and went on to characterize it in more 
detail (Bone,1996; Bone et al., 1997). He noted that the onset of the anti-
inflammatory response appeared early in the course of sepsis but that it developed 
more slowly, than the pro-inflammatory response, and appeared to persist for longer 
(Figure 1). He hypothesized that the role of the anti-inflammatory response was to 
control and regulate the inflammatory response with the aim of restoring 
homeostasis. Anti-inflammatory mediators associated with this response were 
identified in increased concentrations including IL-10, IL-4, IL-13, TNF receptor and 
IL-1β receptor antagonist (Gogos et al., 2000). The effects of these anti-inflammatory 
mediators include down regulation of monocyte MHC class II expression, a reduction 
in antigen presentation and a decrease in cytokine release from various cells of the 
innate immune system (Bone et al., 1997).  Plasma from such patients has been 
shown to act as an immunosuppressive medium when applied to healthy cells 
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(Cavaillon et al., 2001). Bone proposed that the reason for the failure of clinical trials 
targeting specific pro-inflammatory mediators was related to imbalances in the pro 
and anti-inflammatory response and that beyond the very acute phase of illness it 
was often the effects of the anti-inflammatory response which led to secondary 
infection and death (Bone et al.,1997(a); Bone , 1997(b)). 
 
 
 
 
Figure 1a: Compensatory anti-inflammatory response theory in sepsis. Reprinted from 
The Lancet Infectious diseases.  Vol. 1, Van der Poll. Immunotherapy of sepsis, Pages 165-
174. Copyright (2001), with permission from Elsevier. 
 
 
 
1.3.5 Current understanding 
It became clear that sepsis and the systemic inflammatory response was a vastly 
complex event with the course of the disease depending upon the balance between 
the pro and anti-inflammatory response (Reinhart et al., 2012). Current 
understanding is that microbial pathogen associated molecular patterns (PAMPS) 
activate cells of the innate immune system though pattern recognition receptors 
(PRRs) stimulating an acute phase response. In the case of non-septic 
inflammation, the process is triggered by danger associated molecular patterns 
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(DAMPS) released during tissue damage and cellular necrosis (Boomer et al., 
2014). Several families of PRRs have been identified including Toll-like receptors 
(TLR), RIG-I-like receptors, NOD-like receptors and DNA receptors (Kumar et al., 
2011). Binding with the pattern recognition receptors such as the Toll Like Receptor 
(TLR) family causes activation of immune cells and in the case of TLR 4 triggers 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and the 
mitogen-activated protein (MAP) kinase pathway resulting in the release of multiple 
inflammatory mediators including cytokines, chemokines, components of the 
complement system and vasoactive proteins (Stearns-Kurosawa et al., 2011). 
NOD-like receptors form inflammasomes which have a significant role in the 
secretion of IL-1ß and IL-18 (Gotts et al., 2016). Cytokines cause an increase in 
adhesion molecules on endothelial surfaces recruiting additional cells to the site of 
inflammation strengthening the cascade. At the same time enhanced phagocytosis 
of opsonized bacterial pathogens by neutrophils and macrophages takes place 
producing further inflammatory cytokine release. (Stearns-Kurosawa et al., 2011, 
Kumar et al., 2011). 
In addition to stimulating the release of pro-inflammatory mediators, activation of 
cells in the innate and adaptive immune system leads to release of anti-
inflammatory mediators driving the immunosuppression seen. Both macrophages 
and neutrophils release IL-10 and TGF-ß which have anti-inflammatory effects 
(Opal et al., 2000). During sepsis, interactions of antigen presenting cells with cells 
of the adaptive immune system contribute to the anti-inflammatory effects with a 
shift in the balance of T cells from Th1 cells releasing pro-inflammatory cytokines 
such as TNF- α, IL-2, IL-12 and IFN-g to Th2 cells releasing the anti-inflammatory 
mediators IL-4, IL-5, IL-9 and IL-10. (Aziz et al. 2013, Boomer et al., 2014). 
The combined effects of these anti-inflammatory mediators constitutes the 
compensatory anti-inflammatory response. Studies of the effects of this anti-
inflammatory response have revealed defects in all cells of the innate immune 
system.  
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1.4 Role of neutrophils in host defense 
Neutrophils are the key cells responsible for the clearance of bacterial and fungal 
infection. Within their role in the innate immune system they act through various 
mechanisms to engulf and destroy pathogens. Disease states in which abnormalities 
in either number or function of neutrophils occur confirm the importance of 
neutrophils in protection against serious infection. Congenital neutropaenia 
encompasses a range of diagnoses of varying severity all of which show increased 
tendency to serious infection and prior to the era of G-CSF often resulted in death in 
early infancy (Donadieu et al., 2011). Chronic granulomatous disease, a condition in 
which neutrophils display impairment in the respiratory burst and production of 
oxygen free radicals due to mutations in the genes responsible for Nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, is characterised by recurrent 
severe bacterial and fungal infections (Heyworth et al., 2003). Similarly individuals 
with leukocyte adhesion deficiency disorders, where a defect in b2 integrins prevents 
firm adhesion to and migration across the endothelial wall of blood vessels and 
subsequent failure of phagocytosis, display increased susceptibility to infection 
(Anderson et al., 1985). 
 
1.4.1 Neutrophil production and release 
Neutrophils are produced and released from the bone marrow at a rate of up to 
2x1011 per day (Kolaczkowska et Kubes.,2013). Their production is under control 
of the cytokine granulocyte-colony stimulating factor (G-CSF). Mice lacking G-CSF 
have been shown to be neutropaenic (Lieschke et al., 1994), and G-CSF therapy 
is currently utilized in congenital neutropaenia and acquired neutropaenia, e.g. 
post chemotherapy, to restore circulating neutrophil numbers (Donini, 2007; Mehta 
et al., 2015; Metcalf, 2010).  
The subsequent release of neutrophils from the bone marrow is regulated by 
CXCR4 and SDF-1(stromal derived factor – 1) which maintain homeostasis by 
retaining the cells in the bone marrow until required (Summers et al., 2010).  Once 
in the systemic circulation it is thought that neutrophils have a relatively short half-
life moving to the tissues or undergoing apoptosis within hours, however, more 
recent research has suggested that they may persist for up to 5 days (Pillay et al., 
2010), even under basal conditions, although the experimental methods used to 
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measure neutrophil survival in these data have been debated. What seems 
apparent, however, is that when neutrophils are activated their survival is 
increased enabling primed neutrophils to remain present at sites of inflammatory 
insult for longer (Witko-Sarsat et al., 2011).  
Following release of neutrophils into the circulation approximately 50% of the cells 
have been noted to ‘disappear’ and have been shown to be transiting slowly 
through large organs forming the intravascular ‘marginated pool’ residing within 
the liver, spleen, bone marrow and lungs (Summers et al., 2010). These cells can 
be recruited into the circulation at any time in response to pathogen or tissue-
derived molecular signals.  
During the inflammatory response neutrophil number increases markedly due to 
the secretion of G-CSF which interferes with the CXCR4-SDF-1 retention signal 
resulting in release of increased numbers of neutrophils from the bone-marrow 
(Wengner et al., 2008). Upon release from the bone marrow neutrophils rapidly 
migrate from the circulation into affected tissues under the influence of 
chemotactic cytokines released by macrophages and dendritic cells that reside in 
the tissues and trigger the neutrophil response.  
 
1.4.2 Neutrophil recruitment, chemotaxis and extravasation 
Multiple mediators are involved in coordinating the passage of neutrophils from the 
circulation to the site of inflammation and injury. Circulating neutrophils are attracted 
to the endothelial cell surface by cell adhesion molecules called selectins (type 
1membrane glycoproteins which have a characteristic NH2 – terminal lectin domain 
and an EGF-like domain), a process known as tethering. Pattern recognition 
receptors on the endothelial surface detect the presence of pathogens and up 
regulate the expression of both platelet α (P)-selectin and endothelium (E)-selectin 
which bind to their glycosylated ligands on the neutrophil, in particular PSGL1 
maximising neutrophil capture and recruitment (Kolaczkowska et Kubes.,2013). Once 
tethered the neutrophils initiate a ‘rolling’ mechanism whereby the cells are loosely 
adhered to the vessel wall and transition along it in response to chemotactic factors 
Figure 1b). Breakage and reformation of the selectin-ligand bonds allow smooth 
rolling of the neutrophil despite the shear forces of the passing blood flow 
(Ramachnadran et al., 2004).  During the rolling process, as a result of exposure to 
	 16	
stronger, more specific chemotactic signals, in particular CXCL8 (IL-8), the 
neutrophils can become primed and activated. Via high affinity binding between β2 
integrins and glycoproteins they can then firmly adhere to the endothelial cell surface. 
β2 integrins, the cell surface molecules responsible for tight adhesion to the 
endothelium, are composed of variable α subunits CD11a/CD11b/CD11c and a 
common β subunit, CD18. CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac1) are 2 
important β2 integrins on the neutrophil surface and bind via intracellular adhesion 
molecule (ICAM) ligands mediated by calcium- and magnesium-dependent pathways 
resulting in tight adhesion (Burg et Pillinger.,2001). Murine studies examining 
deficiency of either integrin show marked impairment of adhesion (Burg et 
Pillinger.,2001) and in humans, impairment of LFA-1 and Mac-1 results in adhesion 
disorder and functional impairment of neutrophils (Anderson et al., 1985). 
Once the neutrophil has adhered to the endothelium it begins the process of 
transmigration across the endothelial lining into the affected tissues (Figure 2).  
Transmigration can occur at the endothelial cell-cell junctions or transcellularly, the 
former being the preferred, more efficient route (Kolaczkowska et Kubes.,2013; 
Burg et Pillinger.,2001). Neutrophils crawl along the endothelial surface in a 
manner which is both chemokine dependent and independent. Neutrophils are 
also seen to crawl in a direction perpendicular to the flow of blood in a non-
chemokine-dependent nature directly towards the site of transmigration. 
Transmigration is dependent on integrins, in particular integrin associated protein 
(IAP) and platelet/endothelial cell adhesion molecules and passage takes about 
10-20 minutes. This happens across a chemotactic gradient (Kolaczkowska et 
Kubes.,2013; Burg et Pillinger., 2001; Hellewell, 2003). 
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Fig 1b: The updated classical neutrophil cascade. Shown are the sequential steps of 
neutrophil recruitment from the vasculature to the tissue. Two possible methods of 
transmigration are acknowledged: paracellular (between endothelial cells; a) and 
transcellular (through endothelial cells; b). Major groups of adhesion molecules are marked. 
Rolling is mostly selectin-dependent, whereas adhesion, crawling and transmigration depend 
on integrin interactions. Chemokines lining the luminal part of endothelium activate rolling 
neutrophils, thus inducing conformational changes of neutrophil surface integrins and 
allowing for subsequent events. Crawling neutrophils follow the chemokine gradient along 
endothelium, which guides them to the preferential sites of transmigration. The intravital 
microscopy image shows a skin postcapillary venule with neutrophils (LY6G+ cells) labelled 
in red (phycoerythrin antibody conjugate; 10 μg). Mouse skin was infected with 
Staphylococcus aureus and the image was taken 2 hours later. It captured neutrophils at 
different stages of migration: freely circulating cells, rolling cells extending tethers, adhering 
neutrophils and the cells that extravasated out of the blood vessel. Reprinted by permission 
from Macmillan Publishers Ltd : Nat Rev Immunol. 2013;13(3):159-75. Copyright (2013). 
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1.4.3 Bacterial killing; Phagocytosis and superoxide release 
Once within the target tissue the neutrophil begins the process of phagocytosis and 
pathogen destruction, following a new chemotactic gradient, created by molecules 
such as formyl-methionyl-leucyl phenylalanine (fMLF) or C5a, leading to the ‘end-
target’ infecting particle. Neutrophils can phagocytose both opsonised and non-
opsonised particles. Opsonised phagocytosis can be both complement and 
immunoglobulin mediated. The Fc receptors CD32 and CD16 present on resting 
neutrophils bind to immunoglobulin while a subset of β2 integrins (MAC1) binds 
complement coated particles (Lee et al., 2003). In order for the activation of Fc 
receptors to take place phosphorylation of tyrosine residues within an 
immunoreceptor tyrosine activation motif (ITAM) must take place (Lee et al., 2003). 
This process relies on activation of Src-family kinases (Kiefer et al., 1998). Following 
phosphorylation, binding of tyrosine kinase Syk on generated sites stimulates 
phosphatidylinositol-3-kinase (PI3K) which in turn converts phosphatidylinositol 4,5-
biphosphate to phosphatidylinositol 3,4,5-triphosphate. This cascade leads to the 
polymerization of actin and activation of myosin necessary for ingestion of the foreign 
particle (Dale et al., 2008). Once bound, the foreign particle is ingested with or 
without the extension of pseudopods to form a vacuole known as a phagosome. 
Once inside the cell the phagosome fuses with lysosomes (specific granules 
containing cytotoxic enzymes) induced by a rise in intracellular calcium levels and 
activation of protein kinases (Dale et al., 2008). Neutrophil granules are of key 
importance in the processes of bacterial killing and digestion of the pathogen which 
follows.  The processes are also dependent on the oxidase NADPH, contained in 
secondary granules which is essential to the processes of microbial killing (Segal, 
2005; Lee et al., 2003). Via the transfer of negative charge from NADPH contained in 
the cytosol to oxygen molecules within the phagosome superoxide anions are 
created in large numbers (Lee et al, 2003). This marked increase in oxygen 
consumption with the production of oxygen free radicals is known as the respiratory 
burst. The oxygen metabolites, so called reactive oxygen species (ROS), produced 
are toxic to microbes and result in effective killing. Secretion of biologically active 
cytotoxic substances released from neutrophil granules either into the phagosome or 
into the extracellular milieu also contribute to the killing powers of neutrophils (Segal., 
2005). During maturation 3 different types of granules are produced all of which play 
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an important role in the neutrophils response to pathogens. The primary, or 
azurophilic, granules contain MPO, Cathepsin G, elastase and proteinase 3 all of 
which can effect pathogen digestion. MPO in particular is important in the conversion 
of superoxide to the more toxic hypochlorous acid which has increased killing anti-
microbial effect (Borregaard et al.,1997). The secondary, or specific granules contain 
lactoferrin, transcoblamin and gelatinase and are more important in terms of restoring 
membrane components and preventing unwanted free radical reactions. The 
secondary and tertiary granules contain the flavocytochorme b558 which is a vital 
component of NADPH oxidase (Borregaard et al., 1997). In addition, activated 
neutrophils can exhibit extracellular killing with the release of NETs (neutrophil extra-
cellular traps), containing core DNA and antimicrobial histones, proteins and 
enzymes. The NETs capture the pathogens and facilitate killing either via cytotoxic 
proteins and histones or by enabling phagocytosis to occur (Kolaczkowska et 
Kubes.,2013). 
 
1.4.4 Neutrophil apoptosis 
When the life span of the neutrophil has been reached it undergoes a process of 
programmed cell death known as apoptosis. Neutrophils undergoing apoptosis can 
be identified by several characteristic changes in their microscopic appearance 
including prominent densely condensed nuclei and vacuolated cytoplasm (Savill et 
al., 1989). Changes in the surface expression of phosphatydylserine, due to 
alterations in plasma membrane phospholipids, reveals apoptotic neutrophils to 
phagocytic macrophages responsible for their clearance (Fadok et al., 2001). The 
engulfment of apoptotic neutrophils by tissue macrophages is associated with 
inhibition of the secretion of pro-inflammatory cytokines (Fadok et al., 1998). 
Controlled cellular death, happening in this way, prevents the spilling of cytotoxic 
substances from the dying neutrophil. This protective process minimises damage to 
the surrounding environment and is an essential part of tissue recovery. Constitutive 
apoptosis of circulating neutrophils takes place in the liver, spleen and bone marrow 
(Saverymuttu et al., 1985). Neutrophil apoptosis is mediated by multiple factors but 
critically by the family of caspases with caspase 8 and 9 being responsible for 
initiation of apoptosis (Luo et al., 2008; McCracken et al., 2014).  Another family of 
proteins, the Bcl-2 family, includes both pro-apoptotic proteins (Bid and Bax) and pro-
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survival proteins (Mcl-1 and A1). These proteins play a key role in mitochondrial 
integrity affecting the release of further pro-apoptotic factors in the cascade. 
Apoptosis is also under the influence of multiple extracellular mediators many of 
which are increased during infection and inflammation when they exert a pro-survival 
effect leading to a delay in apoptosis. The balance of pro-survival and pro-apoptosis 
proteins determines the rate at which apoptosis occurs (Luo et al., 2008; McCracken 
et al., 2014). Apoptotic neutrophils have been shown to exhibit impairment in various 
aspects of neutrophil function including chemotactic response to stimulus, reduction 
in release of reactive oxygen species and impairment in phagocytosis (Whyte et al., 
1993). The prolonged lifespan of neutrophils secondary to delayed apoptosis in 
sepsis and critical illness and has been shown to be affected by the presence of pro-
inflammatory cytokines and hypoxia (Michlewska et al., 2009; Hannah et al., 1995). 
Although extended neutrophil survival may be beneficial in terms of enhancing the 
host response to infection delayed apoptosis is implicated in the tissue damage seen 
in many inflammatory diseases (Elmore, 2007; Luo et al., 2008)). The 
aforementioned externalisation of phosphatydylserine during the process of 
apoptosis is advantageous for research purposes where apoptotic neutrophils can be 
identified by Annexin V binding for flow cytometry analysis (Akgul et al., 2001). 
 
 
1.5 Immune cell dysfunction in critical illness 
 
1.5.1 Neutrophil dysfunction in critical illness 
During critical illness the overwhelming inflammatory response leads to neutrophil 
dysfunction with impairment of the ability of the neutrophil to facilitate clearance of 
pathogens. Studies have shown defects in all of the key processes namely 
phagocytosis, chemotaxis, ROS and bacterial killing (Wenisch et al., 2001, Lu et al., 
2016). There are some conflicting reports describing enhanced phagocytosis and 
ROS production in some septic patients which may be explained by the severity of 
illness and balance of the pro-inflammatory and anti- inflammatory responses in the 
patient cohorts studied (Martins et al., 2003; Hazeldine et al., 2014). The release of 
large numbers of immature neutrophils into the circulation, due to the effect of 
inflammatory cytokines on CXCR4/CXCL12 signaling in the bone marrow probably 
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contributes to neutrophil impairment (Cummings et al. 1999). Immature neutrophils 
have been shown to display significantly reduced phagocytic capacity when 
compared to neutrophils from healthy volunteers (Taneja et al., 2007; Pillay et al., 
2010). Heterogeneity in the functional capacity of neutrophils in sepsis and critical 
illness may be due to alterations in membrane receptors vital for these processes 
(Pillay et al., 2010; Tarlowe et al., 2005). 
Conway Morris et al, previously confirmed that neutrophil phagocytosis is impaired 
in our target population of critically ill patients when compared with healthy 
volunteers. Studying 68 patients on intensive care, all of whom had suspected 
ventilator-associated pneumonia (VAP), a major ICU-acquired nosocomial infection, 
they showed a 36% absolute reduction in median phagocytic capacity in the 
critically ill patients compared with 21 age and sex-matched healthy controls. 
(Conway Morris et al., 2009). This problem was compounded by the fact that 
patients’ neutrophils were less capable of generating bactericidal reactive oxygen 
species (ROS) and had reduced migratory capacity to chemotactic stimuli 
(Conway Morris et al., 2009). 
In addition to demonstrating that neutrophil phagocytosis was impaired, Conway 
Morris et al went on to show that patients with proven phagocytic dysfunction had 
a more than 5-fold increased risk of developing an ICU-acquired infection during 
their admission (Conway Morris et al., 2011).  
 
 
Figure 1c: Comparison of ICUAI in patients related to presence of 
neutrophil phagocytic dysfunction. Adapted from Conway Morris et al. Blood. 
2011;117(19):5178-88. 
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Previous studies have also confirmed the association of phagocytic impairment 
with poor prognosis for patients with sepsis and septic shock (Danikas et al., 
2008, Stephan et al., 2002). 
 
1.5.2 Monocyte dysfunction in critical illness 
Monocytes originate from progenitor cells in the bone marrow and are released into 
the circulation during septic and non-septic inflammation in response to various 
chemokines including CCL2 and CCL7.Accounting for approximately 10% of the 
circulating human leucocyte population they are involved in host antimicrobial 
defense including antigen presentation, removal of apoptotic cells and scavenging of 
toxins (Auffray et al., 2009). In addition, they have been implicated in the 
pathogenesis of many inflammatory conditions including atherosclerosis, rheumatoid 
arthritis and multiple sclerosis (Shi and Palmer., 2011). Monocyte recruitment into 
the tissues is triggered by local factors and chemokine release and follows the 
previously described pattern of leucocyte migration including rolling, adhesion and 
transmigration. Once in the tissues monocytes can differentiate into both tissue 
macrophages and dendritic cells (Shi and Palmer., 2011). Monocytes have been 
subdivided into 3 types depending on their expression of the cell surface markers 
CD14 and CD16 and are described as classical monocytes CD14++ CD16 low, non-
classical monocytes CD14+ CD16++ and intermediate monocytesCD14++ CD16+ 
(Ziegler-Heitbrock et al., 2010). 
Monocyte dysfunction in sepsis has been recognised for some time. Alterations in 
monocyte function in sepsis are characterised by a reduction in HLA-DR surface 
expression and an accompanying reduction in antigen presentation. Reduced HLA-
DR expression on monocytes has been shown to correlate with poor outcome in 
terms of mortality and secondary infection (Docke et al., 2005;  Cheron et al., 2010).  
HLA-DR is a major histocompatibility complex (MHC) class II cell surface receptor 
responsible for antigen presentation which can be readily measured by flow 
cytometry. It is encoded by the HLA complex on chromosome 6 (Cajander et al., 
2013). Low levels of monocyte HLA-DR have been observed in the majority of 
patients with sepsis at onset but restoration to normal levels within 7 – 10 days has 
been observed in survivors (Tschaikowsky et al., 2006), with persisting low levels of 
monocyte HLA-DR in sepsis having been shown to predict mortality (Monneret G. et 
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al., 2006). Similar patterns of monocyte dysfunction and anergy have also been 
seen in patients presenting with non-septic systemic inflammation for example in 
trauma and burns, and those presenting with ruptured aneurysms. Low levels of 
HLA-DR expression have also being shown to be a predictor of poor outcome in 
these circumstances (Cheron et al., 2010, Venet et al., 2007, Haveman et al., 2006). 
Consequently, monocyte HLA-DR expression has been identified as a surrogate 
marker for immune dysfunction in critical illness and measurement of monocyte 
HLA-DR has therefore been adopted for use in clinical trials to identify patients with 
immunoparesis (Monneret et al., 2006, Hotchkiss et al., 2014, Meisel et al., 2009). 
Monocyte HLA-DR is commonly measured by flow cytometry and an international 
protocol has been developed by Docke et al in an effort to standardise results 
(Docke et al., 2005). Commercially available kits such as the QuantibriteTM kit (BD 
Biosciences) have been developed to facilitate its measurement. Monocyte HLA-DR 
expression levels > 20,000 antibodies per cell are widely accepted to be associated 
with immunocompetence while levels below 5,000 antibodies per cell are considered 
to be in keeping with immunoparalysis. To increase clinical use and reduce variation 
between laboratories other means of measuring HLA-DR are currently being 
explored including polymerase chain reaction (PCR) (Cajander et al., 2013). 
While monocyte HLA-DR expression is now an accepted surrogate marker for 
immunosuppression (Faix, 2013) the effect of restoration of mHLA-DR levels on 
immune function has not been demonstrated.  
 
1.5.3 T Lymphocyte dysfunction in critical illness 
Lymphocyte apoptosis has been shown to be increased in sepsis and critical illness 
with altered differentiation of lymphocyte subsets. Increased apoptosis 
accompanied by a reduction in Th1 lymphocytes without an increase in the Th2 
subset leads to anergy or a state of unresponsiveness to antigens.(Hotchkiss et al., 
2003; Hotchkiss et al., 2003 (2), Kessel et al., 2009). 
In particular, alterations in T regulatory cell (T reg) dominance play a significant role 
in immunosuppression in sepsis. T regulatory cells were first described in the 
1970s when they were known as suppressor cells (Gershon et al., 1972). They play 
a crucial role in suppressing abnormal immune responses such as in autoimmune 
disease and following transplantation. They exert their immunosuppressive effects 
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through 4 different modes i) through the secretion of anti-inflammatory cytokines 
including IL-10 and TGF-ß ii) through cytolysis by releasing granzymes, iii) by 
causing mechanical disruption and iv) by modulating dendritic cell maturation or 
function, necessary for the activation of effector T cells (Vignali et al., 2008).  
T regulatory cells make up about 5-10% of the normal circulating T cell population 
but their relative number is significantly increased in sepsis and critical illness 
(Venet et al., 2009, Tatura et al., 2012). Increased lymphocyte apoptosis leads to 
an overall increase in the proportion of T regulatory cells, despite an overall 
reduction in T reg numbers, probably due to T regs having a greater resistance to 
apoptosis (Venet et al., 2004, Christaki et al., 2010). T regs appear to recover in 
number quicker than other T cell populations and the proportion of T regs is seen to 
rise several days after the onset of critical illness (Venet et al., 2009, Tatura et al., 
2012). There has been increasing importance placed on the significance of T regs 
in sepsis and critical illness in recent years. While there is some evidence for a 
protective effect of T regs in sepsis (Hein et al., 2010; Kulhorn et al., 2013) several 
studies have demonstrated the development of secondary sepsis and poorer 
outcomes in patients with persistently elevated T reg proportions (Conway Morris et 
al., 2013, Venet et al.,2008, Monneret et al., 2003). It is thought that T regs may 
contribute to the state of lymphocyte anergy seen. (Venet et al., 2009) 
T regs express CD4 and CD25 surface receptors and have been identified by the 
presence of the transcriptional factor forkhead box P3 (FOXP3) that appears to be 
necessary for T reg development, maturation and function. Although FOXP3 is a 
very reliable marker of T regs in mice its role in identifying T regs in humans is less 
straightforward.  In addition, identifying the cells through the use of FOXP3 requires 
nucleus staining which takes several hours and makes it not a useful test for rapid 
identification. The low presence of CD127 can instead be used. (Hein et al., 2010; 
Venet et al., 2009, Tatura et al., 2012) T regs can be further subdivided into 
subsets memory and naïve T regs (Booth et al., 2010).  
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1.5.4 Combined immune cell dysfunction 
As discussed the deleterious effects of an overwhelming inflammatory response on 
immune cells are not limited to neutrophil function. Significantly, it has also been 
shown that in episodes of combined dysfunction the risk of nosocomial infection 
rises in a cumulative manner with up to 75% risk of nosocomial infection in patients 
with evidence of neutrophil, monocyte and regulatory T-lymphocyte dysfunction. 
(Conway Morris et al., 2013.) 
 
1.6 Personalised medicine approach 
While previous studies in sepsis and critical illness have failed in seeking to find a 
single target therapy to be used globally across the critically ill population it has 
been increasingly recognised that there is marked heterogeneity in the host 
response to sepsis. It has been observed that many trials of immunomodulatory 
drugs in sepsis have delivered the intervention at a set dose, over an arbitrary 
period of time, without clear understanding of the underlying immune function of 
the patient (Reinhart et al., 2012). Understanding this heterogeneity is vital in 
ensuring that treatments and interventions can be appropriately targeted towards 
individual patients depending on their phenotypic response.  
A large study, published in 2007, examining blood samples from patients with 
community-acquired pneumonia showed that cytokine profiles in more than 1800 
patients presenting to Emergency Departments varied significantly over the course 
of their disease. Measurements of IL-6, TNF and IL-10 taken daily for 1 week and 
then weekly until discharge revealed high levels of IL-6 and TNF at presentation 
which fell quickly but remained elevated for more than a week (Kellum et al., 
2007). A high proportion of patients were also seen to have significantly elevated 
levels of IL-10 throughout. The highest risk of death was seen in patients with high 
levels of both pro-inflammatory IL-6 and anti-inflammatory IL-10.  Interestingly 
unbalanced pro- and anti-inflammatory profiles were rarely seen and were not 
associated with poor outcome. Significant proportions of patients had normal levels 
of both IL-10 (64% survivors and 42% non-survivors) and TNF (61% survivors and 
53% non-survivors) throughout their disease course illustrating that host cytokine 
response profiles vary greatly and are not necessarily associated with poor 
outcome. These data suggested that anticytokine therapies may be ineffective in 
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many and even harmful in some and in addition that the failure of some treatments 
may be due to inadequate duration of therapy with the host cytokine response 
persisting for more than a week (Kellum et al., 2007).  
 
There have been increasing numbers of studies published which have demonstrated 
key genetic differences in patients with disparate responses to sepsis. The Genomic 
Association in Sepsis (GAINS) study carried out in the UK recruited almost 400 
patients with sepsis secondary to community-acquired pneumonia. They carried out 
gene expression analysis to look for evidence of heterogeneity in individual sepsis 
leucocyte transcriptomes. They demonstrated 2 distinct sepsis response signatures 
with a predominant immunosuppressive type once again being associated with a 
worse prognosis. They were able to confirm previous work showing that the state of 
relative immunosuppression occurring in some individuals’ response to sepsis begins 
soon after sepsis onset (Davenport et al., 2016). 
This marked heterogeneity of cytokine response and lack of response to anti-cytokine 
treatments has led the search to focus on differing targets in sepsis including cellular 
function. 
As the neutrophil is the key cell in defending against bacterial and fungal infection it 
has been chosen as the focus of this research. This research will explore the 
potential for reversing the functional impairment seen in neutrophils during critical 
illness, in particular phagocytosis. To exclude the possibility of treating patients with 
adequate neutrophil dysfunction and therefore unlikely to gain additional benefit from 
the therapy, we wish to recruit and therefore target our intervention towards, only 
patients with confirmed neutrophil dysfunction. 
Interventions in sepsis are required to be delivered in a timely manner and as such 
much focus is currently placed on the identification of biomarkers which might be 
used as a rapid diagnostic or point of care test to stratify patients and personalize 
treatment. Isolating neutrophils from whole blood to perform functional assessments 
involves multistep laboratory procedures. We therefore sought to utilise a suitable 
potential biomarker which could be validated for use in rapidly identifying patients 
with neutrophil phagocytic impairment for recruitment into the study. 
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1.6.1 The role of complement in immune dysfunction during critical illness. 
There has been much interest in the role of complement in immune dysfunction 
during critical illness. The complement cascade has been recognized as playing 
an important role in the body’s natural defense system.  When regulated normally 
it enhances both the innate and acquired immune systems through clearance of 
immune complexes, opsonisation of pathogens and direct lysis of invading 
organisms through the formation of the membrane attack complex. (Guo et al., 
2004) 
There are three pathways of complement activation, namely the classical pathway, 
the alternative pathway and the lectin binding pathway. The pathways are activated 
through different mechanisms but all converge at the level of C3 to produce several 
cleavage products. These products act in differing ways to trigger immune cell 
function. (Guo et al., 2004) 
Following activation of the complement system C3 and C5 are converted to the 
anaphylatoxins C3a and C5a. C3a is chemotactic for mast cells and eosinophils 
and induces the release of histamine and vasoactive mediators. (Ward., 2004) C5a 
exerts a more significant effect on granulocytes, monocytes and macrophages 
producing a strong chemotactic response. In addition, C5a can enhance neutrophil 
oxidative burst, phagocytosis (Mollnes et al., 2002) and release of granule enzymes 
and is also effective in reducing neutrophil apoptosis (Perianayagam et al., 2002; 
Guo et al., 2006), enhancing expression of adhesion molecules and activating the 
coagulation pathway. When activation occurs in a regulated manner a localised 
inflammatory response produces a net protective effect with successful clearance 
of invading pathogens. (Guo et al., 2004) This important protective role of C5a has 
been demonstrated in animal studies showing that mice with complement defects 
are very susceptible to sepsis and mount an inadequate defensive response. 
(Fischer et al., 1997)  
During critical illness (sepsis, trauma, burns) however, all three complement 
pathways may be activated simultaneously resulting in excessive release of 
activated products into the systemic circulation producing adverse consequences, 
in particular impairment of the host innate immune responses.  
Studies in rats have revealed increased survival and a reduction in the degree of 
bacteraemia when animals undergoing caecal ligation and puncture (CLP) have 
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been treated with anti-C5a antibodies. The mechanisms for improved survival 
appeared to relate to reversal of C5a-mediated defects in the respiratory burst and 
C5a-mediated impairment in phagocytosis (Huber-Lang et al., 2002). A similar 
study involving CLP rat models showed a reduction in mortality, bacterial load and 
improvement in superoxide generation when C5a was blocked. (Czermak et al., 
1999) An attenuated response has also been seen when Escherichia coli was used 
to induce septic shock and acute respiratory distress syndrome (ARDS) in 
monkeys treated with anti-C5a antibody. 100% of the animals treated with anti-C5a 
antibody survived while 75% of those treated with control antibody died. (Stevens et 
al., 1986) In addition C5a appears to have effects on cytokine release. The effects 
of C5a in sepsis differ from species to species however and rat and murine models 
of C5a in sepsis do not mirror the processes seen in human subjects.  
The mechanisms by which complement products can elicit impairment of the 
immune system are not fully understood, however C5a has been shown, in several 
in vitro studies, to inhibit neutrophil phagocytic function in a dose dependent manner. 
(Huber-Lang et al., 2002, Conway Morris et al.,) Neutrophils have a large number of 
C5a receptors (C5aR/CD88) on their cell surface and when C5a is released into the 
circulation rapid binding of the ligand to the receptor occurs. Once bound the ligand-
receptor complex is rapidly internalised resulting in clearance of C5a from the 
plasma. (Oppermann et al., 1994, Naik et al., 1997). As a result, measurement of 
serum levels is an inaccurate marker of C5a exposure with low neutrophil CD88 
surface expression being a more reliable indicator. Low neutrophil C5aR expression 
is widely seen in sepsis and has been demonstrated to relate to disease severity 
and be associated with poor outcomes. (Furebring et al., 2002, Conway Morris et 
al.,2009, 2013). In addition, this effect has also been seen in individuals with non-
septic critical illness including polytrauma. (Amara et al., 2010)  
Following internalisation the ligand receptor complex is translocated to the golgi 
apparatus where under acidic conditions the C5a is hydrolysed and the receptor 
returned to be expressed on the cell surface once again. (Ward., 2004, Furebring et 
al., 2002) Re-expression of C5a on the cell surface has been shown to be 
associated with functional recovery of neutrophil innate immune function (Guo et al., 
2004). 
A recent study identified a significant positive correlation (r=0.6904, p=0.0004) 
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between neutrophil surface CD88 expression and phagocytic capacity supporting 
the recognized role for C5a in the development of neutrophil functional impairment 
and the potential of CD88 expression as a biomarker for neutrophil dysfunction in 
critical illness. (Conway Morris et al., 2009) The first stage of this study will seek to 
confirm the validity of neutrophil CD88 expression as a biomarker for neutrophil 
phagocytic capacity within our laboratory and as the final step for eligibility for 
participation in the trial phases. 
Having demonstrated dysfunctional phagocytosis in critically ill patients and 
h a v i n g  identified C5a as an apparent culprit for this impairment Conway 
Morris et al sought to investigate mechanisms for restoring phagocytosis in this 
context.  
Conway Morris et al demonstrated that GM-CSF was able to restore phagocytic 
function in neutrophils from healthy volunteers exposed to C5a in the lab and also 
in critically ill patients with suspected VAP. In every one of 24 critically ill patients 
studied, phagocytic function was improved by ex vivo application of GM-CSF. 
(Conway Morris et al., 2009) 
 
1.7 Granulocyte-Macrophage Colony Stimulating Factor 
Colony stimulating factors were first described in the 1960s and were named 
according to their ability to induce colony formation (Gasson et al., 1991). 
Granulocyte-macrophage colony stimulating factor is a cytokine with haematopoietic 
growth factor properties acting on the myeloid line of progenitor cells. Compared to 
G-CSF, GM-CSF has a broader spectrum of leukocyte stimulation. It acts to promote 
proliferation and differentiation of progenitor cells (Gasson et al., 1991)  in the myeloid 
line in addition to delaying apoptosis (Lopez et al., 1986, Brach et al., 1992) , 
promoting survival and increasing the functional capacity of mature granulocytes 
including neutrophils, macrophages and eosinophils (Lopez et al., 1986, Fleischmann 
et al., 1986, Cebon et al., 1990, Weisbart et al., 1987). 
 
1.7.1 Structure of GM-CSF 
GM-CSF is a 23 kDa protein composed of a 4 helical bundle structure. It acts by 
binding to its heterodimeric receptor on granulocytic and macrophage cells (Metcalf, 
2010). Once binding occurs a subsequent cascade of intra-cellular signaling alters 
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cellular function. Native GM-CSF is a glycoprotein with variable glycosylation (Cebon 
et al., 1990). The clinical and physiological importance of glycosylation is not fully 
understood and glycosylation does not appear to be essential for function in vitro or 
in vivo (Lieschke et al., 1992), however there is some evidence to suggest that 
different degrees of glycosylation may influence biological activity including rate of cell 
proliferation and magnitude of superoxide production (Cebon et al.,1990). 
Recombinant forms of GM-CSF have been available since the late 1980s following 
the cloning of the mouse GM-CSF gene in 1984 with cloning of human GM-CSF DNA 
following in 1985 (Cantrell et al., 1985). 
 
1.7.2 Function of endogenous GM-CSF 
Endogenous GM-CSF is a product of many different cells including activated T-
lymphocytes, fibroblasts, endothelial cells, macrophages and stromal cells. It may 
also be produced by B-lymphocytes, mast cells, eosinophils and osteoblasts 
(Lieschke et al.,1992). Its release is inhibited by anti-inflammatory agents including 
steroids, and cytokines such as IL-4, IL-13 and IL- 10. (Lenhoff et al., 1998) 
GM-CSF is usually present in very low levels in human serum (Presneill et al., 2000, 
Lieschke et al., 1992) and at these levels is unlikely to have a systemic effect but it 
probably has an important role when released locally. It appears to be essential in 
maintaining the function of certain populations of macrophage. GM-CSF knock-out 
mice and patients with increased levels of anti-GM-CSF antibodies develop 
significant problems with lung disease due to their inability to clear surfactant (in 
humans the resulting disease is known as pulmonary alveolar proteinosis). In 
addition, these patients have increased mortality from bacterial infections and have 
been demonstrated to have impaired neutrophil function (Uchida et al., 2007). 
Reduced levels of endogenous GM-CSF have been reported in sepsis and 
associated with poor outcomes (Perry et al., 2002). 
Elevation of GM-CSF locally is seen in some inflammatory conditions such as multiple 
sclerosis and rheumatoid arthritis (Xu et al., 1989) where it may have harmful effects 
and contribute to the pathogenesis of these conditions (Williamson et al., 1988). 
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1.7.3 Effects of exogenous GM-CSF 
In the 1980s following the cloning of the genes responsible for both murine and 
human GM-CSF the production of large amounts of these recombinant factors 
enabled more detailed studies of the effects of GM-CSF. Up until this point 
researchers had only been able to extract small amounts of endogenous GM-CSF 
with limited results. 
When GM-CSF is administered both in-vitro and in-vivo it exerts multiple effects on 
cells of the myeloid lineage by increasing the proliferation and differentiation of 
progenitor cells whilst also stimulating the functional activities of mature cells 
including neutrophils, eosinophils, monocytes and macrophages (Rapoport et 
al.,1992, Lopez et al., 1986). In contrast to G-CSF the increase in proliferation of 
progenitor cells is more modest while greater effects are seen on the function of 
mature myeloid cells (Fischmeister et al., 1999). 
The effects of GM-CSF on neutrophils are both direct (prolonging survival and 
promoting degranulation) (Rapoport et al.,1992, Gasson et al., 1984) and indirect 
(enhancing phagocytosis, bacterial killing, respiratory burst and calcium flux), 
(Rapoport et al.,1992, Weisbart et al., 1985). In vitro studies have demonstrated 
enhanced phagocytosis (Fleischmann et al., 1986, Lopez et al., 1986, Conway Morris 
et al.2009) and superoxide release (Weisbart et al., 1985; Lopez et al, 1986) when 
GM-CSF is applied to neutrophils. 
Effects on survival and delayed apoptosis of neutrophils appear to be due to inhibition 
of DNA fragmentation and the production of new RNA and proteins. In vitro 
experiments have demonstrated increases of 25 to 100% in neutrophil survival time 
when GM-CSF is added to incubating medium. (Brach et al.,1992) 
 
1.7.4 Pharmacokinetics of GM-CSF 
Recombinant human GM-CSF can be administered by the subcutaneous and 
intravenous routes. In- vitro studies using human bone marrow cells have shown a 
dose-dependent response in terms of progenitor cell proliferation (Grabstein et al., 
1986), and an increase in chemotaxis and anti-fungal and anti-parasitic activities 
of neutrophils and monocytes (Reed et al., 1987, Reed et al., 1990). Concentrations 
ranging from 1-100ng/ml have been studied. Pharmacological and toxicological 
studies carried out on monkeys showed no major visceral organ pathology following 
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either single dose or daily dosing up to one month by either intravenous or 
subcutaneous preparations using doses up to 200 micrograms/kg/day. As with in 
vitro human studies dose dependent responses were seen in terms of leucocyte 
proliferation, with counts recovering to baseline within 1 -2 weeks (Sanofi-Aventis, 
2013). Human in-vivo pharmacokinetics of GM-CSF have had limited investigation 
and in particular there are little data showing the pharmacokinetics of GM-CSF in 
critically ill patients (Cebon., 1988). Several studies have been performed in healthy 
subjects and in patients with cancer although results appear to vary. Subcutaneous 
administration is associated with lower and less rapid peak levels (Cebon et al., 1988, 
Honkoop et al., 1996, Hovgaard et al., 1993), and probably as a consequence a 
reduced level of adverse reactions (Honkoop et al., 1996, Lieschke et al.,1989). 
When Leukine (sargramostim, yeast derived GM-CSF) was administered 
subcutaneously to healthy volunteers it was detectable in the blood at 15 minutes, 
peak concentrations occurred between 1 and 3 hours and it remained detectable for 
up to 12 hours post injection depending on the dose(Cebon et al., 1988,Hovgaard et 
al.,1993; Sanofi-Aventis, 2013).There is evidence to suggest that there is a lower rate 
of adverse effects seen with yeast-derived GM-CSF compared to Ecoli-derived GM-
CSF and for this reason yeast derived product has been selected for use in this study 
(Dorr 1993).Published pharmacokinetic studies report variable serum levels, in part 
related to dose and route of administration. The efficacy of GM-CSF appears to 
correlate with the length of time for which serum levels are maintained above 1ng/ml 
(Cebon et al., 1988). Following subcutaneous administration serum levels >1ng/ml 
can be achieved for up to 16 hours (Honkoop et al., 1996).  It is likely that in critically 
ill patients absorption may be impaired although clinically immune cell function 
responses have been seen with doses of 3-4 microgrammes per kilogram in previous 
clinical trials (Presneill et al., 200, Meisel et al., 2009,Orcozo et al.,2006). 
 
1.7.5 Metabolism and clearance 
The metabolism of GM-CSF is not fully understood. It is thought to occur within the 
circulation following receptor binding and very low levels of GM-CSF (0.001%-0.2% 
of the injected dose) have been detected in the urine in previous studies (Cebon., 
1990). Pre-treatment levels of serum GM-CSF are reached between 6 and 20 hours 
after injection depending on the dose and route of administration (Hovgaard et al., 
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1993). 
 
1.7.6 Clinical Experience with GM-CSF 
 
1.7.6.1 License  
Sargramostim, a commercially available human recombinant GM-CSF is 
manufactured in the US under the trade name Leukine. It is a glycoprotein of 127 
amino acids produced through the mechanisms of recombinant DNA technology in a 
Saccharomyces cerevisiae-based system. Leukine differs structurally from natural 
human GM-CSF with an alteration in its amino acid sequence - substitution of leucine 
at position 23 (Genzyme, 2009). 
Leukine / sargramostim is currently licensed in the United States of America for 
restoration of the myeloid cell line number post chemotherapy and bone marrow 
transplant. (Genzyme, 2009, Mehta et al., 2015) It is used in the treatment of older 
(55-70 years) neutropaenic patients with acute myeloid leukaemia post-
chemotherapy where it hastens neutrophil recovery and reduces the incidence of, 
and death rate from, serious infections (Rowe et al.,1995, Mehtaet al., 2015).  
 
1.7.6.2 Indications for GM-CSF 
1.7.6.2.1 Post chemotherapy and bone-marrow transplant 
As described above GM-CSF hastens recovery from neutropaenia in patients post –
chemotherapy. Studies of GM-CSF in the treatment of patients post autologous 
and allogenic bone marrow transplant show significant improvements in the rate of 
myeloid engraftment, duration of hospital stay and frequency of infections 
(Nemunaitis., 1991, Powles et al., 1990). A shorter duration of antibiotic therapy 
has also been reported in those patients receiving Leukine post bone marrow 
transplant (Nemunaitis et al., 1991).  
 
1.7.6.2.2 Sepsis 
The largest area of literature in the use of GM-CSF in sepsis relates to the care 
of neutropaenic premature babies. It has been demonstrated to enhance neutrophil 
recovery and possibly reduces nosocomial infection rates but has no impact on 
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survival (Carr et al., 2009, Bilgin et al., 2001). 
Few studies have looked at the use of GM-CSF in the treatment of non-
neutropaenic septic adults, however some recently published studies have shown 
beneficial effects in terms of various parameters of sepsis-related immune 
dysfunction in addition to non-significant benefits in clinical outcomes. 
A double-blind randomised controlled trial of 38 patients with severe sepsis or 
septic shock and evidence for immunosuppression, as indicated by low monocyte 
HLA-DR expression, were randomised to receive treatment with either 
subcutaneous GM-CSF (4mcgm/kg/day) or placebo for 8 days. The primary 
outcome was recovery in monocyte HLA-DR expression. Patients whose monocyte 
HLA-DR levels failed to recover to the normal range had their dose increased to 
8mcg/kg/day at day 5. As well as demonstrating a statistically significant difference 
in the primary outcome, significant reductions were seen in the duration of 
mechanical ventilation and APACHE II score. A trend towards a reduction in ICU 
and hospital stay was also observed (Meisel et al.,2009). 
Another double-blind RCT of nineteen patients, all with severe sepsis and sepsis-
associated respiratory organ dysfunction, randomised participants to receive either 
intravenous GM-CSF 3mcgm/kg/day or placebo for 5 days. Concerns have 
previously been raised regarding the potential of GM-CSF to worsen adult 
respiratory distress syndrome (ARDS). Although the investigators found no 
difference in their primary outcome of mortality, a significant improvement in 
PaO2:FiO2 was seen accompanied by a trend towards a reduction in ARDS in those 
patients treated with GM-CSF (Presneill et al.,2002). Increased alveolar levels of 
GM-CSF have previously been found to be associated with improved survival from 
ARDS (Mateute Bello et al 2000). 
Orozco et al published a trial looking at the use of subcutaneous GM-CSF 
following surgery for abdominal sepsis. Again they randomised patients to receive 
either GM-CSF or placebo finding a significant improvement in the rate of recovery, 
and reductions in length of stay and wound infection in those treated with GM-CSF 
(Orcozo et al.,2006). 
A trial by Rosenbloom et al produced similar positive results including quicker 
resolution of infection in their cohort of septic patients following intravenous infusion 
of GM-CSF for 72 hours. This study, however, recruited a significant proportion of 
	 35	
solid organ transplant patients on systemic immunosuppression and so the results 
are difficult to extrapolate to the ICU population as a whole (Rosenbloom et 
al.,2005). 
No published trials have studied the use of GM-CSF in patients with demonstrated 
neutrophil dysfunction. It is possible that with such targeted intervention results may 
be more significant. 
 
1.7.6.2.3 Other Indications for GM-CSF 
The potential immunomodulatory properties of GM-CSF have been investigated in 
relation to a wide spectrum of disease including prostate cancer (Amato et 
al.,2009, Small et al., 1999), Crohn’s disease (Korzenik et al., 2005), human 
immunodeficiency virus (HIV) infection (Brites et al., 2000), childhood 
neuroblastoma (Yu et al., 2010) and for use in vaccination strategies 
(Dranoff.,2002). Inhaled GM-CSF is currently used in the treatment of patients with 
pulmonary alveolar proteinosis (PAP) where the presence of anti-GM-CSF antibodies 
results in accumulation of surfactant and respiratory failure (Wylam et al.,2006). The 
literature also reports beneficial topical use of GM-CSF for the treatment of burns 
(Zhang et al., 2009) and cervical intraepithelial neoplasia (Hubert et al.,2010). 
However, with the possible exception of prostate cancer and PAP, so far there is 
insufficient evidence to recommend widespread application of GM-CSF in these 
settings. 
 
 
1.7.7 Safety profile and side effects 
Recombinant GM-CSF is used in various areas of clinical practice. The emerging 
consensus is that GM-CSF demonstrates low toxicity when used in doses of less than 
10mcgm/kg/day.  Some concerns have been highlighted in relation to the 
administration of GM-CSF to various patient groups due to the potential for GM-CSF 
to exacerbate underlying disease or development of serious side effects. In particular, 
there are concerns in relation to its use in the following patient groups; haematological 
malignancies, autoimmune diseases, some solid organ cancers and multiple 
sclerosis.  
The drug is contraindicated in any patient with a known hypersensitivity to GM-CSF, 
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any patient with >10% blast cells in the bone marrow or peripheral blood and any 
patient who has received chemotherapy or radiotherapy in the previous 24 hours. 
(Sanofi-Aventis, 2013). 
The side effects of GM-CSF are in part mediated by the production of secondary 
cytokines including TNF-α and IL-6. Common side effects include fever, pain and 
erythema at the injection site and generalized bone pain and myalgia (Lieschke et al., 
1989, Sanofi-Aventis, 2013). Dose-dependent abnormalities in liver enzymes and 
renal function have been seen. (Lieschke et al., 1989, Honkoop et al.,1996, SmPC, 
2011). Thrombotic complications have been reported and are probably related to the 
production of TNF in turn triggering the clotting cascade (Honkoop et al., 1996, 
Sanofi-Aventis, 2013). A ‘first dose syndrome’ is described characterized by flushing, 
tachycardia, dyspnea, hypotension and respiratory distress requiring symptomatic 
treatment only and resolving spontaneously with no recurrence on repeated 
administration (Lieschke et al., 1989, Sanofi-Aventis, 2013). 
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1.8 Hypothesis and aims 
The aim of this work was to investigate the hypothesis that subcutaneous GM-CSF 
can restore effective neutrophil function in critically ill patients in whom it is know to 
be impaired. 
I initially carried out an assay confirmation study, designed with the aim of validating 
the use of neutrophil CD88 expression as a biomarker for neutrophil phagocytic 
impairment. If shown to be a reliable marker, then it would be suitable for use in 
identifying patients eligible for both the dose finding study and the randomized 
controlled trial. 
On completion of the assay confirmation study I undertook the dose finding study 
which aimed to establish the optimum dose and duration of GM-CSF which would be 
both effective in terms of restoring neutrophil phagocytic capacity and safe within the 
patient cohort. 
Finally, informed by the results of both the assay confirmation study and the dose 
finding study I carried out a randomised controlled trial to answer the question of 
whether GM-CSF could restore effective neutrophil function in critically ill patients. In 
completing this work I took the opportunity to examine several different secondary 
laboratory and clinical outcomes relevant to the clinical problem in question. The 
results of this work are described in the chapters which follow.  
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Chapter 2: Materials and Methods 
 
As previously described this research project was composed of 3 phases, comprising 
an initial Assay Confirmation Study, a Dose Finding Study and finally a Randomised 
Controlled Trial. This chapter will outline the design and conduct of each phase of 
this work and describe the materials and methods used. 
 
2.1 Design of the study 
2.1.1 Assay Confirmation Study 
The Assay Confirmation Study (ACS) was an observational study designed to locally 
validate the use of neutrophil surface CD88 (C5aR) expression as a surrogate 
biomarker for impaired neutrophil phagocytic function. As described earlier (Chapter 
1, section 1.6.1) previous research from our group had demonstrated that CD88 
expression on neutrophils was a reliable surrogate marker for phagocytic capacity 
(Conway Morris et al 2009).  
 
2.1.1.1 Aim of the study 
The aim of the ACS was to identify a threshold level of CD88 expression, within our 
local laboratory, which would correspond to a phagocytic capacity of 50% and serve 
as a cut-off for final eligibility for participation in the subsequent phases of the 
research. Concurrently samples from a pool of unmatched healthy volunteers 
underwent the same analysis. 
  
2.1.1.2 Conduct of the study 
This phase of the study was designed to recruit up to 30 patients, all of whom fulfilled 
the criteria for entry into the dose finding study (DFS) and randomised controlled trial, 
and each of whom would undergo blood sampling for paired measurement of 
neutrophil CD88 expression and neutrophil phagocytic capacity.  Only basic 
demographic data (age and sex) were collected on these patients. No alterations in 
clinical care were made. Participation in the study completed following collection of a 
single blood sample. 
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2.1.1.3 Schematic diagram of study design 
 
The schematic diagram below outlines the design of the Assay Confirmation Study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 2a: Schematic diagram of assay confirmation study procedures 
 
Systemic inflammatory response syndrome criteria (SIRS) 
 
• Temperature < 36 or >38 °C  
• White blood cell count <4x109/L or >12x109/L or 10% Band 
• Heart rate > 90 beats per minute 
• Tachypnoea with respiratory rate > 20 breaths per minute or PaCO2 < 4.3kPa  
 
Table 3: Criteria for the systemic inflammatory response syndrome (SIRS) 
 
Screening for eligibility on ICU 
• Fulfil criteria for SIRS (see table 3) 
• Require support of one or more organ systems 
(MV/inotropes / haemofiltration 
• Predicted to require support for at least a 
further 48 hrs (survival deemed most likely) 
• Consent obtained from patient, PerLR or 
ProfLR 
• Admitted to ICU within last 48 hours 
Excluded 
Not suitable for 
enrolment into 
study 
Collection of single 
blood sample 
Assessment of 
neutrophil CD88 
expression 
Assessment of 
neutrophil 
phagocytic capacity 
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2.1.2 Dose Finding Study (DFS) 
The Dose Finding Study was an open labelled study designed to to compare 2 doses 
of GM-CSF administered for 2 different durations of treatment. The study planned to 
recruit up to a maximum of 24 patients in 4 separate dosing sub-groups and compare 
their response to treatment in terms of improvement in phagocytosis. 
 
2.1.2.1 Aim of the study 
The aim of the DFS was to establish the optimum dose and duration of GM-CSF (that 
which would produce a biological response in terms of improvement in phagocytosis 
alongside a favourable safety profile) which would then be carried forward for use in 
the RCT. 
 
2.1.2.2 Conduct of the study 
This phase of the study was designed to recruit patients who would fulfil the criteria 
for entry into the subsequent RCT. Following consent blood would be collected from 
patients to assess their neutrophil phagocytic capacity as the final step in their 
eligibility for the DFS. This would be known as the baseline or ‘day 0’ blood sample. 
Neutrophil phagocytic capacity was measured as the percentage of isolated 
neutrophils ingesting 2 or more zymosan particles following incubation with a 
zymosan ‘meal’. (chapter 2, section 2.16.3).  Those patients with confirmed 
neutrophil phagocytic capacity <50% would continue in the DFS and receive their first 
daily dose of GM-CSF later that day (day 0). GM-CSF would be continued for 4 or 7 
days in total depending on the participant’s sequence in recruitment as outlined 
below. 
 
Patient enrolment number Dose of Leukine  
(Sargramostim, rhu GM-CSF) 
1-6 3µg/kg/day for 4 days 
7-12 3µg/kg/day for 7 days 
13-18 6µg/kg/day for 4 days 
19-24 6µg/kg/day for 7 days 
 
Table 4: Drug allocation schedule for dose finding study 
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2.1.2.3 Schematic diagram of study design 
 
The schematic diagram below outlines the design of the Dose Finding Study. 
 
 
 
Figure 2b: Schematic diagram of the dose finding study procedures. For SIRS 
criteria see table 3. 
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2.1.2.4 Trial-related procedures 
Blood samples would be collected on all study days up to day 9 for assessment of 
neutrophil function, monocyte HLA-DR expression and safety.  The table below 
outlines the schedule of trial-related procedures for the Dose Finding Study. 
 
      Day      
 -1 0 1 2 3 4 5 6 7 8 9 
Eligibility assessment X           
Informed Consent X           
Neutrophil phagocytic 
capacity quantification 
X           
Study drug 
administration 
 X X X X X* X* X*    
Blood sampling      
(safety  ≤10mls) 
 X X X X X X X X X X 
Blood sampling 
(phagocytosis ≤ 20mls) 
 X X X X X X X X X X 
Neutrophil CD88 
/monocyte HLA-DR 
expression/ GM-CSF 
concentration 
 X X X X X X X X X X 
Adverse events  X X X X X X X X X X 
 
Table 5. Trial related procedures in dose finding study 
 
 
2.1.2.5 Dose escalation scheme 
The study was designed to recruit 6 patients to each dosing schedule. To ensure the 
safety of participants at all times it was agreed that within each dose cohort the first 
patient to be recruited would be treated and observed for 3 days, after the initial 
injection of subcutaneous GM-CSF, prior to open recruitment commencing. Safety 
and tolerability data would be collected during the treatment and observation period 
for all six patients in the cohort.  Prior to dose escalation taking place these data 
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would be collated and presented to the Data Monitoring and Safety Committee 
(DMSC). In the event of 2 or more of the 6 patients, treated within a dosing cohort, 
being found to have experienced a dose-limiting toxicity dose escalation would not 
take place. The final decision regarding dose escalation would be made by the 
DMSC.  
 
2.1.2.6 Dose limiting toxicity 
A dose-limiting toxicity was described as ‘any serious adverse event (SAE) which is 
judged to be probably or definitely related to the administration of GM-CSF.’ (Study 
protocol, appendix A). Suspected adverse events would be recorded in line with the 
trial protocols for pharmacovigilance. Following administration of the first dose of GM-
CSF blood would be collected each morning for assessment of neutrophil phagocytic 
capacity, CD88 expression, monocyte HLA-DR, and safety analysis including full 
blood count, biochemical profile and liver function tests. Post-dose blood samples 
were collected for assessment of serum levels of GM-CSF. 
 
2.1.2.7 Selection of optimum dose for RCT 
In selecting the dose of GM-CSF which would be carried forward for use in the RCT 
we planned to evaluate both the efficacy (the ability of the drug to produce a 
demonstrable increase in neutrophil phagocytic capacity) and the tolerability (i.e. <2 
of the 6 patients treated in the cohort experiencing a dose-limiting toxicity) 
of each combination of dose and duration of GM-CSF.  
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2.1.3 Randomised controlled trial 
 
The randomised controlled trial was designed to test the hypothesis that clinical 
administration of GM-CSF in critically ill patients with known neutrophil dysfunction 
would replicate the effects seen ex-vivo in the blood of critically ill patients by 
restoring effective neutrophil phagocytosis. 
 
2.1.3.1 Aim of the study 
The primary outcome of the RCT was  
• Neutrophil phagocytic capacity 2 days after administration of GM-CSF/placebo 
(as measured by the percentage of neutrophils ingesting ³2 zymosan particles 
ex-vivo, chapter 2, section 2.16.3). 
Secondary outcomes included  
• Sequential neutrophil phagocytic capacity on alternate days (to determine 
sustainability of any observed effects in the primary outcome measure) 
• Neutrophil phagocytic capacity measured as ‘area under the curve’ over the 
study period  
• Other assessments of neutrophil function (including reactive oxygen species 
generation, migratory capacity and apoptotic rate)  
• Monocyte HLA-DR expression  
• Sequential Organ Failure Assessment (SOFA) score (Vincent et al., 1998)  
• Length of stay in ICU 
• Incidence of ICUAIs (as defined by the Hospitals in Europe Link for Infection 
Control Surveillance (HELICS) criteria (Mertens et al. 1996) 
• All cause mortality 30 days post randomisation  
• Number of days of mechanical ventilation to day 30. 
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2.1.3.2 Conduct of the study 
In line with the DFS, on the morning following screening and obtaining consent, blood 
was drawn for assessment of neutrophil phagocytosis (by incubation of isolated 
neutrophil with a zymosan ‘meal’, section 2.16.3) as the final step in assessment of 
eligibility for entry into the trial. If the neutrophil phagocytic capacity was found to be 
less than 50% the patient would continue in the trial and would undergo double-blind 
randomisation to receive a daily injection of either GM-CSF (at a dose of 3µg/kg/day 
or 6µg/kg/day) or placebo for 4 or 7 days depending on the outcome of the DFS. 
During the RCT blood was drawn for assessment of neutrophil phagocytosis, 
neutrophil functional assays, monocyte HLA-DR expression and other tests of 
inflammation on alternate study days up until day 9. Blood was drawn on a daily 
basis for safety assessment (these samples formed part of usual clinical care). 
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2.1.3.3 Schematic diagram of study design 
 
The schematic diagram below outlines the design of the randomised controlled trial. 
 
 
 
Figure 2c: Schematic diagram of the randomized controlled trial procedures 
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2.1.3.4 Trial-related procedures 
During the RCT blood samples would be collected at baseline, day 2 and alternate 
study days up to day 9 for assessment of neutrophil function, monocyte HLA-DR 
expression and Blood samples would be collected on all study days up to day 9 for 
assessment of safety.  The table below outlines the schedule of trial-related 
procedures for the randomized controlled trial. 
 
Table 6: Trial procedures for randomised controlled trial.  * Duration of administration of 
study drug to be decided following outcome of DFS. ** Blood samples collected on alternate 
days during RCT- day 4 or 5, day 6 or 7, day 8 or 9 depending on availability of research 
laboratory staff. HELICS, hospitals in Europe Link for infection control and surveillance; HLA-
DR, human leucocyte antigen–antigen D related; ICU, intensive care unit; SOFA, sequential 
organ failure assessment;  
  
       Day      
 -1 0 1 2 3 4 5 6 7 8 9 10-30 
Eligibility assessment X            
Informed consent X            
Neutrophil CD88 
quantification 
 X  X  X**  X**  X**   
Randomisation  X           
Study drug 
administration 
 X X X X X* X* X*     
Blood sampling 
(safety ≤10ml) 
 X X X X X X X X X X  
Blood sampling  
(phagocytosis ≤ 20ml) 
 X  X  X  X  X   
SOFA score  X X X X X X X X X X X 
ICU status (i.e. 
whether still in ICU) 
 X X X X X X X X X X X 
Adverse events  X X X X X X X X X X  
Survival analysis  X X X X X X X X X X X 
ICUAI (by HELICS 
criteria) 
 X X X X X X X X X X X 
Neutrophil functional 
assays, monocyte 
HLA-DR expression 
≤5mls 
 X**  X**  X**  X**  X**   
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2.2 Regulatory approvals  
Prior to commencing the studies, the necessary approvals were sought from the 
appropriate regulatory authorities.  
Ethical Approval was granted by the Leeds West National Ethics Committee (REC 
Ref: 12/YH/0083). This committee were specialised in the assessment of Clinical 
Trials of Investigational Medicinal Products (CTIMPs) and flagged for trials involving 
Adults Lacking Capacity. This requires the ethics committee to have a member with 
professional experience of the disease and patient population concerned or to co-opt 
such a member from another REC or to seek advice from an independent 
professional expert. Ethical approval for all 3 studies was granted at the outset.  
As this study was a Clinical Trial of an Investigational Medicinal Product approval 
was also sought from and granted by the Medicines and Healthcare Technology 
Regulatory Authority (MHRA).  
The relevant Research and Development (R&D) departments at each of the 
participating sites granted local approval for the study to take place namely, 
Newcastle upon Tyne Hospitals NHS Foundation Trust (Sponsor R&D – Royal 
Victoria Infirmary and Freeman Hospital sites) and Queen Elizabeth Hospital 
Gateshead R&D. Both of these hospitals took part in all 3 phases of the trial.  
Approval was received from the Ethics Committee, the MHRA and the local R&D 
department for Sunderland Royal Hospital to join the trial as an additional site for the 
Randomised Controlled Trial. 
 
2.3 Clinical trial registration  
The trial was registered with the European Clinical Trials Database (EudraCT No: 
2011-005815-10) and International Standard Randomised Controlled Trial Number 
(ISRCTN: 95325384). All trial procedures were carried out to Good Clinical Practice 
standards. 
The study was also registered with the INVOLVE open-access database 
(http://www.involve.org.uk), part of the National Institute for Health Research, which 
supports active public involvement in NHS research. During the design phase of the 
study the protocol for both the DFS and RCT was shared with members of CritPaL 
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(The Patient Liaison Committee of the Intensive Care Society) for their comments 
and feedback. 
 
2.4 Sponsorship and Funding  
The trial was sponsored by Newcastle upon Tyne Hospitals NHS Foundation Trust 
and was funded by the Medical Research Council through the Developmental Clinical 
Studies scheme (Grant No: G1100233). 
 
2.5 Study Management  
The study was managed by Newcastle Clinical Trials Unit, with 2 trial managers 
allocated (one at any given time) over the course of the study (Ms Melinda Jeffels 
and Mrs Jennie Parker). The trial steering committee / project management group 
comprised of the chief investigator, the principal investigators at each site, the clinical 
research associate and the trial managers convened at regular intervals during the 
set-up and course of the trial. 
 
2.6 Consent for participation  
Where possible, consent for participation in the trial was obtained from the individual 
concerned. Because of the nature of the trial, in the vast majority of cases the 
participant did not have capacity to give informed consent.  In these circumstances 
consent was obtained from a close relative or friend (Personal Legal Representative, 
PerLR) or where no such person existed a Professional Legal Representative 
(PerLR, a doctor not connected with the conduct of the trial, who was responsible for 
the patient's care). Because of the fact that eligibility for recruitment to the trial 
included some time dependent factors patients or their PerLR / ProfLR were asked to 
provide a decision regarding consent within six hours if they felt able to do so. A 
period of up to 24 hours was offered to those making a decision regarding provision 
of consent where this was requested. 
The law surrounding consent for Adults Lacking Capacity participating in Clinical 
Trials of Investigational Medicinal Products (CTIMPs) differs from that of non-CTIMPs 
and is set out in the Medicines for Human Use (Clinical Trials) Regulations 2004. 
One of the key differences is that for adults lacking capacity informed consent is 
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given by the legal representative (rather than assent in the case of non-CTIMPs) and 
is considered to represent the subjects presumed will. The threshold for carrying out 
CTIMPs including Adults Lacking Capacity is higher than that for those with capacity 
and relies on several principles. The trial must relate directly to the condition with 
which the patient is suffering, there must be a clear expectation that the potential 
benefit of the IMP in question must outweigh any potential risks and the trial must be 
necessary to validate data already collected which could not be validated further 
without including such a population. Where possible the individual concerned should 
be involved as far as possible in the decision making process being provided with 
information appropriate to their level of capacity. In line with the guidelines for gaining 
consent in such circumstances the participants or their PerLR /Prof LR were informed 
that consent could be withdrawn at any time without prejudice. 
Once a participant’s capacity had been deemed to have returned retrospective 
consent was sought in all cases. Where consent to continue in the trial was not given 
the participant was withdrawn from the trial at that stage. The participant was then 
asked whether they gave consent for the data already collected to be used for the 
purposes of the research. 
 
2.7 Screening and recruitment 
 
2.7.1 Critically ill patients (ACS/DFS/RCT) 
Screening took place of all patients on each intensive care unit on a daily basis from 
Monday to Friday inclusive. Patients were eligible for participation in all phases of the 
study if they met the following criteria: 
To ensure patient safety in this proof of concept study a comprehensive list of 
exclusion criteria was put in place aiming to minimise the risk of any potential harm.  
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Table 7: Exclusion criteria for ACS, DFS and RCT  
Inclusion criteria 
• Fulfil the criteria for SIRS (see section 2.1.1) 
• Requires the support of 1 or more organ system (mechanical ventilation, inotropes, 
haemofiltration) 
• Predicted to require support for at least a further 48 hours (survival most likely 
outcome) 
• Admitted to ICU within last 48 hours. 
Exclusion criteria 
 
• Absence/refusal of informed consent 
• Current prescription of a colony stimulating factor 
• Any history of allergy/adverse reaction to GM-CSF 
• Total white cell count >20x109/litre at time of screening 
• Haemoglobin < 8.5g/dl at the time of screening 
• Age < 18 years 
• Pregnancy or lactation 
• Known in-born errors of neutrophil metabolism 
• Known haematological malignancy and/or known to have >10% peripheral blood 
blast cells   
• Known aplastic anaemia or pancytopenia 
• Platelet count <50x109/litre 
• History of cancer (unless curative resection / treatment performed) 
• Chemotherapy or radiotherapy within the last 24 hours 
• Solid organ or bone marrow transplantation 
• Use of maintenance immunosuppressive drugs other than maintenance 
corticosteroids (allowed up to 10mg prednisolone/day or equivalent) 
• Known HIV infection 
• Active connective tissue disease (e.g. rheumatoid disease, systemic lupus 
erythematosus) requiring active pharmacological treatment. 
• ST-segment elevation myocardial infarction, acute pericarditis (by ECG criteria) or 
pulmonary embolism (radiographically confirmed) in previous week 
• Involvement in any study involving an investigational medicinal product in the 
previous 30 days 
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If all inclusion criteria were met and there was no evidence to exclude participation, 
the patient and/or their family were approached by a member of the trial team and 
provided with a full verbal explanation of the study and a copy of the patient 
information sheet. The patient and/or their PerLR were then given time to consider 
the study and a member of the research team returned to answer any further 
questions. As discussed because of the time-dependent nature of the study patients 
or their legal representatives were given up to 24 hours to make a decision regarding 
consent but were asked to make a decision within 6 hours if they felt able. 
Signed consent was taken from the relevant individual and a copy of the consent 
form given to the patient / PerLR / ProfLR, filed in the patient’s notes and stored in 
the site file. In the event that the patient recovered capacity the law states that the 
consent given by the legal representative stands but the patient should be consulted 
and their views respected. Retrospective consent was sought from all patients who 
regained capacity during the course of the study. 
 
2.7.2 Healthy volunteers (ACS only) 
Healthy volunteers were recruited from the university staff and student population. 
Healthy volunteers, 18 years of age and older, were invited to participate via posters 
displayed on university noticeboards and via email within our research institute. 
Healthy volunteers responding to the information were provided with a participant 
information sheet outlining the purpose of the study, the risks and benefits of taking 
part, the exclusion criteria and the procedure for collection of their blood sample. 
Healthy volunteers were excluded from participation if any of the following 
circumstances existed 
I. the volunteer had donated blood in the previous 90 days (either to the Blood 
Transfusion Service or to any research study) 
II. the volunteer had donated more than 1 litre of blood in total over the previous 
12 months 
III. the volunteer had been anaemic at any time in the last 12 months 
IV. the volunteer was on any regular medication (oral contraceptive pill was 
permissible in female patients) 
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Once a healthy volunteer had been deemed eligible to participate, and had been 
given ample opportunity to read and consider the patient information sheet, written 
consent was obtained. 
Following donation of the blood sample each volunteer was offered a £5 book token 
in recognition of the time taken and inconvenience experienced in participating in the 
study. 
 
2.8 Assessment of baseline phagocytic capacity (DFS/RCT) 
As the final assessment of eligibility for participation in both the DFS and RCT blood 
was drawn for baseline assessment of neutrophil phagocytic capacity. If the 
neutrophil phagocytic capacity, as measured by the percentage of isolated 
neutrophils ingesting 2 or more zymosan particles ex-vivo, was less than 50% the 
patient continued in the study. If the patient demonstrated adequate phagocytic 
capacity (phagocytosis ≥50%) they were excluded from the study at this stage. 
 
2.9 Randomisation (RCT) 
Following assessment of the neutrophil phagocytic capacity those patients with 
neutrophil phagocytic capacity <50% were to be randomised in a double-blind 
fashion to receive either IMP (GM-CSF) or placebo. A member of the study team with 
delegated responsibility for randomisation entered the patient’s initials, date of birth 
and site into an online randomisation system managed by the Newcastle Clinical 
Trials Unit. The site was password protected and accessible only to designated 
members of the clinical trial team. Randomisation was performed in a 1:1 ratio. An 
independent statistician was responsible for determining the randomisation allocation 
schedule. The allocation schedule was stratified by site and designed to contain 
permuted blocks of variable length in order to minimise the risk of breach of 
concealment. The randomisation schedules were held within the clinical trials 
pharmacy at each site.  
Following generation of the participant randomisation number via the online 
programme a prescription including the randomisation treatment number was 
completed by a member of the trial team and delivered to the clinical trials pharmacy 
from where the IMP/placebo was issued.  
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2.10 Blinding (RCT) 
The DFS was designed to be run as an open label study with all participants 
receiving the IMP (GM-CSF). Participants, researchers and the usual clinical team 
were all aware of the prescription and participation in the DFS at all times.  
The RCT was designed to be run as a double blinded study with the participants, 
researchers and usual clinical team intended to be blinded to allocation at all times. 
Laboratory measures were completed by clinical and laboratory staff who were fully 
blinded and had no access to allocation information at any time. All study results, 
including laboratory outcomes and clinical outcomes, were presented to the 
independent statistical team in a blinded manner and treatment allocation was not 
revealed until after the independent statistical team had completed their analysis of 
all of the data. 
During the course of the study a protocol was in place for the mechanism by which to 
unblind the clinical and/or research team should the need arise.  
Several technical and logistical aspects of the trial mandated that the reconstitution 
and administration of the IMP was required to be an unblinded task. Members of the 
research nursing team were specifically trained to complete this. The following 
factors contributed to the need for this: 
i) The cost of a pre-manufactured, matched placebo was prohibitively expensive 
(i.e. outside the funding envelope in the grant). Therefore, normal saline was 
used as placebo on the basis that at the point of administration, normal saline 
and GM-CSF were identical in appearance (a clear, colourless liquid). 
 
ii) Due to its short shelf life once reconstituted (6 hours), the drug could not be 
prepared by the clinical trial pharmacy, as no staff were available at 
weekends. It was therefore necessary for it to be prepared by research nurses 
just prior to administration. 
 
iii) Due to limited resources and budget for staff costs, and the need to be able to 
deliver the IMP seven days a week at short notice, it was not possible to 
recruit a separate unblinded team of research nurses from the local clinical 
research network. 
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The only personnel to be unblinded at any stage in the course of the RCT were the 
research nursing staff involved in the reconstitution and administration of the study 
drug. All other clinical and research staff, the patient and their relatives remained fully 
blinded to the treatment allocation at all times. 
 
2.11 Investigational medicinal product (DFS / RCT) 
The investigational medicinal product (IMP) used in the DFS and RCT was 
Sargramostim (Leukine, recombinant human GM-CSF). Recombinant GM-CSF is 
clinically available in 2 forms; as a glycosylated compound derived from a yeast-
based system and as a non-glycosylated compound prepared in an E. coli-based 
system. The two compounds have broadly comparable clinical effects. However, the 
yeast-derived product has been shown to demonstrate a superior safety profile and it 
was on this basis that it was selected for use in the DFS and RCT. 
 
2.11.1 Sourcing of IMP (DFS / RCT) 
Sargramostim is owned by Genzyme (a subsidiary of Sanofi-Aventis). It has been 
approved by the FDA and is widely used for the restoration of myeloid cell 
populations in cancer patients following chemotherapy or bone marrow transplant. In 
addition to stimulating myeloid cell recovery it has a role in reducing the risk of 
serious infection in such patients. 
It is manufactured in the US to GMP requirements using recombinant DNA 
technology in a Saccharomyces cerevisiae-based system. It is marketed under the 
trade name Leucine.  
As the drug is not licensed in the EU a Qualified Persons Certificate was provided by 
the drug importing company (Mawdsley Brooks and Co., Quest 22, Quest Park, 
Doncaster), confirming that the drug had been manufactured to GMP standards. In 
addition, an Importer’s Marketing Authorisation was supplied as required by the 
MHRA. 
The drug was labelled by Mawdsley Brooks and Co. in compliance with the Annex 13 
Guidelines regarding investigational medicinal products for use in clinical trials 
(European Commission, 2010). 
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2.11.2 Storage of IMP (DFS / RCT) 
Stocks of IMP/placebo were stored in the clinical trial pharmacy at each participating 
site according to the manufacturer’s instructions. Following issue of the IMP/placebo, 
to a research nurse with designated responsibility for the unblinded reconstitution 
and administration of the study drug, it was transported in a black bag contained 
within a sealed container to the locked fridge at the ICU site. The IMP /placebo was 
stored between 2-8° C in a fridge with alarmed continuous temperature monitoring. 
The fridge was locked at all times and only accessible to members of the research 
nursing team with responsibility for administration of the IMP.  
 
2.11.3 Reconstitution of IMP (DFS / RCT) 
During the DFS GM-CSF was reconstituted in an open-label, unblinded fashion with 
members of both the usual clinical nursing team and the research nursing team being 
involved in this task. 
During the RCT reconstitution of the IMP/drawing up of placebo was performed by 2 
trained, unblinded members of the research nursing team within a locked location 
away from the patient’s bedside and out of sight of all blinded members of the 
research team and the usual clinical care team. Sargramostim (GM-CSF) was 
presented as a white lyophilized powder for reconstitution. Each vial of Sargramostim 
contained 250µg of GM-CSF and was reconstituted with 1ml of sterile water. The 
IMP/placebo was reconstituted to a final volume, calculated according to weight in 
weight ranges to the nearest 5kg. The clear, colourless liquids were indistinguishable 
and unidentifiable as IMP or placebo at the point of administration to ensure 
maintenance of blinding. The syringe containing IMP/placebo was labelled with the 
patient’s name, date of birth and study number and the final volume of IMP/placebo 
before being taken to the bedside. In all circumstances, once reconstituted the drug 
was required to be used within 6 hours. 
 
2.11.4 Administration of the IMP / placebo (DFS / RCT) 
During the DFS, following reconstitution, GM-CSF was administered in an open-
label, unblinded fashion with members of both the usual clinical nursing team and the 
research nursing team being involved in this task. 
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During the RCT, following reconstitution, the IMP/placebo was administered by an 
unblinded member of the research nursing team.  
Both the IMP and placebo were administered by subcutaneous injection using sterile 
technique. The patient’s skin was cleaned with an alcohol swab and allowed to dry 
prior to administration of the subcutaneous injection. In order to minimise risk of 
discomfort to the patient the injection was allowed to come to room temperature prior 
to administration. In addition, the injection site was rotated on a daily basis and the 
injection was administered slowly (over 30-60seconds) using a 25G needle. The 
volume of IMP/placebo, date and time of injection and injection site were recorded in 
the patient notes and in the CRF. 
 
2.11.5 Study drug termination criteria (DFS / RCT) 
During the DFS and RCT the study drug was continued until any one of the pre-
determined study drug termination criteria was met: 
• maximum treatment period (for the RCT this was to be defined following the 
DFS) 
• study drug-related serious adverse reaction (SAR) 
• discharge from a critical care environment 
• death 
• discontinuation of active medical treatment 
• the patient, PerLR or ProfLR requests withdrawal from the study 
• decision by the attending clinician that the study drug should be discontinued 
on safety grounds. 
 
In order to minimise the risk of harm to participants related to the potential effect of 
GM-CSF in expanding the myeloid cell population consideration would be given to to 
either discontinuing the study drug or reducing the dose by half in the following 
circumstances: 
• WCC > 50,000 cells/mm3 
• Platelet count > 500,000 cells/mm3 
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2.11.6 Drug accountability (DFS / RCT) 
On completion of the prescribed dosing schedule for the IMP/placebo all empty, used 
vials and any unused vials were returned to the Clinical Trials Pharmacy along with 
the reconstitution log.  
During the RCT, vials and reconstitution logs were returned to pharmacy inside a 
black plastic bag contained within a box by an unblinded member of the research 
team. Each vial and the black plastic bag was marked with the patient’s study 
number. At the end of the study unallocated and unused study drug was destroyed, 
with permission from the Sponsor, in accordance with the site pharmacy procedure 
for the destruction of IMP. 
 
2.12 Blood sample collection (ACS / DFS / RCT) 
2.12.1 Healthy volunteers (ACS only) 
During the ACS all healthy volunteer blood samples were collected at approximately 
8 am on the day of study and always between 8 am and 10 am to match the timing of 
collection of the critically ill patient blood samples. Each blood sample was taken with 
the volunteer seated in a reclining chair to minimise the risk of fainting either during 
or after the procedure. 30mls of blood was collected for participation in the ACS. 
Following collection of the blood sample the volunteer was asked to rest and given a 
drink of water or fruit juice along with some biscuits or chocolate. This was in line with 
procedure followed by the blood transfusion service. 
 
2.12.2 Critically ill patients (ACS / DFS / RCT) 
Blood samples from critically ill patients were collected each morning at 
approximately 8am. A 2-hour time window existed either side of 8 am during which 
blood samples could be collected depending on the availability of research staff and 
the logistics surrounding transport of the samples to the research laboratory in 
Newcastle University. The reason for unifying the timing of collection of the daily 
blood samples was that there is evidence in both mice and humans to show that 
diurnal variation in neutrophil function, including phagocytic capacity exists (Shiraishi 
et al., 1996, Knyszynski et al., 1981). Where possible all blood samples were 
collected from an indwelling line (arterial line or central venous catheter) to minimise 
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discomfort to the patient. All blood samples were collected using sterile technique. 
Following collection blood was placed in a 50ml Falcon tube (Beckton Dickinson 
Biosciences) for isolation of neutrophils, with 5mls placed in an 
Ethylenediaminetetraacetic acid (EDTA) tube for flow cytometric analysis and 5 mls 
placed in a serum gel tube for preparation of autologous serum. The samples were 
then transported immediately to the laboratory at Newcastle University for analysis. 
The EDTA tube was stored at 4°C until analysis. 
Where no indwelling line was present blood was drawn by venesection from a 
peripheral vein using aseptic technique. 
During both the DFS and the RCT blood samples were collected for safety analysis 
on a daily basis as part of usual clinical care. These samples were collected by the 
usual nursing care team and analysed in the hospital laboratory at each site. 
 
2.12.2 Blood sample collection schedule 
The table below outlines the blood sample collection schedule for each phase of the 
study. 
 
Phase of study D0 D1 D2 D3 D4 D5 D6 D7 D8 D9 
ACS X          
DFS X X X X X X X X X X 
RCT X  X  X*  X*  X*  
 
Table 8: Blood sample collection schedule.  * During the RCT blood samples were 
collected on day 4 or 5, day 6 or 7 and day 8 or 9 depending on availability of research 
laboratory staff. 
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2.13 Safety, Pharmacovigilance and Trial Oversight (DFS and RCT) 
 
2.13.1 Data Monitoring and Safety Committee 
The trial was run in accordance with Good Clinical Practice guidelines. A Data 
Monitoring and Safety committee was established consisting of 3 independent 
Intensive Care Clinicians, 1 independent Haematologist and an independent 
Statistician all of whom had experience of clinical trials. The Data Monitoring and 
Safety Committee met once prior to the commencement of the DFS. Data were 
communicated by email during the DFS following the completion of the first and third 
patient for review by the DMSC prior to the subsequent patients being enrolled. 
Screening and recruitment were put on hold following the first and third patient until 
the data had been reviewed and the committee were satisfied that it was safe to 
proceed with the study. Subsequently the DMSC met via teleconference at 3-6 
monthly intervals during the active phases of the DFS and RCT. During the DFS all 
data was presented in an unblinded fashion. During the RCT blinded and, if 
requested by the DMSC, unblinded data (prepared by independent statisticians), 
including adverse events, were presented to the committee at each meeting during 
open and closed sessions respectively. At each time point the DMSC gave 
permission for recruitment to continue following review of the available data. 
 
2.13.2 Safety bloods 
During the DFS and the RCT safety bloods were collected and analysed for 
alterations in full blood count (FBC), urea and electrolytes (U&Es) and liver function 
tests over the 10-day study period. These results were reviewed by the trial study 
team and appropriate action taken where necessary. 
 
2.13.3 Adverse event reporting 
Adverse events were defined as ‘any untoward medical occurrence in a patient or 
clinical trial subject administered a medicinal product and which does not necessarily 
have a causal relationship with this treatment.’ (Trial protocol Appendix A). 
Serious adverse events were defined as ‘any adverse event, adverse reaction or 
unexpected adverse reaction that: a)results in death ; b)is life-threatening (i.e. the 
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subject was at risk of death at the time of the event; it does not refer to an event 
which might have caused death if it were more severe); c)requires hospitalisation or 
prolongation of existing hospitalisation; d)results in persistent or significant disability 
or incapacity; e)is a congenital anomaly or birth defect; f)is any other important 
medical event(s) that carries a real, not hypothetical, risk of one of the above 
outcomes’ (Trial Protocol, Appendix A). 
An adverse reaction was defined as any adverse event which was thought to be 
related to administration of the study drug. Several more common adverse reactions 
that are recognised to occur with the administration of GM-CSF were recorded on a 
daily basis in the adverse event (AE) form contained within the e-CRF. These 
included: 
• Skin reaction at the site of injection 
• Fever up to 38°C 
• Elevated white cell count > 50,000 cells/mm3 
• bone pain 
• myalgia 
• first dose syndrome 
 
In view of the nature of the study population it was recognised that the likelihood of 
participants to undergo an adverse event during the study period, as part of their 
underlying critical illness, was high. Therefore, it was agreed and stated within the 
trial protocol that any adverse events that were in keeping with the participant’s 
underlying critical illness were not reported as adverse events. All adverse events 
thought possibly, probably or likely to be related to the study drug were reported and 
recorded in the adverse event log contained in the CRF. 
Because the study was recruiting many patients who had life-threatening conditions it 
was also expected that patients may suffer serious adverse events related to their 
underlying critical illness. Therefore, serious adverse events in keeping with the 
underlying clinical course, and collected as outcomes in the study data e.g. death 
and organ dysfunction, were not reported as serious adverse events. Any serious 
adverse events thought possibly, probably or likely to be related to the study drug 
were recorded as such on the SAE notification forms and faxed to the Newcastle 
Clinical Trials Unit within 24 hours of the event being recognised. In particular, any 
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AEs /SAEs occurring within 1 hour of the study drug administration were 
recommended to be considered as being related. Responsibility for the reporting of 
AEs lay with the PI at each site. Assessment of causality and expectedness was 
carried out by the PI or their nominated designated person. Where any doubt existed 
the PI was required to discuss with the chief investigator who may elect to refer on to 
the DMSC for further assessment. 
The Newcastle Clinical Trials Unit was responsible for onward reporting of any 
suspected, unexpected serious adverse reactions (SUSARs) to the relevant 
regulatory authorities and the trial sponsor within the required timeframe. Reporting 
of all SUSARs to the DMSC in a timely manner was also stipulated. 
 
2.14 Data Collection (all studies) 
For the observational Assay Confirmation Study and open-label DFS data were 
collected on a paper case report form by members of the trial team. CRFs were 
stored in a locked cupboard within each trial site and underwent monitoring by a 
member of the Newcastle CTU at regular intervals.  
For the RCT an electronic case report form (e-CRF) was developed which was 
password protected and accessible only to designated members of the trial team. 
Clinical data collected included patient demographic details, reason for admission to 
ICU, regular clinical observations, length of stay, selected drug data, SOFA score 
and incidence of suspected ICUAIs. All clinical data were collected from source data 
(the ICU observation charts and clinical notes) completed by the usual clinical care 
team.  
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2.15 Laboratory Materials  
The following laboratory materials were used to carry out laboratory procedures 
within the three phases of the study. Materials and reagents are listed alphabetically 
with the supplier and catalogue number in brackets afterwards. Antibodies are listed 
according to the cellular property of interest with supplier and catalogue number in 
brackets afterwards. 
 
2.15.1 Plastics 
The following plastics were supplied by Beckton Dickinson (BD) Biosciences (Oxford, 
U.K.): 50ml polypropylene conical Falcon tubes (352070), 15ml polypropylene 
conical Falcon tube (352096), EDTA coated 3ml blood tubes (367835), Rapid serum 
gel tubes (368774). 
The following plastics were supplied by Greiner Bio-one Limited (Stonehouse, 
Gloucestershire, U.K.): 50ml polypropylene conical tubes (227261), 15ml 
polypropylene conical tubes (188271), 5ml serological pipettes (606180), 10ml 
serological pipettes (607180), 96 well sterile flat bottomed microplates (655101). 
The following plastics were supplied by Fisher Scientific (Loughborough, 
Leicestershire, U.K.): 0.5ml Eppendorf tubes (FB74023), 1.5ml Eppendorf tubes 
(FB74031), 2ml Eppendorf tubes (FB74111). 
The following plastics were supplied by Starlab U.K. Limited (Milton Keynes, U.K.): 
3ml graduated Pasteur pipettes (E1414-0311) ,1000µl pipette tips (S1111-2721), 
200µl pipette tips (S1111-1700), 0.1-10µl natural pipette tips (S1111-3700). 
The following plastics were supplied by Scientific Laboratory Supplies Limited 
(Nottingham, U.K.): 24-well multiwell plate with lid (sterile) (S3526) 
2.15.2 Glassware 
The following glassware was supplied by Sigma-Aldrich (Billingham, Dorset, U.K.): 
Corning microscope slides (CLS294875x25-1440E). 
The following glassware was supplied by VWR (Pennsylvania, U.S.) microscope 
cover slips (631-0150). 
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2.15.3 Reagents 
The following reagents were supplied by Sigma-Aldrich (Billingham, Dorset, U.K.): 
Agarose 2%, high resolution (A4718), Albumin from bovine serum ( A7906), Calcium 
chloride solution (Ca Cl2) (21114), Citrate concentrated solution, sodium citrate 3.8% 
(S5770), Cytochrome C (C2037), Dulbecco’s phosphate buffered solution 10x 
(without Ca2+/Mg2+) (D1408), Dulbecco’s phosphate buffered solution 1x (without 
Ca2+/Mg2+) (D8537),  fMLF (N-formyl methinyl leucyl phenylalanine) (47729), Gelatin 
2% solution (G1393), Giemsa (48900), Hank’s balanced salt solution with Ca2+/Mg2+, 
HBBS+ (55037), Hank’s balanced salt solution without Ca2+/Mg2+, HBSS- (H6648), 
Methanol (179957), Paraformaldehyde (P6148), Platelet activating factor, PAF 
(P260), Superoxide dismutase (S5395), Sodium chloride solution (0.9%), NaCl 
(S5886), Trypan blue (T6146),Tween 20 (P1379), Zymosan A from Saccharomyces 
cerevisiae (Z4250). 
The following reagents were supplied by Pharmacosmos (Holbaek, Denmark): 
Dextran T500, 6% (5510050090070). 
The following reagents were supplied by Invitrogen (Paisley, U.K.): Iscove’s modified 
dulbecco’s medium, IMDM (21980065). 
The following reagents were supplied by GE Healthcare Lifescience (Little 
Charlefont, Buckingham, U.K.): Percoll Plus (GZ17544501). 
The following reagents were supplied by BD Biosciences (Oxford, U.K.): Pharmlyse 
(10x concentrate) (555899). 
 
2.15.4 Antibodies 
The following antibodies were used to carry out laboratory procedures as 
documented. Suppliers and catalogue numbers appear in brackets. 
 
2.15.4.1 Neutrophil CD88 expression 
PE Rabbit anti-human CD88 (BD Biosciences, 552993) 
PE Rabbit IgG isotype control (R&D Systems, ICI05P) 
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2.15.4.2 Monocyte HLA-DR expression 
QuantiBRITETM PE, Phycoerythrin Fluorescence Quantitation Kit (BD Biosciences, 
340495) 
QuantiBRITETM anti-HLA-DR PE, clone L243 / anti-monocyte PerCP-Cy5.5, clone 
MØP9 (BD Biosciences, 340827) 
 
2.15.4.3 T lymphocyte population studies 
Alexa Fluor 488 anti-human CD127 (IL-7Ra), Clone A019D5, isotype mouse IgG1, k, 
(Biolegend, 351314)  
APC Mouse anti-human CD4, Clone RPA-T4, isotype mouse IgG1, k, ( BD 
Biosciences 555349) 
Brilliant Violet 421 anti-human CD25, Clone M-A251, isotype mouse IgG1,k, (BD 
Biosciences, 562442) 
PE anti-human CD3, Clone SK7, isotype IgG1, k,  (Biolegend, 344806) 
PE-CyTM7 Mouse anti-human CD45RA, Clone HI100, isotype mouse IgG2b, k, ( BD 
Biosciences 560675) 
PerCP anti-human CD45RO, Clone UCHL1, isotype mouse IgG2a (Miltenyi Biotec, 
130-095-451) 
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2.15.4.4 Analysis of Neutrophil Apoptosis 
APC Annexin V (Biolegend, 640920) 
Propidium iodide solution (Biolegend, 421301) 
Annexin V binding buffer solution (Biolegend, 422201) 
 
2.15.4.5 Analysis of serum GM-CSF concentration 
Human GM-CSF ELISA kit (BD Biosciences, 555126) 
 
2.16 Laboratory Procedures  
 
2.16.1 Isolation of neutrophils from whole blood (ACS / DFS / RCT) 
Neutrophils were isolated from whole blood by dextran sedimentation and percoll 
gradient separation. Samples were collected in a 50 ml Falcon tube containing 1ml 
sodium citrate 4% /10mls blood. When samples arrived in the laboratory whole blood 
was centrifuged at 300g with no brake for 20mins at room temperature.  
Following centrifugation the plasma was transferred to a glass vial and placed in a 
water bath at 37°C with calcium chloride (CaCl2, 220µl per 10ml plasma). Warmed, 
filtered dextran was added to the remaining cell pellet at a volume of 2.5mls per 
10mls of cell pellet. This suspension was then made up to the original blood volume 
with warmed 0.9% saline. The Falcon tube was inverted gently to ensure the 
suspension was fully mixed. The lid was loosened and the suspension left to stand at 
room temperature for 30 minutes to allow sedimentation.  
After 30 minutes the leucocyte rich upper layer was aspirated and transferred to a 
new Falcon tube where it was made up to 50mls with warmed saline and centrifuged 
at 200g for 5 minutes at room temperature.  
Following centrifugation, the supernatant was discarded and the cell pellet was re-
suspended in 2.5mls of 55% Percoll and layered on a 70%/81% Percoll gradient. The 
gradient was centrifuged at 700g with zero brake for 20 minutes at room 
temperature, to allow separation of the cells.  
	 68	
After centrifugation the neutrophils were collected from the 70/81% interface and 
transferred to a new Falcon tube (Figure 2d). The cells were then washed in Hanks 
Balanced Salt Solution without calcium and magnesium (HBSS-) and centrifuged at 
200g with zero brake for 5 minutes at room temperature.  
 
 
 
Figure 2d: Cell populations within percoll gradient ready for harvesting 
 
 
2.16.2 Cell count (ACS / DFS / RCT) 
Following isolation 100µl of suspended neutrophils were mixed with 5µl of trypan blue 
and placed in the chamber of a haemocytometer to perform a cell count using light 
microscopy. Using the known dilution factor the total number of isolated neutrophils 
was calculated for each sample.  
 
  
Monocyte layer 
 
Neutrophil layer 
 
Red cell pellet 
	 69	
2.16.3 Assessment of neutrophil phagocytic capacity (ACS / DFS / RCT) 
The cells were re-washed (200g for 5 minutes, room temperature) and re-suspended 
in Iscove’s Modified Dulbecco’s Medium (IMDM) at a concentration of 1million 
cells/ml. 500ul of neutrophil suspension was pipetted into 4 wells of a 24 well plate. 
The cells were incubated for 30 minutes with 1% autologous serum at 37°C in a 5% 
CO2 incubator. Zymosan was opsonised in autologous serum at 37°C in a water bath 
for 30 minutes. After opsonisation the zymosan was washed twice in IMDM at 
10,000g for 1 minute at room temperature and re-suspended in 100µl of IMDM. 
0.02mg of zymosan was added to the neutrophils in 3 of the 4 wells. The plate was 
then incubated for a further 30 minutes at 37°C in a 5% CO2. After incubation was 
completed the wells were washed 3 times with Phosphate Buffered Saline (PBS), 
fixed with methanol (200µl per well) and stained with Giemsa 1:10 for 15 minutes. 
Finally, the cells were washed with deionised water until aspirating clear and allowed 
to air dry. 
Using light microscopy, the number of neutrophils containing 2 or more zymosan 
particles were then counted and expressed as a percentage of the total number of 
neutrophils assessed. Four fields of 100 cells / field were counted in each well.  
 
 
 
Figure 2e: Assessing neutrophil phagocytic capacity by light microscopy. the number 
of neutrophils containing 2 or more zymosan particles were then counted (four fields of 100 
cells per well) and expressed as a percentage of the total number of neutrophils assessed.  
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2.16.4 Assessment of neutrophil CD88 expression (ACS/ DFS / RCT) 
Flow cytometry was used to assess neutrophil CD88 expression in all patients. 
Whole blood was collected in EDTA as described and stored at 4°C until analysis. 
50ul of blood was placed in each of three 1.5ml Eppendorf tubes (a, b and c). The 
blood was then incubated unstained (a), with 30µl PE rabbit IgG isotype control (b) or 
with 15µl PE Rabbit anti-human CD88 (c) for 30mins at 4°C in the dark. Following 
incubation 1.4ml of 1x Pharmlyse solution (10x Pharmlyse solution was diluted with 
de-ionised water pH 7.3) was added to each Eppendorf tube, which was then 
vortexed, and placed in the dark for 20 minutes at room temperature to allow red cell 
lysis to take place. Following lysis, the samples were transferred to labelled FACS 
tubes and washed 3 times in a FACS wash machine before being analysed. Analysis 
was performed by flow cytometry on FACS Canto. Neutrophils were identified by 
forward scatter and side scatter and gated accordingly. Mean, median and geometric 
mean fluorescence were recorded for CD88. 
 
     A 
 
    B             C 
Figure 2f: Assessing neutrophil surface CD88 expression by flow cytometry.  
A) Neutrophils were identified and distinguished from monocytes and lymphocytes by 
forward scatter (FSC-A) and side scatter (SSC-A) characteristics and gated accordingly (P1). 
Neutrophil CD88 PE expression isotype control sample (B) and stained neutrophils (C). 
Example flow scatter plot shown from subject A04.
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2.16.5 Assessment of monocyte HLA-DR expression (ACS / DFS / RCT) 
Monocyte HLA-DR expression (antibodies bound per cell (Ab/cell) was calculated by 
flow cytometry using QuantiBRITETM Anti-HLA-DR PE/ Anti-monocyte PerCP-Cy5.5 
QuantiBRITETM PE Fluoresecence Quantitation Kit (BD Biosciences).  
Prior to sampling fluorescence quantitation was performed using the QuantiBRITETM 
Phycoerythrin Fluorescence Quantitation Kit. Kits were stored at 4°C. The lyophilised 
pellet of beads conjugated with four levels of lot-specific PE was reconstituted with 
500µl flow buffer (PBS + 0.2% BSA) and vortexed. The tube was run on a FACS 
Canto machine and bead singlets identified and gated using forward scatter and side 
scatter. 10,000 events were collected. The 4 bead peaks were selected on a 
histogram plot and the geometric means displayed. The lot-specific values for PE 
molecules per bead were plotted against the recorded GMFs to calculate the 
correlation co-efficient to be applied to calculate a sample’s ABC. 
Whole blood was collected in EDTA as described and kept at 4°C until analysis 
commenced. 50µl of blood was placed into a 1.5ml Eppendorf tube and 20µl of 
QuantiBRITETM PE solution added. The blood was then vortexed. The test Eppendorf 
and matched control were placed in the dark at room temperature for 30mins until 
incubation was complete. Following incubation cells were lysed with 1.4ml Pharmlyse 
solution in the dark for 20 minutes. Cells were then transferred to FACS tubes and 
washed 3 times in the FACS wash machine prior to analysis. 
Monocytes were identified initially by side scatter and forward scatter characteristics 
and then by PerCP-Cy5.5 (CD14 / CD64) positivity to ensure detection of all 
monocytes (both CD14 high and CD14 low). Once the monocyte population had 
been identified the HLA-DR geometric mean fluorescence was recorded and the 
antibodies per cell calculated using the correlation co-efficient determined during the 
quantitation analysis. Analysis was performed by flow cytometry on FACS Canto. 
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        A        B 
 
        C          D 
Figure 2g: Assessment of monocyte HLA-DR expression by flow cytometry. Monocytes 
were gated by forward scatter, side scatter and CD14+CD64+ characteristics and gated 
accordingly (A+B). mHLA-DR expression was assessed by measurement of geometric mean 
fluorescence and the number of antibodies per cell calculated using the correlation co-
efficient determined during the quantitation analysis. 
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2.16.6 Measurement of superoxide anion release by neutrophils (RCT only) 
Measurement of superoxide release by neutrophils was determined by the 
calculating the amount of superoxide dismutase-inhibitable reduction of cytochrome 
C. Isolated neutrophils were re-suspended in HBSS containing calcium and 
magnesium (HBSS+) at a concentration of 10 million cells /ml. 50µl of the cell 
suspension (500,000 cells) were placed in each of 8 labelled Eppendorf tubes as 
outlined in table 9. 
Cells were primed (P) with 0.5µl PAF (100nM) or unprimed (H) and incubated with an 
equivalent volume of HBSS+. Incubation took place in a shaking water bath at 37°C 
for 10 minutes. 
Following priming cells were either stimulated (F) with formyl methionine leucine 
phenylalanine fMLF (50µl, 100nM end concentration) or made up to the equivalent 
volume with HBSS+ control (50µl). 25µl of superoxide dismutase (S) was added to 
four of the Eppendorf tubes with an equivalent volume of HBSS+ being added to the 
other four tubes as a control. Finally, 375µl of cytochrome C (1mg/ml end 
concentration) was added to each of the eight Eppendorf tubes. The cells were again 
incubated in a shaking water bath for 10-15 minutes at 37°C. 
 
Eppendorf Priming agent Stimulation Superoxide 
dismutase 
H None None No 
HS None None Yes 
HF None fMLF No 
HFS None fMLF Yes 
P PAF None No 
PS PAF None Yes 
PF PAF fMLF No 
PFS PAF fMLF Yes 
 
Table 9: Measurement of superoxide anion release in neutrophils. PAF, platelet 
activating factor; fMLF, formyl methionine leucine phenylalanine. 
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Following incubation, the reaction was stopped by placing the cells on ice for 5 
minutes. The cell suspensions were then centrifuged at 10,000g for 3 minutes at 4°C 
and the supernatants transferred into a 96 well plate (100µl/well). The plate was read 
as soon as possible at 550nm using a plate reader. The generation of O2- was 
determined by the amount of superoxide dismutase-inhibitable reduction of 
cytochrome c which occurred. Results were expressed as nanomoles of superoxide 
generated per 106 neutrophils (nmol/106 neuts). 
 
2.16.7 Assessment of neutrophil chemotaxis (RCT only) 
Neutrophil chemotaxis was assessed by the under agarose method (Nelson et al., 
1975). In advance glass microscope slides were cleaned with ethanol and dried with 
lens cleaning tissue. The slides were dipped in gelatine solution and allowed to dry. 
Agarose medium was prepared by combining 2ml of 25% Bovine Serum Albumin 
(BSA) with 6.25ml of 2% gelatine and 25ml of 2% agarose. The medium was made 
up to 50 ml with IMDM. Using a pipette, 5ml of the agarose medium was slowly 
applied to the surface of each coated slide ensuring that no bubbles appeared within 
the medium. The slides were left to set overnight. Once prepared the slides were 
stored at 4°C and used within 48 hours. 
Immediately prior to use a template was used to cut 3 wells into each side of the 
slide. The central plug of agarose was gently aspirated from each well using a 
vacuum pump taking care not to damage the integrity of the well. 
Freshly isolated neutrophils were re-suspended at 25x106/ml in IMDM containing 1% 
autologous serum. 
10µl of the neutrophil suspension (250,000 cells) were placed in each central well. 
The chemoattractant (fMLF100nM) was placed in one adjacent well and IMDM alone 
(as a control) in the other adjacent well. This was duplicated on each slide.  
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Figure 2h: Assessment of neutrophil chemotaxis by under agarose method. 
 
The slides were incubated at 37°C in a 5% CO2 incubator for 2 hours. Following 
incubation, the slides were fixed in 2.5% paraformaldehyde overnight before being 
rinsed in deionised water, allowed to air dry and stained with Giemsa solution. 
The chemotaxis migration distance (µm) was measured using computer image 
analysis. The mean neutrophil chemotaxis migration distance was measured by 
subtracting the distance between the origin of the cells and the leading edge of cells 
migrating towards the IMDM control (i.e. random migration) from the distance 
between the origin of the cells and the leading edge of the cells migrating towards the 
fMLF chemoattractant.  
 
 
Figure 2i: Assessment of neutrophil migration distance by computer imaging analysis.  
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2.16.8 Assessment of neutrophil apoptosis (RCT only) 
Neutrophil apoptosis was assessed by flow cytometry. 
Isolated neutrophils were re-suspended in HBSS- at 10x106/ml. 100µl of cells (1 
million cells) were placed into each of 2 Eppendorf tubes (one for control(a) and one 
for stained cells(b)). Both Eppendorf tubes were centrifuged at 300g for 3 minutes at 
room temperature. The supernatants were removed and each of the cell pellets was 
re-suspended in 100µl of Annexin V buffer (pre-diluted 1:10). 5µl of Annexin V 
allophycocyanin (APC) was added to the test sample (b). The Eppendorf tubes were 
incubated in the dark at room temperature for 10 minutes. After 10 minutes 1µl of 
propidium iodide (PI) was added to the test sample (b). Both Eppendorf tubes were 
topped up with 200µl Annexin V buffer and incubated for a further 10 minutes in the 
dark. The cells were then manually washed and re-suspended in 200µl Annexin V 
buffer before being analysed. 
The samples were analysed by flow cytometry on a FACS Canto machine. Early 
apoptosis was identified in those cells staining positive for Annexin V but negative for 
PI. Late apoptosis was identified in those cells staining positive for both Annexin V 
and PI.  
 
Figure 2j: Assessment of neutrophil apoptosis by flow cytometry.  Early apoptosis was 
identified in cells staining positively for Annexin V APC (635 660/20-A) and negatively for 
propidium iodide (488 585/42-A) – Q4. While late apoptosis was identified in cells staining 
positively for both Annexin V APC (635 660/20-A) and propidium iodide (488 585/42-A) – Q2  
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2.16.9 Assessment of regulatory T cell proportions (RCT only) 
 
The regulatory T cell population was identified by flow cytometry. Whole blood was 
collected in EDTA as described and kept at 4°C until analysis commenced. 50ul of 
blood was placed into four 1.5ml Eppendorf tubes and a panel of antibodies was 
applied to enable identification of the total T lymphocyte population and the subset of 
regulatory T cells (Tregs) including differentiation of the memory and naïve fractions 
of the Treg population. An unstained sample acted as a control for these studies. 
Antibody staining took place as described in Table10. 
 
Cells of interest Antibodies 
T lymphocytes CD3, CD4, CD25,  CD127, CD45RO, 
CD45RA 
Memory Tregs T lymphocyte panel minus CD45 RA 
Naïve Tregs T lymphocyte panel minus CD45 RO 
 
Table 10: Fluorochrome labelled antibodies used for assessment of regulatory T cell 
proportions. Treg, regulatory T cells. 
 
Following addition of the antibodies the Eppendorf tubes were incubated at 4°C in the 
dark for 30 minutes. On completion of the incubation period 1.4mls of Pharmlyse was 
added to each Eppendorf. The Eppendorfs were then vortexed, and placed in the 
dark for 20 minutes at room temperature to allow red cell lysis to take place. 
Following lysis, the samples were transferred to labelled FACS tubes and washed 3 
times in a FACS wash machine before being analysed. CD4+ T lymphocytes were 
identified by gating on CD3 and CD4 positive cells. Regulatory T cells were identified 
as those which were CD25+ and CD127 low within the T cell population. The 
percentage of Tregs as a proportion of the total T cell population was calculated. 
Memory T cells were identified as those which were CD3+CD4+CD25+CD127low 
CD45RO+CD45RA- while naïve T cells were CD3+CD4+CD25+CD127low 
CD45RA+CD45RO-. 
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2.16.10 Serum measurement of GM-CSF concentration (DFS only) 
Serum GM-CSF concentration was measured by ELISA using a Human GM-CSF 
ELISA SET (BD Biosciences). 
The standard used was recombinant human GM-CSF. During preparation of the 
standard 148ng of the lyophilised product was diluted in 4.93ml of sterile water giving 
a final concentration of 30ng/ml. A 6µl aliquot of this solution was then further diluted 
into 594µl giving a stock standard at a concentration of 300pg/ml. Serial dilution took 
place to give 7 standards (300pg/ml, 150pg/ml, 75pg/ml, 37.5pg/ml, 18.8pg/ml, 
9.4pg/ml, 4.7pg/ml). 
The required number of microwells on a 96 well plate were coated with 50µl of 
capture antibody (anti-human GM-CSF diluted 1:250 with coating buffer (0.1M 
bicarbonate buffer, pH 9.5)), covered with parafilm and placed in the fridge overnight. 
The following morning excess coating antibody/buffer solution was thrown away and 
the wells were covered with 200µl of assay buffer (PBS containing 0.5% BSA and 
0.1% tween). The plates were incubated at room temperature for 1 hour. During the 
incubation dilutions of the participant serum samples took place. After 1 hour the 
blocking solution was aspirated and the plates were washed 3 times with PBS tween 
and blotted on absorbent paper. 100µl of each standard, serum sample and control 
were applied to the relevant microwells on the 96 well plate. The plate was sealed 
and incubated at room temperature for 2 hours. Following incubation each well of the 
plate was aspirated and washed with PBS Tween 5 times. After the final wash the 
plate was inverted and blotted on absorbent paper to remove any residual solution 
form the wells. 100µl of working detector (containing detection antibody; biotinylated 
anti-human GM-CSF and the enzyme reagent; streptavidin-horseradish peroxidase 
conjugate, diluted 1:250 in assay buffer) was added to each well. The plate was once 
again sealed and incubated for 1 hour at room temperature. Following incubation, the 
plate was aspirated and washed seven times and100µl of substrate solution was 
added to each well. The plate was incubated unsealed for 30 minutes at room 
temperature in the dark. Finally, 50µl of stop solution was added to each well and the 
plate was transferred to the plate reader. Following labelling of standards absorbance 
was read at 450nm within 30 minutes of the reaction stopping. 
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2.16.11 Storage of samples (ACS / DFS / RCT) 
All samples of whole blood for collection of serum or plasma were centrifuged as 
soon as possible after collection. Plasma / serum was aspirated carefully using a 
Pasteur pipette and placed into 1.5ml Eppendorf tubes in aliquots of 750µl. The 
Eppendorf tubes were labelled with the patient study number, the date and 
corresponding study day on which the sample was collected, and the nature of the 
sample. The samples were then stored in a locked freezer at -80°C until required for 
analysis. Following completion of the trial the samples will be stored for up to 15 
years. Consent for storage of all samples was taken at the time of enrolment into the 
study. 
Flow cytometry samples were discarded after analysis had been completed on the 
day of collection. 
Cytospin slides of isolated neutrophils were labelled with the study identification 
number and date and corresponding study day of sample and will be stored in the 
chief investigators laboratory for up to 15 years.  
	 80	
2.17 Clinical Assessments /Data Scores 
2.17.1 Sequential Organ Failure Assessment Score 
The Sequential Organ Failure Assessment Score (SOFA score) was used to 
measure patient organ dysfunction / morbidity over the course of the study. The 
SOFA score is an internationally recognised tool for assessing acute organ 
dysfunction and failure in critically ill patients (Vincent et el., 1998). It is composed of 
6 parameters assessing respiratory, renal, hepatic, cardiovascular, haematological 
and neurological organ function. It is an objective, useful tool for assessing change in 
status of organ function over time and has been widely used in clinical trials for this 
purpose.  
 
Table 11: Sequential organ failure assessment score (SOFA Score). MAP, mean arterial 
pressure; PaO2, partial pressure of oxygen; Fio2, inspired oxygen concentration; GCS, 
Glasgow Coma Scale 
Organ system 0 1 2 3 4 
Respiratory 
PaO2/FiO2 
(mmHg)  
> 400 ≤ 400 ≤ 300 ≤ 200 ≤ 100 
Renal 
Creatinine  
(µmol/L) 
< 106 106-168 169-300 300-433 
urine < 
500ml/day 
>433 
urine < 200ml/day 
Hepatic 
Bilirubin (µmol/L) 
<20 20-32 33-100 101-203 >203 
Cardiovascular 
Hypotension 
No 
hypotension 
MAP < 
70mmhg 
Dopamine 
≤5µg/kg/min 
Dopamine <5 
or 
Epinephrine ≤0.1 
or 
Norepinephrine 
≤ 0.1 µg/kg/min 
Dopamine >15 
or 
Epinephrine ≥ 0.1 
or 
Norepinephrine 
≥ 0.1 µg/kg/min 
Haematological 
Platelet count 
(x103/mm3) 
>150 ≤ 150 ≤ 100 ≤ 50 ≤ 20 
Neurological 
GCS 
15 13-14 10-12 6-9 < 6 
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2.17.2 Acute Physiology and Chronic Health Evaluation Score  
The Acute Physiology and Chronic Health Evaluation (APACHE) II Score was 
introduced in 1981 as a modification of the original APACHE score. It is widely used 
across the world to evaluate the severity of disease in patients admitted to intensive 
care environments (Knaus et al., 1985).  The score takes into account the patient’s 
age, the severity of their acute illness and their co-morbid disease status. It has been 
validated as a tool with which to predict mortality from critical illness. The score is 
calculated within the first 24 hours of admission to intensive care. The score was 
recorded for all patients entering the trial. 
 
2.17.3 Incidence of ICU-Acquired Infection 
Incidence of ICUAI was determined using the Hospitals in Europe Link for Infection 
Control through Surveillance (HELICS) criteria. The HELICS criteria were devised as 
part of a European project to standardise methods of surveillance for hospital-
acquired infection (HAI) and enable comparison of infection rates across 
international, national and regional healthcare networks (Mertens et al.,1996). As well 
as identifying rates of infection the framework enables identification of factors which 
may help prevent the acquisition of HAI (HELICS Protocol 6.1, 2004).) 
During the RCT data were collected enabling assessment of the acquisition of ICUAI 
according to the HELICS criteria. These data included; clinical suspicion of infection, 
temperature, heart rate, white cell count, microbiological samples requested and 
corresponding results, use of indwelling catheters and use of antibiotic therapy. All 
patients were assessed for the development of ICUAI up to day 30. 
 
2.17.4 PaO2:FiO2 
The PaO2:FiO2 is calculated by dividing the partial pressure of oxygen (PaO2) in 
kilopascals by the inspired oxygen fraction as a fraction of 1 (e.g. breathing room air, 
21% O2 equals an inspired oxygen concentration of 0.21). The partial pressure of 
oxygen was measured by arterial blood gas analysis at least once a day as part of 
usual clinical care with blood samples drawn from an indwelling arterial line. The 
inspired oxygen fraction was recorded on the ICU observation chart at hourly 
intervals 
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2.18 Statistical analysis 
2.18.1 Assay confirmation study 
The assay confirmation was designed solely to examine the correlation between 
neutrophil CD88 expression and neutrophil phagocytic capacity when analysed within 
our laboratory. Minimal demographic data was collected and no comparative analysis 
was performed. Descriptive statistics were used to describe the results. The 
correlation between CD88 expression and phagocytic capacity was examined by 
Spearman’s correlation. 
 
2.18.2 Dose finding study 
The sample size for the DFS was derived pragmatically. A sample size of n=6 per 
group (24 in total) was calculated to provide 80% power to detect an effect size of 1.8 
at a significance level of 0.05 between any 2 groups using the 2-sample t-test. 
Data for the primary and secondary outcomes will be summarized within each dosing 
group using descriptive statistics (means, medians, standard deviations, interquartile-
ranges for continuous data and frequencies, proportions and rates for dichotomous 
and categorical data) with confidence intervals. Descriptive summaries of 
demographic and operational data will be presented in a similar way. No comparative 
hypothesis testing or statistical modelling will be carried out. 
Safety data will also be reported in a descriptive fashion. Missing data will be 
described but no data replacement or imputation will be carried out. 
Analysis will be carried out using GraphPad Prism computer software. 
If low dose, short duration (3µg/kg/day) GM-CSF is demonstrated to be  
effective (i.e. we observe a phagocytosis rate on day 2 that is protective against 
infection (≥50% in all patients) and if there is no toxicity observed, then we will 
proceed directly to RCT at that dose. Higher doses would then seem unlikely to 
further reduce infection risk significantly, while carrying an increased risk of toxicity. 
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2.18.3 Randomised controlled trial 
For the RCT, on the basis of the group’s prior ex-vivo data in critically ill patients, 
showing a mean rate of neutrophil phagocytosis of 39% (standard deviation (SD) 
13%) (Conway Morris et al 2009), we believed an effect size incorporating an 
absolute increase of at least 15% (i.e. from 39% to 54% mean phagocytosis) would 
be clinically important. Our power calculation estimated that a sample size of 17 in 
each group would give a power of 90% to detect a difference (absolute difference in 
mean phagocytosis of 15%) between the groups at 2 days with a significance level of 
0.05 using the 2-sample t-test. This was equivalent to an effect size of 1.15 with 
respect to change from baseline within the two groups. To allow for an attrition rate of 
approximately 10% we planned to recruit 38 patients (19 per group). 
The statistical analysis plan for the RCT was devised by the independent statisticians 
(Dr Thomas Chadwick and Dr Anthony Fouweather, Department of Statistics, 
Institute of Health and Society, Newcastle University) and agreed by the PMG and 
DMSC prior to any analysis being undertaken. 
As this study was a small phase 2 clinical study, the analysis planned outlined that 
descriptive statistics would principally be reported including means and standard 
deviation for continuous data, frequency, median and inter-quartile range for ordinal 
data and proportions / rates for dichotomous / categorical data. Confidence intervals 
would be reported as appropriate. Baseline demographic and clinical data (including 
the SOFA score) would be described and summarised by group. 
Adverse events, serious adverse events and suspected unexpected serious adverse 
events would be summarised by group but would not be undergo any formal 
statistical analysis. Operational data including withdrawals etc. would be reported in a 
similar manner. 
The primary outcome (neutrophil phagocytic capacity on day 2 following 
administration of GM-CSF) would undergo comparative analysis, between the two 
treatment arms, by two-sample t-test however this would be exploratory rather than 
definitive in nature due to the small sample size. Where the data was considered to 
be non-normal the Mann Whitney U test for non-parametric analysis would be used.  
Where appropriate Analysis of Covariance (ANCOVA) would be used to adjust for 
differences between the groups in relation to baseline values or site effect.  
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Secondary outcomes including laboratory and some clinical data would be examined 
using similar methods including comparative analysis by two-sample t-test or Mann 
Whitney U test as appropriate. Dichotomous variables would be analysed by Fisher’s 
exact test. 
Data would initially be analysed on an intention to treat basis. Following this per-
protocol analysis (including patients receiving at least 2 doses of GM-CSF / placebo) 
would be carried out. 
Secondary clinical outcomes including length of stay on ICU and in hospital, duration 
of mechanical ventilation and incidence of ICUAIs would be summarised by group.  
Statistical significance was set at 0.05. 
Descriptive statistics would be used for both the incidence of ICUAIs and 30-day 
mortality as the study was not adequately powered to assess these. Laboratory 
safety measures would be subject to comparative analysis as described for the 
secondary outcome measures above. 
Missing data (other than due to mortality) would be described and examined to 
determine the extent of and reason for such omissions.  Multiple imputation 
techniques may be considered for the primary outcome but given the exploratory 
nature of this study the value of such data may be limited.  
 
For the purposes of this thesis, I conducted my own independent statistical analysis 
following the same analysis plan as had been set out by the independent study 
statisticians. I previously described I used GaphPad Prism statistical analysis 
software to conduct all analyses. I assessed normality of data for each data set using 
the D’Agostino-Pearson test (as recommended by the GraphPad Prism software) 
and used the outcome of this to determine the appropriate statistical test; using the 2-
sample t-test for normally distributed, parametric data and the Mann Whitney U test 
for non-normal, non-parametric data. 
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Chapter 3: Assay Confirmation Study 
 
This chapter will outline the results of the preliminary phase of the study, the assay 
confirmation study. It will begin by stating the aim of the study, then describe the 
screening, recruitment and consent process, and subsequently go on to report the 
results. Lessons learnt during screening and recruitment and the impact of the results 
on the subsequent phases of the study will then be discussed along with the 
limitations and conclusions of the ACS. 
 
3.1 Aim of study 
The assay confirmation study (ACS) was designed to determine whether neutrophil 
surface CD88 expression could reliably be used as a surrogate marker for neutrophil 
phagocytic capacity in identifying patients eligible for participation in the DFS/RCT. 
As outlined previously background work leading to this study had identified a 
significant correlation between neutrophil surface CD88 (C5aR) expression and 
neutrophil phagocytic capacity (Conway Morris et al., 2009, Conway Morris et al., 
2011). In the search for rapid diagnostics and biomarker-guided therapies we tested 
whether neutrophil CD88 could be used as a biomarker in this setting. 
 
3.2 Recruitment 
The ACS ran from August 2012 to December 2012 inclusive. All adult admissions to 
3 intensive care units in the North East of England (Royal Victoria Infirmary General 
ICU, Freeman Hospital Critical Care Unit and Queen Elizabeth Hospital, Gateshead 
Critical Care Unit) were screened for eligibility to take part in this phase of the study 
using the same inclusion and exclusion criteria as would be used in the subsequent 
phases of the study (see Table 7, Chapter 2; section 2.7). All patients were screened 
each morning for up to 48 hours following their admission. Screening did not take 
place at weekends when no researcher was available. More than a thousand 
screening episodes took place on more than 500 patients from which a total of 16 
patients were found to be eligible to participate. Consent to participate in the study 
was provided by the patient in three cases, a personal legal representative in 10 
cases and a professional legal representative in 2 cases. One patient declined to 
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give consent and therefore a total of 15 patients were recruited.  No patients 
withdrew, or were withdrawn, from the study following consent. The commonest 
reasons for exclusion from the study were abnormalities in full blood count 
parameters (haemoglobin <8.5g/dL, total white cell count >20 x 109/L, platelet count 
< 50 x 109/L), a history of cancer and the use of maintenance immunosuppressive 
drugs. Following acquisition of consent, a single 20mL blood sample was collected 
from each patient for assessment of CD88 expression, neutrophil phagocytic 
capacity and HLA-DR expression. All blood samples were collected at approximately 
the same time in the morning (median time 08:10 am, range 07:55 – 10:10 am) and 
were processed as soon as possible after collection (within 1 hour). 
 
3.3 Demographic Data 
Mean age was 64.5 years (s.d +/- 15.5, range 31-85). Male to female ratio was 7:8. 
There was a wide range of diagnoses responsible for the underlying critical illness 
with 8 patients having been admitted with a primary surgical diagnosis and 7 a 
primary medical diagnosis.  
In the healthy volunteer population mean age was 38.1 years (s.d +/- 7.5, range 30 – 
43). Male to female ration was 4:5. 
The table below summarises the demographic and diagnostic data for the critically ill 
patients included in the ACS. 
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Patient 
Study No 
Age 
(years) 
Sex Study 
Site 
Reason for admission 
A01 78 F RVI Oesophageal perforation 
A02 85 M RVI Gallbladder empyema 
A03 78 M FRH Femoral embolectomy / fasciotomy 
A04 61 M FRH Liver failure, GI bleed / cirrhosis 
A05 80 M RVI Community acquired pneumonia 
A06 78 F FRH Pancreatitis 
A07 62 M FRH Elective AAA with post-op resp failure 
A08 31 F FRH Gallstone pancreatitis 
A09 66 M QEH ALD, sepsis, renal failure 
A10 52 F RVI Cellulitis, renal failure 
A11 71 F QEH Rhabdomyolysis 
A12 38 M FRH Pancreatitis 
A13 68 F QEH Bowel obstruction 
A14 65 F RVI Exacerbation of COPD / CAP 
A15 55 F QEH Asthma exacerbation 
 
 
Table 12 Demographic data for ACS participants 
AAA, abdominal aortic aneurysm; ALD, alcoholic liver disease; CAP, community-acquired 
pneumonia; COPD, chronic obstructive pulmonary disease; FRH, Freeman Hospital, 
Newcastle upon Tyne; GI, gastrointestinal; QEH, Queen Elizabeth Hospital, Gateshead; RVI, 
Royal Victoria Infirmary, Newcastle upon Tyne.  
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3.4 Neutrophil phagocytic capacity  
3.4.1 Critically ill patients 
Neutrophils were extracted from whole blood and isolated by dextran sedimentation 
and a percoll gradient separation technique as outlined in chapter 2 (section 2.16.1). 
Phagocytic capacity was then assessed by light microscopy following incubation of 
neutrophils with zymosan that had been opsonised in autologous serum.  
In one patient’s sample (DCS-A01) the neutrophil extraction process failed due to 
loss of cells from the 24 well plate during the final wash. This was thought to be due 
to contamination of the PBS used in the washing process. As a result, the phagocytic 
capacity could not be measured in this patient. Results were available for the 
remaining 14 patients. Neutrophil phagocytosis (defined as the proportion of 
neutrophils ingesting ≥2 zymosan particles) ranged from 7.3% to 53.7%. These 
values fell within the expected range for a population of critically ill patients. Overall 
mean neutrophil phagocytosis was 34.8% (s.d +/- 13). Only one patient (1/14, 7.1%) 
had neutrophil phagocytic capacity greater than or equal to 50% (i.e. adequate 
phagocytic capacity).  
 
 
 
Figure 3a:  Individual mean phagocytic capacity in critically ill patients 
Phagocytosis assay failed for 1 patient, n=14.  
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3.4.2 Healthy Volunteers 
Healthy volunteer blood samples from university staff and students were analysed 
simultaneously. Due to the cohort of donors these samples were not matched for age 
and sex. As with the patient samples these samples were collected around 8 am and 
processed as soon as possible and always within 1 hour from the time of collection. 
The samples showed a similar phagocytic rate compared with previously studied 
healthy cohorts with phagocytic capacity ranging from 44.8 -90% (Conway Morris et 
al., 2009). Mean phagocytic capacity was 74% (s.d. +/- 14.8). 
 
 
Figure 3b:  Individual mean phagocytic capacity in healthy volunteers (HV). 
 
 
3.4.3 Comparison between critically ill patients and healthy volunteers 
There was a statistically significant difference in mean neutrophil phagocytic capacity 
between the two groups when analysed by two-sample t-test. 
 
  
Figure 3c: Mean phagocytic capacity healthy volunteers and critically ill patients. 
Healthy volunteers (HV) mean phagocytic capacity 74% (s.d. +/-14.8%) compared with 
critically ill patients (CIP) 34.8% (s.d. +/- 13%) P <0.001 by two-sample t-test.  
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3.5 Assessment of CD88 (C5aR) Expression  
As previously described (chapter 2, section 2.16.4) blood was collected in an EDTA 
tube for analysis of neutrophil surface CD88 expression by flow cytometry. Whole 
blood was incubated at 4°C with CD88 PE stain prior to red cell lysis by pharmlyse. 
Finally, the cells were washed prior to analysis. 
CD88 expression was measured by flow cytometry (FACS Canto, Becton Dickinson). 
Neutrophils were gated by forward scatter and side scatter characteristics and total 
CD88 expression measured. 
 
3.5.1 Critically ill patients 
Individual CD88 PE median fluorescence ranged from 825 – 3845 arbitrary units with 
a group median of 1852 arbitrary units.  
 
 
  
Figure 3d: Median neutrophil surface CD88 expression in critically ill patients. 
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3.5.2 Healthy volunteers 
CD88 expression measurement was available for 7 of the nine healthy volunteers. 2 
samples could not be analysed due to unavailability of the CD88 PE antibody. 
Individual CD88 PE fluorescence ranged from 2353 – 6258 with a group median 
fluorescence of 4305 arbitrary units. 
 
  
Figure 3e: Median neutrophil surface CD88 expression in healthy volunteers. 
Mean expression 4191 (SD+/- 1250) (arbitrary units). 
 
 
3.5.3 Comparison between critically ill patients and healthy volunteers 
There was a statistically significant difference in median CD88 PE expression 
between the two groups with lower expression among the critically ill patients.  
 
 
Figure 3f: Comparison between median neutrophil CD88 surface expression in 
critically ill patients and healthy volunteers. Critically ill median expression 1852 (IQR 
1531-2108) vs Healthy volunteer median expression 4305 (IQR 3012-4591) (arbitrary units). 
P =0.0001. Mann Whitney U Test. 
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3.6 Correlation between neutrophil phagocytic capacity and neutrophil surface 
CD88 expression 
 
The correlation between neutrophil phagocytic capacity and CD88 expression was 
then examined in an attempt to identify a CD88 level which would correspond to 50% 
phagocytic capacity and which could therefore potentially be used to identify patients 
eligible for the DFS and RCT. 
 
   
 
Figure 3g: Correlation between neutrophil surface CD88 expression and neutrophil 
phagocytic capacity amongst critically ill patients. (r=-0.07, p=0.82, Spearman’s test). 
 
 
  
 
Figure 3h: Correlation between neutrophil surface CD88 expression and neutrophil 
phagocytic capacity. Pooled data for critically ill patients (black dot, n=14) and healthy 
volunteers (black star, n=7). (r=0.52, p=0.015, Spearman’s test). 
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The was no correlation between neutrophil phagocytic capacity and CD88 surface 
expression when analysing either critically ill patients (r= -0.07) or healthy volunteers 
(r=0.14) alone. When data were pooled for critically ill patients and healthy 
volunteers, however, the correlation improved to moderate with a correlation co-
efficient r=0.52 (p=0.015). The strength of the correlation was not in keeping with 
previous work suggesting a strong correlation between the two variables (Conway 
Morris et al., 2009, r=0.69, p=<0.001). 
 
3.7 Monocyte HLA-DR Expression 
As described in chapter 2 (section 2.15.5) monocyte HLA-DR expression was 
assessed using a commercial QuanitbriteTM kit, and expressed as the median 
number of molecules of antibody per cell. Measurement of mHLA-DR expression 
provided additional confirmation of the presence of immunoparesis in our patient 
cohort. 
 
3.7.1 Critically ill patients 
Monocyte HLA-DR expression in the critically ill group of patients was relatively low 
with a median of 4,796 antibodies per cell (IQR 2760-6868).  
 
 
  
Figure	3i:	Monocyte	HLA-DR	expression	in	critically	ill	ACS	participants.	Ab,	antibodies.	
Median	expression	4,796	Ab/cell	(IQR	2760-6868),	n=15.	
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3.7.2 Healthy volunteers 
Amongst healthy volunteers, median monocyte HLA-DR expression was 25,699 (IQR 
17,667 – 31,697). Analysis was lost in 1 patient. 
 
 
 
Figure 3j: Monocyte HLA-DR expression in healthy volunteers (HV).  
Ab, antibodies. Median expression 25,699 (IQR 17,667-31,697), n=8. 
 
 
Previous studies examining monocyte HLA-DR as a marker of immunosuppression 
have identified a cut-off of 5,000 antibodies per cell (Ab/cell) to identify those with 
immune paralysis and an increased risk of sepsis, following surgery. (Docke et al., 
2005, Strohmeyer et al., 2003). A multicentre standardised study evaluating the use 
of BD QuantibriteTM found a healthy reference standard value of ~25700 for the 
median number of HLA-DR antibodies per cell with 2.5th -97.5th percentiles of 14100-
42500, with values in the range of 5000-15000 antibodies per cell in keeping with 
moderate to severe immunosuppression and greater than 15000 indicating immune 
competence. (Docke et al., 2005) 
 
3.7.3 Comparison between critically ill patients and healthy volunteers 
There was a statistically significant difference in the monocyte HLA-DR expression 
level between healthy volunteers and critically ill patients (p=<0.0001, Mann Whitney 
U Test), with the majority of the critically ill patients (9/15, 60%) falling into the 
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moderate to severe immunosuppression (5000 – 15000 Ab/cell) and only 1 patient 
(6.7%) having levels associated with immune competence (>15000 Ab/cell). 
 
 
 
Figure 3k: Monocyte HLA-DR expression in healthy volunteers (HV) compared to 
critically ill patients. Critically ill median expression 4,796 Ab/cell (IQR 2,760-6,868) vs 
Healthy volunteer median expression 25,699 Ab/cell (IQR 17,667 – 31,697). p <0.0001. 
Mann Whitney U Test. Ab, antibodies 
 
 
3.8 Correlation between monocyte HLA-DR expression and neutrophil 
phagocytic capacity 
There was a similar correlation between monocyte HLA-DR expression and 
phagocytic capacity as there was between neutrophil CD88 expression and 
neutrophil phagocytic capacity with a Spearman’s co-efficient of r=0.60. 
 
 
 
Fig 3l: Correlation between monocyte HLA-DR expression and neutrophil 
phagocytosis. Data from healthy volunteers (n=8) and critically ill patients (n=14) are 
pooled. r=0.55, p=0.008, Spearman’s test. 
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3.9 Outcome 
Patients were followed up at 30 days from collection of the blood sample to 
determine their outcome. 5 patients (5/15, 33.3%) had died during their admission to 
hospital: 4 whilst on ICU (4/15, 26.7%) and 1 following discharge to the ward. 1 
patient remained an inpatient on ICU (1/15,6.7%). 8 further patients (8/15, 53.3%) 
remained in hospital but had been discharged from ICU to a ward. 1 patient 
(1/15,6.7%) had been discharged home.  
 
Table 13. Outcome data for ACS participants. AAA, abdominal aortic aneurysm; ALD, 
alcoholic liver disease; CAP, community-acquired pneumonia; COPD, chronic obstructive 
pulmonary disease; GI, gastrointestinal; ICU, intensive care unit; resp, respiratory 
 
 
 
Patient 
Study ID 
Age 
(years) 
Sex Reason for admission Outcome 
A01 78 F Oesophageal perforation Discharged to ward  
A02 85 M Gallbladder empyema Discharged to ward 
A03 78 M Femoral embolectomy / fasciotomy Died on ICU 
A04 61 M Liver failure, GI bleed / cirrhosis Died on ICU 
A05 80 M Community acquired pneumonia Died on ward 
A06 78 F Pancreatitis Discharged to ward 
A07 62 M Elective AAA post-op resp failure Inpatient ICU 
A08 31 F Gallstone pancreatitis Discharged to ward 
A09 66 M ALD, sepsis, renal failure Died on ICU 
A10 52 F Cellulitis, renal failure Discharged to ward 
A11 71 F Rhabdomyolysis Discharged to ward 
A12 38 M Pancreatitis Discharged home 
A13 68 F Bowel obstruction Died on ICU 
A14 65 F Exacerbation COPD / CAP Discharged to ward 
A15 55 F Asthma exacerbation Discharged to ward 
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3.10 Discussion 
 
The ACS aimed to confirm whether neutrophil CD88 expression could reliably be 
used as a surrogate marker for neutrophil phagocytic capacity in determining 
eligibility for the subsequent phases of the trial.  
As expected neutrophil phagocytic capacity, CD88 expression and monocyte HLA-
DR expression were all reduced in critically ill patients compared with healthy 
volunteers. The level of all 3 parameters was within the expected range for patients 
with critical illness-associated immune dysfunction, suggesting that we were 
successfully recruiting our target population to the study. 
The assay confirmation study provided further valuable information that influenced 
the design of the subsequent phases of the trial in several areas. 
 
3.10.1 Reliability of neutrophil CD88 expression as a marker of neutrophil 
phagocytic capacity 
Within this patient cohort, in our laboratory, CD88 was not found to be a suitably 
reliable marker with which to identify patients with impaired neutrophil function who 
would be eligible for entry into the DFS and RCT.  
The reason for the discrepancy between our own results and the previous results of 
Conway Morris et al is unclear however it may in some part have been due to a 
combination of the small sample size, the unmatched healthy volunteer population 
and differences in the clinical status of the recruited patient cohorts. 
The ACS initially set out to recruit up to 30 patients however due to slow recruitment 
and time constraints an interim analysis was carried out after 15. The correlation 
coefficient of r=0.52 (p=0.015) was not felt to be adequate to ensure that CD88 
expression could reliably determine eligibility for the study and therefore a decision 
was made to proceed to the DFS using the neutrophil phagocytic assay itself as the 
final determinant of eligibility, with only those participants with impaired neutrophil 
phagocytic capacity (i.e. < 50% neutrophils ingesting 2 or more zymosan particles) 
continuing.  
The proportion of patients with adequate neutrophil phagocytic capacity was lower 
than expected when compared with Conway Morris’ previous work where 
approximately 30% of critically ill patients retained satisfactory neutrophil phagocytic 
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capacity (Conway Morris et al., 2011). The finding that only 1 of the 14 (7.1%) 
patients, in whom phagocytic capacity was successfully assessed, had neutrophil 
phagocytic capacity ≥50% may reflect the fact that we had recruited a sicker 
population of patients. In Conway Morris’ initial cohort patients were recruited 
following admission to intensive care if they were clinically suspected to have 
developed ventilator-associated pneumonia (VAP) (Conway Morris et al., 2009). This 
requires a patient to have been ventilated for at least 48 hours and in fact median 
duration of mechanical ventilation in these patients at the point of sampling was 8 
days. There was a strong correlation between neutrophil CD88 expression and 
neutrophil phagocytic capacity with r=0.69 (Conway Morris et al., 2009). Compared 
to our study cohort, these patients were recruited and sampled at a different point in 
the natural history of their critical illness, having already developed a secondary 
infection, perhaps following a period of relative immunosuppression / paresis. The 
results may therefore not be directly comparable. Conway Morris went on to study a 
second cohort of patients, all of whom were recruited early in their admission to ICU 
with very similar inclusion and exclusion criteria to our own. In this cohort the 
correlation was once again demonstrated with r=0.80, suggesting that the timing of 
sampling and /or phase of critical illness may not be responsible for our failure to 
reproduce this strength of correlation between CD88 expression and phagocytosis 
(Conway Morris et al., 2011). 
Our use of university staff and students as healthy volunteers meant that it was not 
possible to match our groups by age. As increasing age is known to have an effect 
on various aspects of immune function (Panda et al., 2009). it is possible that having 
a healthy control population unmatched for age may have an impact on the 
correlation between these two markers of immune function. In Conway Morris’ first 
cohort of patients/healthy volunteers, the volunteers were recruited from a local 
general practice and were fully age and sex matched. In his second cohort, however, 
the healthy volunteer population was also recruited from university students and staff 
and therefore it is unlikely that these were age and sex matched any more closely 
than our own cohort, suggesting that this factor may not be of significant importance 
in terms of the correlation. 
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3.10.2 Suitability of inclusion and exclusion criteria 
Through the screening process, during the ACS, it was recognised that the inclusion 
and exclusion criteria set to determine eligibility for the study were excluding some 
individuals, within the target population, who may stand to benefit from the 
intervention being studied. As discussed the ratio of patients screened to patients 
recruited was greater than 30:1. 
In terms of the inclusion criteria the commonest reasons for patients not meeting the 
eligibility criteria were i) they did not require the support of one or more organ system 
and ii) they did not fulfil the criteria for SIRS. A significant proportion of patients on 
intensive care units have been admitted post-operatively for high level observation 
following elective surgery. These patient often do not require organ support and in 
addition may not meet the criteria for SIRS. In circumstances where their surgery has 
been uncomplicated such patients would be expected to make a steady recovery 
with early discharge from the intensive care unit. This cohort of patients accounted 
for a significant proportion of screened patients who were found to be not eligible for 
participation in the study.  Such patients were not in the intended target population 
and therefore appropriately did not meet the inclusion criteria. 
A much smaller proportion of patients did not meet the eligibility criteria because they 
did not fulfil the defined criteria for SIRS, despite being critically ill and requiring 
organ support. It has been recognised for quite some time that the SIRS criteria lack 
both sensitivity and specificity in identifying critically ill patients with sepsis. The SIRS 
criteria focus on the pro-inflammatory response and pre-date the accepted 
understanding that sepsis is a highly complex immune state involving dysregulated 
pro and anti-inflammatory pathways (Singer et al., 2016). A recently published study 
conducted in Australia and New Zealand, including more than a million patients, 
identified that 1 in 8 patients with severe sepsis and organ dysfunction admitted to 
ICUs do not meet the criteria for SIRS despite having a comparable mortality rate to 
those individuals who do (Kaukonen et al., 2015). As at the time of designing the 
study the SIRS criteria were still widely accepted as a useful indicator of eligibility for 
trials in critical illness we did not opt to alter this criterion. Since that time the sepsis 
criteria have been further revised, with the publication of Sepsis 3, and no longer 
include the SIRS criteria reflecting the improved understanding of the 
pathophysiology of sepsis (Singer et al., 2016). 
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The exclusion criteria had been set with extreme attention paid to safety and the 
potential risk of harm to patients. Following the recognition that a significant number 
of critically ill patients who may have stood to benefit from the intervention were 
being excluded on the basis of the stringent exclusion criteria a review of the existing 
criteria was made in advance of proceeding to the DFS and RCT. After careful 
consideration, revisiting the relevant literature and seeking advice from independent 
experts, it was agreed between the Trial Steering Committee and the Ethics 
Committee that some of the criteria should be revised in order to ensure recruitment 
of the target population. It was felt that the proposed alterations to the eligibility 
criteria would not pose any increased risk to patients entering the study but would 
enable patients to be appropriately recruited.  
Revision of the following exclusion criteria took place prior to the commencement of 
the DFS. 
i) Haemoglobin <8.5g/dL at the time of screening – this criterion had been set to 
ensure that patients would not experience clinically significant anaemia as a 
consequence of alternate day or daily blood sampling during the DFS and RCT. 
Many critically ill patients have anaemia as a consequence of their critical illness, 
however current critical care guidelines recommend that blood transfusion only be 
administered if the haemoglobin level falls below 70 g/L, aiming for a target 
haemoglobin following transfusion of 70-90 g/L. (Retter et al., 2013) After 
consultation with a local independent Consultant Haematologist we were reassured 
that the volumes of blood being collected during both the DFS and RCT phases of 
the study would not significantly impact on the haemoglobin level of participants and 
that it was therefore safe and ethical to lower the cut-off for entry to 7.5g/dL. 
ii) Total white cell count > 20x109/ litre at the time of screening – this criterion 
had been set to ensure that patients would not have a clinically significant rise in their 
white cell count following administration of GM-CSF to a level whereby they may 
suffer harmful consequences of leucocytosis. A significant proportion of patients with 
sepsis and non-septic critical illness experience a rise in their white cell count in 
excess of 30x109/L. Again following advice from an independent Consultant 
Haematologist, it was agreed that this criterion could be safely increased to 
30x109/litre without increasing the risk of significant adverse events secondary to 
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leucocytosis including leukostasis, which is usually seen with WBC counts of greater 
than 100x109/L. (Ganzel et al., 2012) 
The in-hospital mortality rate of 33.3% and ICU mortality rate of 26.7% in the cohort 
of patients in this phase of the study are in keeping with expected mortality for ICU 
patients suffering sepsis and critical illness (Vincent J-L et al., 2006) and represent 
the expected mortality for our target population in the subsequent phases of the trial. 
 
3.10.3 Effects of critical illness on the neutrophil separation technique 
During the isolation of neutrophils, it was noted that the percoll gradient separation of 
leucocytes in patients with critical illness was less well defined than in healthy 
volunteers with a much broader neutrophil band being present which on occasions 
was seen to merge with the band of isolated mononuclear cells. This stage of 
neutrophil extraction relies on the separation of cells on the basis of their relative 
density, with mononuclear cells appearing at the 55%/70% layer and neutrophils 
appearing at the 70%/81% layer (Chapter 2, section 2.16.1). We postulated that the 
presence of increased fractions of immature neutrophils, being released from the 
bone marrow in response to systemic inflammation, may result in less distinction 
between the cell populations in terms of their densities. Immature neutrophils are 
larger and less dense then fully matured neutrophils and may have been responsible 
for the band just below the mononuclear cell population, which was often seen to 
merge with the usually distinct mature neutrophil population. Harvesting of the 
mononuclear cell layer revealed contamination with what morphologically appeared 
to be immature neutrophils.  
Similar findings have been reported in studies of both animal and human neutrophils 
in a variety of pro-inflammatory conditions. What have been termed as low-density 
neutrophils or granulocytes (LDN/ LDGs) have been found in a range of disease 
states including sepsis (Morasaki et al., 1992), systemic lupus erythematosus (SLE) 
(Carmona-Rivera et al., 2013), human immunodeficiency virus infection (Cloke et al., 
2012) and cancer (Sagiv et al.,2014). 
Hacbarth et al. were the first to report the finding of low-density neutrophils 
contaminating the mononuclear layer of Ficoll-Hypaque gradient separation samples 
in patients with SLE and rheumatoid arthritis. They described these cells as low 
buoyant density neutrophils and demonstrated that normal density healthy 
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neutrophils could be altered to become low-density neutrophils by the addition of 
serum from an affected patient or through complement activation by addition of inulin 
to autologous serum. In these circumstances the proportion of low-density 
neutrophils found in the mononuclear cell layer increased significantly (Hacbarth et 
al., 1986).  Hacbarth et al hypothesised that the reason for the low density in these 
cells was a result of degranulation with an associated increase in cell volume. They 
reported that the neutrophils found in the mononuclear cell layer were mature 
neutrophils, however they did not comment on how this was confirmed or whether 
there was also evidence of immature neutrophils within the neutrophil population. 
They excluded the possibility of cell aggregation being the reason for an increase in 
buoyant neutrophils via light microscopy. Subsequent work by Denny et al aimed to 
characterise these LDNs in more detail. They showed that these cells had a similar 
activation status to both normal density granulocytes in the same patients and 
neutrophils from healthy controls. The LDNs had a reduced capacity for phagocytosis 
but an enhanced ability to produce neutrophil extra-cellular traps (NETs). In addition, 
the researchers carried out ultra-structural analysis of the LDN population, with 
transmission electron microscopy, which demonstrated nuclei compatible with a 
range of immature neutrophil subsets and evidence of intact intracellular granules 
(Denny et al., 2010). Contrary to the findings of Hacbarth et al, these findings 
suggest that LDNs represent immature cells within the blood rather than cells that 
have degranulated.  
Pember et al carried out in-vitro and in-vivo studies of LDNs in experimental sepsis. 
Neutrophils harvested from mice and humans showed a wide band of density 
distribution following activation compared to controls. Stimulation of high-density 
neutrophils with endotoxin-activated serum induced a shift in cell density to lower 
levels. A similar effect was seen in human neutrophils exposed to fMLF where the 
reduction in density was associated with an increase in mean cell volume. Cells 
prompted to de-granulate also showed a shift to a lower density but to a lesser extent 
than those exposed to LPS. (Pember et al., 1983) 
A Japanese study in patients with sepsis subdivided isolated neutrophils into high-
density, intermediate-density and low-density cells and compared the relative 
proportions of each cell type in the septic cohort against healthy controls. The 
predominant cell type in the healthy controls was high-density neutrophils with a 
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mean of 76 +/- 9%. Patients with evidence of moderate infection had an increased 
proportion of intermediate-density neutrophils whilst in those with severe infection 
low-density neutrophils made up 40% of the total neutrophil population (Morasaki et 
al., 1992). Further functional analysis of the cell density subtypes showed a reduction 
in chemotactic response in low-density neutrophils compared to high-density 
neutrophils in both septic patients and healthy volunteers. Electron microscopy of the 
low-density neutrophils from the septic cohort showed evidence of degranulation and 
the presence of vacuoles, leading the researchers to conclude that the increased 
proportion of LDNs seen in septic patients was secondary to degranulation of high 
density neutrophils (Morasaki et al., 1992). 
Recent reviews suggest that no single factor is responsible for the appearance of 
LDNs and that the presence of immature neutrophils, activated degranulated 
neutrophils and granulocytic myeloid-derived suppressor cells (G-MDSCs, seen in 
cancer and HIV), may all contribute to the LDN population in varying proportions 
depending on the disease state (Scapini et al., 2010). 
As we wished to study neutrophil function as a whole in critically ill patients we 
collected the entire neutrophil population from the whole bandwidth in each case. In 
practice, the absence of a clear band of separation between the neutrophil and 
mononuclear cell populations undoubtedly results in the unavoidable loss of a portion 
of the neutrophil population during harvesting, in order to ensure purity of the 
neutrophil population. Review of the literature, however, did not reveal any 
recommendation for an alteration in the composition of the percoll gradient in such 
circumstances.  
 
3.10.4 Effects of heparin on preparation of serum 
During the processing of patient whole blood samples, following centrifugation, the 
platelet-rich plasma was transferred to a glass serum bottle and CaCl2 added. The 
sample was then incubated in a water bath at 37°C until a platelet clump had formed. 
Autologous serum was then collected for use in subsequent phagocytosis assays. 
It was noted that in several of the samples from critically ill patients a platelet clump 
failed to form despite extended incubation with CaCl2. Review of these patients found 
that they were receiving therapeutic doses of systemic heparin therapy for a variety 
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of indications including continuous veno-venous haemofiltration and anticoagulation 
of a Novalung extracorporeal CO2 removal circuit.  
It was acknowledged that therapeutic anticoagulation with heparin was likely to affect 
a significant proportion of the patient samples collected during the DFS and RCT in 
view of the nature of the participants’ underlying illnesses. Reversal of the 
anticoagulant effects of heparin can be achieved through the administration of 
protamine sulphate. 
Both heparin and protamine sulphate have been shown to have an effect on 
neutrophil phagocytosis, with heparins having an inhibitory effect and protamine a 
stimulatory effect.  (Salih et al., 1997, Peterson et al., 1984.) 
In view of the fact that the purpose of the trial was to assess the potential for GM-
CSF as a therapy for critically ill patients it was agreed that alteration of the 
participants’ serum profile with, for example, protamine to reverse the effects of 
heparin may produce a misleading result in terms of real-life clinical application. For 
the same reason it was felt inappropriate to exclude patients receiving 
anticoagulation. It was therefore decided that 2 mL of the original 20mL whole blood 
sample would be collected into a serum gel tube to allow preparation of autologous 
serum for use in subsequent neutrophil functional assays. 
 
3.11 Limitations of the Assay Confirmation Study 
The main limitations to the ACS were in relation to the sample size and the lack of 
matching in the healthy volunteer comparison cohort. 
 
3.11.1 Sample Size 
As discussed the ACS initially set out to recruit up to 30 patients. Rate of recruitment 
was significantly below target recruitment, in part related to the stringent entry 
criteria. Over a period of 4 1/2 months, 15 patients were recruited from 3 ICUs. 
Interim analysis of the correlation between neutrophil phagocytosis and neutrophil 
surface CD88 expression did not suggest a strong enough correlation to advise use 
of neutrophil surface CD88 expression as a surrogate marker for neutrophil 
phagocytic capacity to determine final eligibility for entry into the study. As there was 
a suggestion of a moderate correlation it was felt that this relationship warranted 
further investigation in the DFS and RCT phases of the study. The aim of the ACS 
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was to determine the validity of CD88 expression as a surrogate marker for 
neutrophil phagocytic capacity however the strength of the correlation may have 
been under estimated by insufficient numbers of patients being included in this phase 
of the study. 
 
3.11.2 Unmatched healthy volunteers 
Because our cohort of healthy volunteers came from a university population of staff 
and students we were unable to match basic demographic data in particular in terms 
of age. Increasing age is known to be associated with alterations in innate immune 
function and therefore differences in two groups unmatched for age may not reflect 
simply the presence of critical illness in the patients. (Berrut et al. 2015). There is no 
available literature looking directly at the effect of age on neutrophil CD88 expression 
in adults. Any correlation between these two parameters may be age-dependent and 
may therefore have affected our results. 
 
3.12 Conclusions of Assay Confirmation Study 
In conclusion the ACS did not confirm a strong enough correlation between 
neutrophil CD88 expression and neutrophil phagocytic capacity for CD88 to be used 
as a surrogate marker to confirm eligibility for the study. In the process of this 
assessment several issues were highlighted in relation to the inclusion and exclusion 
criteria for the study requiring modification. On completion of the ACS minor 
modifications were made to the inclusion and exclusion criteria for the DFS and RCT 
following which recruitment to the DFS commenced. 
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Chapter 4: Dose Finding Study. 
 
This chapter will outline the results of the dose finding study. It will begin by stating 
the aim of the study, give details regarding the conduct of the study, describe the 
screening, recruitment and consent process, and will then go on to report the results. 
 
4.1 Aim of study 
The aim of the dose finding study was to establish the optimum dose and duration of 
GM-CSF which would demonstrate evidence of a biological response in terms of 
improvement in phagocytosis alongside a favourable safety profile. This dose would 
then be carried forward for use in the randomised controlled trial. 
 
4.2 Study Design 
The dose finding study was designed to test 2 doses of GM-CSF (3µg/kg/day and 
6µg/kg/day, for 2 lengths of administration (4 and 7 days), in 4 sub-groups of 
patients. 6 patients were planned to be recruited to each sub-group of dose/duration. 
Sample size for the dose finding study was derived pragmatically on the basis that 
similar numbers of participants in similar situations have previously provided 
meaningful results.  A sample size of 6 per group (24 in total) was calculated to give 
a power of 80% power to detect an effect size of 1.8 with a probability of 0.05, 
between any 2 treatment groups, using a 2 sample t-test. 
Low dose GM-CSF (3µg/kg/day) would be trialled for 4 days in the first instance 
(patients 1-6) followed by seven days (patients 7-12), after which the dose would be 
doubled (6µg/kg/day) and trialled for the same two durations of treatment; 4 days 
(patients 13-18), 7 days (patients 19-24). (Table 14). 
Following completion of the Assay Confirmation study it was recognised that some of 
the inclusion and exclusion parameters were excluding patients within the target 
study population. As discussed in chapter 3 minor modifications to the inclusion and 
exclusion criteria were therefore made and approved by the relevant regulatory 
bodies prior to commencing enrolment to the dose finding study; 
 
I. The cut off for haemoglobin was lowered to 7.5g/dL 
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II. The cut off for white cell count was raised to 30x109/L 
 
In addition, it was observed that the correlation between neutrophil CD88 expression 
and neutrophil phagocytic capacity was not as strong in the ACS cohort of patients 
as in the previous work carried out by Conway Morris et al. It was therefore decided 
to use neutrophil phagocytic capacity itself as the final eligibility criterion for entry into 
the dose finding study and randomised controlled trial and to continue to explore the 
potential use of neutrophil CD88 expression as a surrogate marker for phagocytic 
capacity during these final stages of the trial. The dose finding study protocol is found 
in Appendix 1. 
 
Patient Enrolment Number Dose of Leukine (Sargramostim, rhu GM-CSF) 
1-6 3 µg/kg/day for 4 days 
7-12 3 µg/kg/day for 7 days 
13-18 6 µg/kg/day for 4 days 
19-24 6 µg/kg/day for 7 days 
 
Table 14. GM-CSF dosing schedule for participants in Dose Finding Study 
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4.3 Study outcomes 
 
4.3.1 Primary outcome 
The primary outcome for the DFS was neutrophil phagocytic capacity on day 2 post-
administration of GM-CSF 
4.3.2 Secondary Outcomes 
The study included several secondary outcomes 
I. Neutrophil CD88 expression after administration of GM-CSF 
II. Monocyte HLA-DR expression after administration of GM-CSF 
III. Serum GM-CSF level after administration of GM-CSF 
IV. Safety analysis including blood profile and PaO2:FiO2 
 
4.4 Study conduct 
To ensure safety during the administration of GM-CSF, following discussion with the 
DMSC, it was agreed that the first three patients would be recruited one at a time 
during the dose finding study with a brief report submitted to the DMSC following 
completion of each patient’s drug dosing and blood sampling follow-up. The report 
included data regarding daily phagocytic capacity, blood parameters, safety analysis 
and a description of the clinical course followed. The data were reviewed by the 
DMSC prior to any additional patients being recruited. If the DMSC were satisfied 
that there were no issues of concern in relation to safety they would confirm that the 
trial could continue. This decision regarding single sequential recruitment was made 
particularly in light of previous concerns over the possible link between colony 
stimulating factors including GM-CSF and acute lung injury (ALI) and the adult 
respiratory distress syndrome (ARDS). (Goodman et al., 1999) In view of the fact that 
all patients recruited to the trial would by definition have critical illness the risk of 
development of ALI/ARDS, independent of GM-CSF therapy, was high. (Rubenfeld et 
al., 2007). Data were collected on PaO2:FiO2 pre- and post-drug administration to 
specifically look for evidence of this occurrence. 
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4.5 CONSORT Diagram 
The CONSORT diagram below outlines the screening and recruitment of patients to 
the dose finding study. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4a:  Dose finding study CONSORT diagram. (only sub-group 1 was completed) 
4.6 Recruitment  
The DFS commenced on 5th January 2013 with the first patient being recruited to the 
study on 8th January 2013. All admissions to each intensive care unit were screened 
on a daily basis during the working week for eligibility for inclusion in the trial. Almost 
1000 screening episodes took place. Screening did not take place on a weekend 
when there was no researcher available. As discussed above (section 4.2) we 
planned to recruit up to 24 patients to the dose finding study with 6 patients recruited 
to each dose-duration sub-group. 24 of the patients screened were found to be 
eligible for participation in the first phase (3µg/kg/day) of the Dose Finding Study. 
There were 7 instances of declined consent (2 by patients and 5 by personal legal 
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representatives). 17 patients or personal or professional legal representatives gave 
consent for participation in the study. The final patient was recruited on 30th July 
2013. 
 
4.7 Final eligibility 
The final step of the eligibility assessment occurred on day 0 when blood was 
collected for assessment of neutrophil phagocytic capacity. Participants only 
proceeded at this stage if they were confirmed to have evidence of neutrophil 
dysfunction with neutrophil phagocytic capacity < 50%. Of the 17 patients who gave 
consent to participate in the study 11 were excluded from the study at this stage prior 
to receiving GM-CSF (4 patients had phagocytic capacity ≥ 50%, 3 patients had 
discontinued organ support, 2 patients had platelet counts less than 50x109/L, 1 
decision was made by a clinical consultant that the patient should no longer continue 
in the trial and 1 patient was found to be already enrolled in an interventional clinical 
trial which therefore precluded their participation). 6 patients (R01, F01, R02, Q03, 
R04, Q06) went on to receive GM-CSF as part of group 1 in the dose finding study. 
 
 
Figure 4b:  Baseline individual mean phagocytic capacity in critically ill patients 
recruited to Dose Finding Study. Patients with neutrophil phagocytic capacity ≥ 50% 
(dotted red line) were excluded from the study (n=4). Patients excluded for other reasons 
(red hatching); 2 discontinued organ support, 2 platelet count less than 50, 1 decision made 
by clinical consultant ,1 already enrolled in an interventional clinical trial. 
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4.8 Baseline demographics of patients enrolled into the Dose Finding Study 
The patient population recruited was broadly representative of a typical ICU cohort of 
patients. The cohort of patients proceeding past the final eligibility step was younger 
than those who were excluded at that stage. 
 
Table 15. Demographic data for participants in Dose Finding Study 
CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; 
APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure 
assessment; WBC, white blood cell; s.d., standard deviation; PaO2, partial pressure of 
oxygen; FiO2, inspired concentration of oxygen 
 
 
Baseline 
demographic 
Treatment group phagocytosis  
<50%  (n=6) 
Excluded group  
phagocytosis >50%  (n=4) 
Sex (M:F) 3:3 1:3 
Age: Median  
(years, range) 
56.5  (25-66) 70.8 (58 – 79) 
Admission diagnosis Community acquired pneumonia 
(CAP) 
Anastomotic leak 
Clostridium difficile colitis 
Bacterial endocarditis 
Oesophageal perforation 
Small bowel obstruction 
Respiratory failure post burns 
CAP / acute kidney injury 
Pedestrian polytrauma 
Exacerbation COPD 
APACHE II Score 
Median (range) 
19.5 (13-25) 16 ( 12 – 22) 
Weight 
Median (kg, range) 
95 (56 - 144) N/a 
SOFA Score 
Median (range) 
9.5 (2-14) N/a 
PaO2:FiO2  kPa 
(best prev 24hours) 
37.7 +/- 19.2 (16.3 – 69.7) N/a 
WBC x109/L 
Mean +/- s.d. (range) 
13.06 +/- 4.53 (8.91 – 21.1) N/a 
Neutrophils x109/L 
Mean +/- s.d. (range) 
10.8 +/- 9.85 (6 – 18.7) N/a 
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4.9 Study drug administration 
All patients entering this phase of the study received a daily injection of 
subcutaneous GM-CSF at a dose of 3 microgram / kg /day. Daily administration of 
the drug was continued until any one of the study drug termination criteria was met:  
• maximum treatment period  
• study drug-related serious adverse reaction 
• discharge from a critical care environment 
• death 
• discontinuation of active medical treatment 
• the patient, PerLR or ProfLR requests withdrawal from the study 
• decision by the attending clinician that the study drug should be discontinued 
on safety grounds 
There were 2 situations whereby the protocol decreed that consideration should be 
given to either discontinuing the administration of GM-CSF or reducing the dose by 
half: 
• WCC > 50,000 cells/mm3 
• Platelet count > 500,000 cells/mm3 
(Trial protocol, appendix 1). 
 
GM-CSF was prescribed according to actual body weight up to a maximum weight of 
120kg, corresponding dose of 360 µgm. Doses were prescribed within weight ranges 
to the nearest 5 kg. Median weight was 95kg with a range of 56 – 144kg and 
corresponding doses ranged from 165mcgm daily to 360mcgm daily. Above 1ml 
volume (255µg) doses were rounded to the nearest 0.1 of a ml. Five of the six 
patients received all four prescribed doses from day 0 to day 3. One patient did not 
receive their final dose on day 3 due to a fall in platelet count on this day. As GM-
CSF is known to affect platelet count this triggered the study drug termination criteria 
above and a decision was made by the attending clinician to withhold the study drug 
on the grounds of ensuring patient safety. 
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4.10 Blood sampling 
As described in chapter 2 blood samples were collected from patients each morning 
from D0 to D9. Blood samples for phagocytosis and other assessments of neutrophil 
function were not collected at weekends when no researcher was available. Blood 
samples for safety analysis including full blood count, urea and electrolytes and liver 
functions were collected everyday, including weekends, as part of usual clinical care. 
 
4.11 Results 
 
4.11.1 Neutrophil phagocytic capacity 
4.11.1.1 Baseline phagocytic capacity 
Neutrophil phagocytosis was measured at baseline (day 0, prior to administration of 
GM-CSF) and then on each day thereafter up to day 9. Mean baseline phagocytosis 
on day 0 was 38.7% (SD+/-10.6, range 21.2% - 47.6%). 
 
4.11.1.2 Neutrophil phagocytic capacity on day 2. 
The phagocytosis assay failed for 1 patient (R01) on day 2 due to lysis of cells at the 
final wash with PBS. This was thought to be due to contamination of the PBS 
solution. Therefore, no phagocytic capacity result was available for that patient on 
that day. All 5 other patients were found to have an improvement in their neutrophil 
phagocytosis on day 2 post administration of GM-CSF (the day for assessment of the 
primary outcome). In addition, all 5 patients with available data had a neutrophil 
phagocytic capacity ≥50% on day 2 following administration of GM-CSF. Mean 
neutrophil phagocytic capacity on day 2 post administration of GM-CSF was 59.6% 
(SD +/- 7.9) compared with neutrophil phagocytic capacity 38.7% (SD +/- 10.6) at 
baseline (p=0.06). 
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Figure 4c. Change in individual mean neutrophil phagocytosis between day 0 and day 
2. GM-CSF improves neutrophil phagocytosis by day 2. Percentage neutrophils ingesting 2 
or more zymosan particles (n=5). Note two patients results overlapping. 
 
 
Although not part of the formal analysis plan, when imputation by mean for the 
dataset (59.6) or minimum for the dataset (53.8) substitution was applied for missing 
variable R01 D2 there was a statistically significant difference in mean phagocytosis 
at day 2. (Mean substitution p=0.03, minimum substitution p=0.03). 
 
 
 
Figure 4d. Change in individual mean neutrophil phagocytosis between day 0 and day 
2 GM-CSF improves neutrophil phagocytosis by day 2. Mean substitution for missing 
variable R01 D2 (p=0.03 by Wilcoxon matched pairs rank test) Mean difference 20.9%, 
median difference 15.5% between day 0 and day 2 (n=6). Note 3 patients results 
overlapping. 
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4.11.1.3 Neutrophil phagocytic capacity over study period. 
Improvement in mean neutrophil phagocytic capacity was seen to persist at day 7 
(last day where all 6 patients were sampled) however did not reach statistical 
significance. Overall mean neutrophil phagocytic capacity was 65% (SD+/-9.2) on 
day 7 compared with 38.7% (SD+/-10.6) on day 0 (p=0.06). In one patient (Q03) after 
an initial improvement in neutrophil phagocytic capacity on day 2, the neutrophil 
phagocytic capacity was seen to fall until day 7 rising again on days 8 and 9. 
 
 
 
 
Figure 4e. Individual mean neutrophil phagocytosis over study period. The trend 
towards improvement in neutrophil phagocytic capacity persists at Day 7 but did not reach 
statistical significance (p=0.0625 by Wilcoxon matched pairs rank test comparing D0 and D7) 
Mean diff 26.9%, median diff 28.38% D0 – D7. 
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4.11.1.4 Summary descriptive statistics for neutrophil phagocytic capacity 
days 0, 2 and 7. 
Mean neutrophil phagocytic capacity rose by 20.9% between day 0 and day 2 and 
27.2% between day 0 and day 7.  
 
Statistical Value D0 D2 D7 
No of values (n) 6 5 6 
Minimum 21.2 53.8 29.0 
25% percentile 30.1 54.6 56.9 
Median 42.2 55.7 70.6 
75% percentile 47.1 66.6 84.5 
Maximum 47.6 73.2 77.2 
Mean 38.7 59.6 65.9 
Sd 10.6 7.9 19.2 
S.E.M 4.3 3.6 7.8 
Lower 95% CI 27.6 49.7 45.8 
Upper 95% CI 49.8 69.4 86.0 
 
Table 16. Summary descriptive statistics for neutrophil phagocytic capacity days 0, 2 
and 7. 
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4.12 Monocyte HLA-DR Expression 
 
4.12.1 Baseline monocyte HLA-DR expression 
As described in chapter 2 monocyte HLA-DR was measured at baseline and daily on 
weekdays in all patients by flow cytometry using the QuantibriteTM kit. Baseline 
monocyte HLA-DR expression was low with 5 of the 6 participants having monocyte 
HLA-DR level below 15,000 Ab/cell in keeping with moderate to severe immune 
dysfunction. 3 of these 5 patients had mHLA-DR levels below 5000 Ab/cell in keeping 
with immunoparalysis. Only 1 patient had a HLA-DR level greater than 20,000 Ab/cell 
suggestive of immune competence. Median mHLA-DR at baseline was 4297 Ab/cell 
(range 2852-10100Ab/cell). 
 
 
Figure 4f. Individual monocyte HLA-DR expression at baseline. Measurement performed 
by QuantibriteTM analysis. Median mHLA-DR 4297 Ab/cell (2852 – 1911 Ab/cell). 
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4.12.2 Monocyte HLA-DR expression over study period 
Following administration of GM-CSF there was a general trend towards an increase 
in monocyte HLA-DR expression with a rise being seen in all but one patient. Median 
mHLA-DR D0 - 5091 (3348-13642) vs D2 - 25881 (14722-64300); vs D3 – 27599 
(17002-31710); vs D5 – 13255 (3681-24561); vs D7 – 4603 (2530-6786); vs D9 – 
4387 (3036-8792). Following completion of the study drug on D3 mHLA-DR levels 
were seen to fall. In all cases, by study day 9, mHLA-DR had fallen to levels 
previously seen in patients with at least moderate immunosuppression i.e. less than 
15,000 Ab/cell. 
 
 
Figure 4g. Individual monocyte HLA-DR expression over study period 
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4.12.3 Correlation between monocyte HLA-DR expression and neutrophil 
phagocytic capacity 
A weak correlation was seen between baseline mHLA-DR (D0) and neutrophil 
phagocytic capacity (Spearman’s r = 0.41.) 
 
 
Figure 4h. Correlation between baseline monocyte HLA-DR expression and neutrophil 
phagocytic capacity. (Spearman’s r = 0.41, p = 0.15, n=6) 
 
There was no correlation seen between mHLA-DR and neutrophil phagocytic 
capacity following the administration of GM-CSF. 
 
  
Figure 4i. Correlation between m HLA-DR expression and neutrophil phagocytic 
capacity following GM-CSF administration. (Spearman’s r = 0.07, p = 0.72, n=29)
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4.13 Neutrophil CD88 Expression 
4.13.1 Baseline neutrophil CD88 expression 
Mean baseline neutrophil CD88 expression was 830 arbitrary units (s.d. +/- 304.5), 
median 778. 
 
 
Figure 4j. Individual neutrophil CD88 expression at baseline. Mean neutrophil CD88 
expression was 830 (s.d. = +/- 304.5, median 778 (576-1085). 
 
4.13.2 Neutrophil CD88 expression over study period 
Following administration of GM-CSF there was a general trend towards an increase 
in neutrophil CD88 expression seen in all patients.  
 
 
Figure 4k. Individual neutrophil CD88 expression over study period. Median neutrophil 
CD88 expression (arbitrary units) was as follows -  D0 778 (575 – 1085) vs; D2 608 (493 – 
2057), D3 1037 (476 – 1764), D5 1062 (879 – 1967), D7 1821 (1080 – 4292), D9 1530 (1322 
– 2481). 
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4.13.3 Correlation between neutrophil CD88 expression and neutrophil 
phagocytic capacity 
A strong correlation was observed between baseline neutrophil CD88 expression and 
neutrophil phagocytic capacity within the pool of screened participants (Spearman’s r 
= 0.6, p = 0.03).  
 
Figure 4l. Correlation between baseline neutrophil CD88 expression and neutrophil 
phagocytic capacity. (Spearman’s r = 0.6, n= 13). 
 
There remained a moderate correlation between neutrophil CD88 expression and 
neutrophil phagocytic capacity following the administration of GM-CSF, (r=0.43).  
 
Figure 4m. Correlation between neutrophil CD88 expression and neutrophil 
phagocytic capacity following GM-CSF administration. (Spearman’s r = 0.43, n= 34)
0 1000 2000 3000 4000
0
20
40
60
80
Neutrophil CD88 expression (arbitrary units)
%
 n
eu
tro
ph
ils
 in
ge
st
in
g 
2 
or
 m
or
e 
zy
m
os
an
 p
ar
tic
le
s
0 1000 2000 3000 4000 6000
0
20
40
60
80
100
Neutrophil CD88 expression (arbitrary units)
%
 n
eu
tro
ph
ils
 in
ge
st
in
g 
2 
or
 m
or
e 
zy
m
os
an
 p
ar
tic
le
s
! 123!
4.14 Serum GM-CSF concentration 
Blood was collected each morning for measurement of serum GM-CSF 
concentration. In addition, samples were taken 2 hours, 4 hours and 6 hours post 
administration of GM-CSF on day 0 and day 3. Following collection these blood 
samples were kept at 4°C and transported to the lab immediately following collection 
of the 6-hour post-dose sample. ELISA failed in one of three patients in whom it was 
performed. 
 
 
Figure 4n. Serum GM-CSF concentration following administration of subcutaneous 
rhu GM-CSF 3µg/kg. Serum GM-CSF levels measured by ELISA. (n=2) 
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4.15 PaO2:FiO2 
As discussed, due to the concerns regarding the potential for GM-CSF to induce or 
exacerbate ALI/ ARDS PaO2:FiO2 was measured in all patients on a daily basis at 
baseline and up to day 9. This was included as part of usual clinical care. The 
maximum PaO2:FiO2 (kPa) was recorded for each 24-hour period. This assessment 
only took place when the patient had an arterial line in situ. Once an arterial line had 
been removed daily oxygen saturations and inspired oxygen concentration were 
recorded.  
There was no evidence to suggest a deterioration in gas exchange, as measured by 
PaO2:FiO2, following administration of GM-CSF. 
 
 
 
Figure 4o. Individual maximum daily PaO2:FiO2 over study period. Highest PaO2:FiO2 
recorded each day for last 24 hours (kPa). 
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4.16 Adverse Events 
4.16.1 Serious adverse events 
As outlined in chapter 2 (section 2.13.3), because the study was recruiting patients 
with critical illness it was expected that many of them may experience serious 
adverse events as part of their disease course. It was therefore agreed prior to the 
study that such events should not be reported as SAEs. All other SAEs were to be 
reported. There were, however no SAEs reported during completion of the DFS. 
 
4.16.2 Expected adverse events 
 Expected adverse events were recorded on a daily basis within the case report form 
(CRF). All patients experienced temperatures up to 38°C during the course of the 
study. It was not possible to ascertain whether these temperatures were due to the 
study drug or the patients’ underlying conditions as in all cases patients were 
experiencing temperatures prior to commencing GM-CSF and the underlying 
conditions are frequently associated with elevated body temperature. 
 
Expected adverse event Occurrence 
Temperature up to 38 C 6/6 
Elevated white cell count  6/6 
Reaction at injection site 0/6 
Bone pain 0/6 
Myalgia 0/6 
‘First dose syndrome’ 0/6 
 
Table 17. Expected adverse events 
 
All patients had some degree of rise in their white cell count (WCC). This was 
extremely variable with the peak rise ranging from 3.2 to 28.3 x109/L. The general 
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trend was for the white cell count to rise over days 0-3 while the patient was receiving 
the study drug and then to fall slowly. There were no incidences of the white cell 
count rising above 50 x109/L (the cut off at which the protocol recommends stopping 
the drug or reducing the dose by half). 
 
 
 
 
 
 
 
 
 
Figure 4p. Daily assessment of white blood cell count post GM-CSF 
 
There were no recorded instances of a reaction at the injection site. No patients 
reported bone pain or myalgia. However, 5 out of 6 patients were intubated and 
sedated and therefore this may have been masked and was difficult to measure. No 
patients displayed signs of the first dose syndrome. 
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4.16.3 Unexpected adverse events 
There were 3 reported adverse events documented in the adverse event pages of 
the CRF. These all occurred in the same patient (Q03). Two of these events were 
classified as being unlikely to be related to the study drug and one as possibly being 
related to the study drug. One event was deemed to be moderate in severity with the 
other two being deemed to be of mild severity. The patient concerned had been 
admitted with sepsis secondary to bacterial endocarditis. They had a background 
history of chronic liver disease secondary to alcohol excess, hypertension, chronic 
kidney disease and previous breast cancer. The patient was transferred to the 
regional cardio-thoracic intensive care unit on day 4 and underwent emergency aortic 
valve repair (AVR) the following day. 
 
Nature of adverse 
event 
Severity Relationship to drug 
Atrial Tachycardia 
(Q03) 
Moderate Unlikely  - Occurred 2 hours 
post GM-CSF injection, patient 
agitated and fighting ventilator 
at time of onset 
Hypotension (Q03) Mild Unlikely – Occurred 1 hour 
post GM-CSF injection, patient 
had just been put back onto 
continuous veno-venous 
haemofiltration (CVVH) 
Thrombocytopaenia 
(Q03) 
Moderate Possibly -  Patient was septic, 
history of chronic liver 
disease, on CVVH.  Other 
causes deemed more likely 
 
Table 18. Unexpected adverse events 
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4.17 Safety bloods 
Bloods were taken each day to look for unwanted side effects of GM-CSF which may 
have compromised patient safety. Daily analysis of full blood count, urea and 
electrolytes and liver function tests was performed. GM-CSF is known to increase the 
number of circulating cells in the myeloid population. There have been reports of 
rises in bilirubin, hepatic enzymes and creatinine being seen in some patients with 
pre-existing renal and hepatic disease within uncontrolled trials. 
 
4.17.1 Neutrophil count 
All patients had some degree of rise in their neutrophil count post administration of 
GM-CSF. The response was very variable and probably also reflected individual 
changes in clinical condition. The maximum rise in neutrophil count was to a peak of 
35.5 x109/L. 
 
 
 
 
 
 
 
 
 
Figure 4q. Daily assessment of neutrophil count post-GM-CSF 
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4.17.2 Platelet count 
One patient experienced a fall in their platelet count while receiving the study drug. 
The fall in platelet count was thought to be possibly related to the drug by the 
patient’s clinical team. However other causes were felt to be more likely. The patient 
had a diagnosis of bacterial endocarditis and a background history of chronic liver 
disease and was on CVVH at the time. In view of the fall in platelet count the final 
dose of GM-CSF was not administered on day 3. Other patients tended to have a 
rise in their platelet count following administration of the study drug. 
 
 
 
 
 
 
 
 
 
Figure 4r: Individual platelet count data over study days 0-9 
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4.17.4 Creatinine 
There were no obvious changes seen in creatinine level post GM-CSF. Two patients 
(Q03 and Q06) were receiving CVVH during the study period patient. 
 
 
 
 
 
 
 
 
 
Figure 4s: Creatinine data over study days 0-9 
 
4.17.5 Liver function tests 
In this study elevation in liver enzymes was seen in 2 patients. The first patient R04 
was admitted with a perforated oesophagus and had elevated aspartate 
aminotransferase (AST) on admission. He commenced GM-CSF 2 days following 
admission to ICU. His perforation was not endoscopically apparent initially and he 
remained septic with bilateral pleural empyema for several days. He was 
subsequently commenced on total parenteral nutrition (TPN). His alanine 
transaminase (ALT) and alkaline phosphatase (ALP) rose steeply from study day 3 
peaking on study day 9. His LFTs settled gradually over several weeks following a 
second peak in ALP/ALT 3 weeks following admission. 
In the second patient, R01, this occurred 10 days after the drug had been stopped 
(not illustrated) and coincided with an increase in WCC, C reactive protein (CRP) and 
temperature in association with right upper quadrant pain. An ultrasound scan at the 
time showed the presence of gravel-like calculi in the gallbladder. The rise and fall in 
liver enzymes occurred quickly and the patient was followed up until complete 
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resolution of their liver function abnormality had occurred. These findings were 
discussed in a DMSC meeting and thought to be unlikely to be related to the study 
drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4t: Individual liver function test 
data over study days 0-9 
!
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4.18 Outcome 
At 30 days all six patients were alive. Two patients had been discharged home from 
hospital, 1 had been discharged from ICU but remained a hospital inpatient, 3 
patients remained on ICU.  
One patient subsequently died (Q03) 2 months post GM-CSF treatment. This patient 
was admitted with bacterial endocarditis and was transferred to the local cardio-
thoracic unit for emergency AVR. They had a slow wean from the ventilator post 
operatively with the patient finally being weaned off all ventilatory support after 
approximately 7 weeks. Shortly afterwards the patient deteriorated with a further 
episode of sepsis and after discussion with the family a decision was made not to re-
escalate care due to her pre-existing frailty and poor prognosis. 
 
Study Number 30 day outcome Final outcome 
R01 Discharged home Discharged home day 16 
F01 Surgical inpatient Discharged home at 3 months 
R02 HDU inpatient Medical inpatient at 5 months 
Q03 ITU inpatient Died 2 months post GM-CSF 
R04 Discharged home Discharged home day 30 
Q06 ITU inpatient Discharged home at 4 months 
 
Table 19: Outcome for patients recruited to dose-finding study!
!
!
!
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4.19 Discussion 
The DFS set out to determine the optimum dose and duration of GM-CSF that would 
both be effective in terms of producing a demonstrable increase in neutrophil 
phagocytic capacity, and demonstrate an acceptable safety profile. In terms of safety, 
it was pre-determined that the dose which would be carried forward to the RCT 
should be associated with dose-limiting toxicity in less than 2 of the 6 patients within 
the cohort in which it had been demonstrated to be effective (Trial Protocol Section 
5.6.1.3, appendix). 
During the conduct of the DFS, prior to analysis of the data, it was also determined 
that if low-dose and short duration GM-CSF was found to be both safe and effective 
i.e. resulting in neutrophil phagocytic capacity which would be protective against 
ICUAI (≥ 50%) then the trial may proceed directly to RCT without dose escalation 
(Trial Protocol, appendix). 
 
4.19.1 Optimum dose and duration of GM-CSF 
4.19.1.1 Effect of GM-CSF on neutrophil phagocytic capacity 
GM-CSF administered at a dose of 3µg/kg/day for a duration of 4 days was seen to 
be associated with an increase in neutrophil phagocytic capacity in all patients. On 
day 2, the day for assessment of the primary outcome, neutrophil phagocytic 
capacity was seen to be above 50% in all patients (apart from the one patient whose 
phagocytic capacity assessment failed on this day and therefore could not be 
measured). Neutrophil phagocytic capacity ≥50% has previously been shown to be 
the level associated with less ICU acquired infection (Conway Morris et al 2011). The 
difference in mean neutrophil phagocytic capacity between day 0 and day 2 was 
20.9%. This is in excess of the absolute mean difference in neutrophil phagocytic 
capacity, applied to our power calculation for the sample size required to detect a 
difference between groups for the RCT with a power of 90% (chapter 2, section 
2.18.3).  The mean rise, on day 2, in individual neutrophil phagocytic was 22.7%. The 
response to GM-CSF varied however with the minimum rise, on day 2, being 8.3% 
leading to a mean phagocytic capacity of 55.3% for the patient concerned. 
In all but one patient a continued improvement in neutrophil phagocytic capacity was 
seen at day 7 which was the last day on which all 6 patients were sampled (due to 
samples not always being collected on weekend days when no researcher was 
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available). Mean neutrophil phagocytic capacity on day 7 was 65.9% (s.d. 19.2) 
compared with day 2 mean of 59.6 (s.d. 7.1) and day 0 mean 38.7 (s.d.10.6). This 
may suggest that the effect of GM-CSF on neutrophil phagocytic capacity persisted 
after the treatment had been discontinued on day 3. This difference did not reach 
statistical significance however due to the decline in neutrophil phagocytic capacity in 
one patient (Q03) on this day. 
Patient Q03 had been admitted with sepsis secondary to bacterial endocarditis on a 
background of chronic liver disease. As a result of the bacterial endocarditis affecting 
the aortic valve the patient became increasingly unstable necessitating transfer to a 
regional cardiothoracic unit and was required to undergo emergency cardiothoracic 
surgery to replace the aortic valve on day 5 of their admission. The cardiothoracic 
surgery required the patient to be on cardiopulmonary bypass. Cardiopulmonary 
bypass has previously been shown to impair neutrophil phagocytosis for at least 12 
hours following surgery (Hamano et al., 1996) and this may well have accounted for 
the decline in this patient’s neutrophil phagocytic capacity following an initial apparent 
response after the administration of GM-CSF. 
Interestingly all patients were seen to have an initial fall in their neutrophil phagocytic 
capacity on day 1 post administration of GM-CSF (mean neutrophil phagocytic 
capacity day 1 = 31.6% (s.d. +/- 8.8) vs day 0 = 38.7% (s.d +/- 10.6). As GM-CSF is 
known to result in an increase in the absolute number of circulating neutrophils it may 
be that the effects in terms of neutrophil number occur more quickly than the effects 
in terms of neutrophil phagocytic activity therefore resulting in a net reduction in 
neutrophil phagocytic capacity on day 1 followed by a net rise by day 2. 
 
4.19.1.2 Safety profile of GM-CSF 
The administration of GM-CSF was not associated with a serious adverse event in 
any of the patients treated in the dose finding study. The occurrence of common 
adverse events was recorded on a daily basis in the case report form, namely; rise in 
white cell count, the development of a temperature up to 38°C, a reaction at the 
injection site, bone pain, myalgia and the first dose syndrome (Steward, 1993). All 
patients were seen to have a rise in their white cell count and in their body 
temperature following administration of GM-CSF. In no cases was there a rise in the 
total white cell count to a level which would trigger the study drug termination criteria 
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or be associated with the potential of a complication related to leucocytosis. As 
documented previously it was not possible to determine whether the rises seen in 
white cell count and body temperature were due to the patients underlying clinical 
condition or the effects of GM-CSF. Both indices, while known side effects of GM-
CSF therapy, are frequently elevated in critical illness and form part of the SIRS 
criteria used to establish eligibility for participation in the trial (Members of the 
ACCP/SCCM Consensus Conference Committee, 1992). 
There were no instances of a reaction at the injection site in any patient. Neither 
bone pain nor myalgia were reported however 5 of the 6 patients were sedated and 
ventilated and therefore detection of this was extremely difficult. Finally, the ‘first 
dose response’ which manifests as hypotension, dyspnea and flushing during or 
shortly after administration of the first dose only, was not observed in any of the 6 
participants. 
All three reported adverse events occurred in the same patient. Two of these events 
were assessed as being unlikely to be related to the study drug. The one adverse 
event which was recorded as being possibly related to GM-CSF, the development of 
thrombocytopaenia, was deemed to be of moderate severity.  GM-CSF has been 
more commonly associated with the development of thrombocytosis (Vesole et al 
1994, Sanofi-Aventis, 2013). Increased levels of GM-CSF have however also been 
observed in patients with both immune and non-immune thrombocytopaenia (Abboud 
et al., 1996). The patient in whom this adverse event was reported had a history of 
chronic liver disease secondary to alcohol excess and was receiving CVVH for acute 
renal failure, both of which can be associated with the development of 
thrombocytopaenia. In this case, it was felt that the observed thrombocytopaenia was 
more likely to have been a result of these factors. To ensure patient safety, however, 
and to avoid the potential for a further decline in platelet count, which could 
potentially lead to a risk of bleeding, the final dose of GM-CSF was withheld from this 
patient. All other patients tended to show a degree of rise in their platelet count 
following administration of GM-CSF. 
There were no other instances of an alteration in blood profile leading to triggering of 
the study drug termination criteria. As expected GM-CSF administration was 
associated with a rise in both total white cell count and neutrophil count in all 
recipients (Sanofi-Aventis, 2013), however, the response was quite variable and the 
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counts were seen to decline slowly on completion of the study drug dosing schedule 
on day 3. 
The Leukine Summary of Product Characteristics reports that in some patients with 
pre-existing renal or hepatic impairment alterations in these blood markers of renal or 
hepatic dysfunction have been observed in uncontrolled trials. No statistically 
significant difference has been demonstrated in controlled trials (Sanofi-Aventis, 
2013). In terms of renal function there was no significant rise in creatinine seen in 
any of the patients participating in the dose finding study. Two patients were 
receiving CVVH prior to and during the treatment period. Alteration in liver function 
was however observed in 2 patients during the study treatment and follow-up period. 
In neither case did this lead to a reduction in or cessation of the study drug. In one 
patient, R04, this occurred on study day 3 and resolved slowly over several weeks. In 
the second patient the rise in liver function occurred 10 days after completion of the 
study drug and was thought to be unlikely to be related by the independent DMSC. 
 
4.19.1.3 Selection of dose of GM-CSF for use in RCT 
Low dose (3µg/kg/day), short duration (4 days) subcutaneous GM-CSF was seen to 
be both effective (associated with a demonstrable increase in neutrophil phagocytic 
capacity, in all patients, to a level associated with protection against ICUAI) and safe 
(producing a dose-limiting toxicity in < 2 of the 6 patients in whom it had been shown 
to be effective) in the first cohort of patients who were recruited to the DFS. On the 
basis that an escalation in dose may be associated with an increase in adverse 
events but was unlikely to confer additional clinical benefit a decision was made to 
proceed directly to the RCT at this dose, in keeping with the study protocol. 
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4.19.2 Study conduct 
As discussed, because of the concerns regarding the potential for a serious adverse 
reaction to the administration of GM-CSF, in particular in relation to the possibility of 
inducing ALI/ARDS (Goodman et al., 1999), the DMSC directed that patients should 
be recruited 1 at a time for the first 3 patients with submission of a detailed report to 
the DMSC prior to recruitment of the subsequent patient. Whilst this was a necessary 
requirement, to ensure patient safety as a priority, it had a significant impact on 
recruitment to the study. The DFS had initially been estimated to be completed within 
approximately six months with a total of 24 patients being recruited to 4 different 
dosing schedules. In reality, it took a total of seven months to recruit 6 patients to the 
first sub-group of the dose finding study and this undoubtedly had an influence on the 
decision to proceed directly to RCT with low-dose short-duration GM-CSF when an 
effect was seen at this dose. Again, as was seen in the ACS there was a very high 
screening to eligibility ratio and subsequently a 4:1 ratio of patients meeting the initial 
eligibility criteria to those who went on to receive the study drug. 
 
4.19.3 Suitability of inclusion / exclusion criteria 
The dose finding study offered the opportunity for further assessment and analysis of 
the suitability of the inclusion and exclusion criteria set for entry into the RCT. It was 
noted that despite the changes made prior to the DFS there remained 3 particular 
groups of patients within the target population who may be being excluded 
unnecessarily. 
I. Patients with a history of cancer (unless curative resection or treatment 
performed) 
II. Critically ill patients with an initial requirement for organ support but whose 
need for organ support had resolved prior to administration of the first dose of 
GM-CSF 
III. Patients admitted to ICU outside of the 48-hour window necessary for 
inclusion 
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Colony stimulating factors have been widely used for many years in patients 
undergoing chemotherapy for solid organ malignancies to aid recovery of neutrophil 
numbers. More recently however there have been concerns in relation to the 
potential for GM-CSF to act as a stimulant to tumour growth in patients with GM-CSF 
receptor positive tumours and that some of these tumours may follow a particularly 
aggressive pathway with accelerated progression (Aliper et al., 2014). Meanwhile, 
however, GM-CSF has been investigated as an adjuvant therapy in the treatment of 
certain solid organ malignancies including prostate cancer and melanoma (Amato et 
al., 2008, Grotz et al., 2014) with evidence of tumour response and delayed 
recurrence. 
During the screening process we encountered numerous patients with solid organ 
malignancies, many of whom had very indolent disease including low grade prostate 
cancer and a history of previous breast and bladder cancer under long-term follow-up 
without evidence of recurrence but in whom cure could not be guaranteed. Our 
concern was that many of these critically ill patients could potentially stand to benefit 
from treatment with GM-CSF during critical illness but were being excluded from the 
trial on the basis of their history of malignancy. In addition, these patients represent a 
significant proportion of the ICU population. We sought advice from two independent 
oncologists regarding the need to exclude these patients from our trial. Both were of 
the opinion that the potential of benefit to such patients from participation in the trial 
far outweighed the risk of stimulation of an underlying malignancy by GM-CSF. 
Consequently, following discussion with the DMSC an application was made to 
amend the exclusion criteria by removal of this point and this was approved. 
During the DFS a total of 3 patients had to be excluded from the trial following the 
consent process due to a resolution of their need for organ support prior to the first 
administration of GM-CSF. This represented almost 18% (3/17) of the consented 
patients. It was observed that while these patients no longer had a need for organ 
support they remained critically ill. In the 2 patients whose organ support was 
discontinued after blood had been drawn for the final assessment of eligibility the 
neutrophil phagocytic capacity was found to be 19.2% and 28.6% putting them both 
at significant risk for the development of an ICUAI. It was acknowledged by all within 
both the trial and clinical teams that cessation of organ support did not indicate a 
reduction in risk of ICUAI nor a recovery in terms of neutrophil phagocytic capacity 
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and that excluding these patients at this stage, on these grounds was inappropriate. 
An additional amendment was therefore sought to alter this inclusion criterion to read 
• Has required support of one or more organ systems (invasive ventilation, 
inotropes or haemofiltration) during current ICU stay 
 
This amendment was approved by the relevant regulatory authorities and supported 
by the independent DMSC. 
Finally, as screening did not routinely take place on a Saturday and Sunday, when no 
researcher was available, it became apparent that patients admitted between Friday 
lunchtime (after screening had taken place) and early Saturday morning (more than 
48 hours before screening took place on a Monday morning) were consequently 
being excluded from the study by virtue of the time of their admission to ICU. It was 
felt to be inappropriate to be excluding a cohort of patients on this basis and 
therefore a final application was made to extend the inclusion criteria for patients to 
72 hours following their admission to ICU. This amendment was again approved and 
put in place prior to proceeding to the RCT. 
 
4.19.4 Consent issues 
It was noted that there was a higher incidence of declined consent by PerLRs and 
ProfLRs in the DFS than was observed in the ACS. This was perhaps not 
unexpected in view of the nature of the intervention in the DFS. Although the sample 
size did not allow for any statistical comparative analysis it was noted by the 
researchers during the process of seeking informed consent that PerLRs were more 
likely to decline consent on behalf of an older patient often saying that they felt that 
their relative had been through enough and had less to gain from participation in a 
clinical trial at their age. This may account for the slight difference seen in the median 
age of the cohort in the DFS compared to the ACS (DFS median age 56.5 years 
(range 25-66) versus ACS median age 66yrs (range 31-85)). 
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4.19.5 Effect of GM-CSF on monocyte HLA-DR expression 
As in the ACS monocyte HLA-DR was seen to be low in the majority of patients with 
5 of the 6 patients having an mHLA-DR level below 15,000 Ab/cell indicative of 
moderate to severe immunodepression. Median mHLA-DR was very similar in the 
patient cohort in the DFS compared to the ACS with median of 4297 Ab/cell 
compared to 4796 Ab/cell respectively. 
Monocyte HLA-DR was seen to rise following the administration of GM-CSF until day 
3-4 following which it was seen to fall again. Levels rose to above 20,000 Ab/cell in 4 
of the 6 patients suggestive of restoration of immune competence. The subsequent 
fall following completion of GM-CSF may suggest that the effect of GM-CSF on the 
restoration of immune function was lost quickly on cessation of the study drug on day 
3. In a similar study by Meisel et al looking at the effect of GM-CSF on monocyte de-
activation (Meisel et al., 2009), GM-CSF was continued in all patients for 8 days. At 
day 5 all patients with a mHLA-DR level below 15,000 Ab/cell had their dose 
increased from 4µg/kg/day to 8µg/kg/day. All 19 patients in this study cohort 
achieved a monocyte HLA-DR level > 15,000 Ab/cell which they classified as normal 
(Meisel et al., 2009). The response to GM-CSF in Meisel’s study was greater than 
that seen in our patient cohort with mean mHLA-DR 43,676 (+/-24,517) at day 4 
versus 5,609 (+/- 3,628) at baseline in Meisel’s study compared to mean mHLA-DR 
14,279 (+/- 3243) on day 4 versus 7,814 (+/- 7343) at baseline in our own cohort. In 
Meisel’s study all patients received a 33% greater dose of GM-CSF subcutaneously 
each day. 
While mHLA-DR is widely accepted as a reliable marker of immune dysfunction the 
biological significance of the restoration of circulating MHLA-DR expression following 
treatment with GM-CSF is not clear. No assessment of the immune function of 
monocytes following recovery of mHLA-DR expression has been reported in the 
literature to my knowledge. Within our patient cohort despite a weak correlation 
between mHLA-DR and neutrophil phagocytic capacity at baseline no correlation was 
seen between mHLA-DR and neutrophil phagocytic capacity following administration 
of GM-CSF. 
The significance of the fall in mHLA-DR following completion of the GM-CSF dosing 
schedule is not clear but may potentially indicate an inadequate duration of treatment 
to ensure maintenance of restoration of immune function. 
! 141!
4.19.6 Effect of GM-CSF on neutrophil CD88 expression 
Within this cohort of patients there was a general trend towards an increase in 
neutrophil CD88 expression following the administration of GM-CSF. As had been 
reported previously by Conway Morris et al there was a significant correlation seen 
between neutrophil CD88 expression and neutrophil phagocytic capacity at baseline 
(Spearman r = 0.6). A moderate correlation was seen to persist following 
administration of GM-CSF (Spearman r = 0.43). In Conway Morris’ previous ex-vivo 
work the correlation between neutrophil CD88 expression and neutrophil phagocytic 
capacity was not studied following the application of GM-CSF. GM-CSF was seen to 
restore phagocytic capacity but the effect on restoration of neutrophil CD88 
expression was not assessed (Conway Morris et al., 2009). 
 
4.19.7 Serum GM-CSF levels following administration of study drug 
Serum GM-CSF levels were seen to rise following subcutaneous injection of GM-
CSF peaking at between 4 and 6 hours post-dose. The pharmacokinetics of GM-CSF 
are variably reported with studies showing a range in time to peak serum GM-CSF 
levels following administration of a bolus sub-cutaneous injection between 1 – 20 
hours post dose (Steward,1993, Hovgaard et al., 1991, Cebon et al., 1988). 
Measured peak serum GM-CSF levels in our cohort were between 50-110 pg/ml. 
Similar levels were seen in Meisel’s study where the treated cohort mean GM-CSF 
levels were 40.3 (+/-77.1) pg/ml. Pharmacokinetic studies of GM-CSF have shown 
peak serum levels to be related to both the dose and route of administration of GM-
CSF. The sub-cutaneous route of administration was chosen for use in this study due 
to its more favourable safety profile (Honkoop et al., 1996). There are limited data on 
the absorption of drugs administered subcutaneously in critically ill patients however 
available studies suggest that absorption may be significantly impaired due to poor 
tissue perfusion particularly associated with vasopressor use (Smith et al., 2012, 
Dorffler-Melly et al., 2002). One study examining serum anti-factor Xa levels in 
critically ill patients on ICU receiving low molecular weight heparin (the most 
commonly administered sub-cutaneous drug in ICU) showed that only 28% of 
patients receiving the recommended dose were found to have reached the desired 
range for thromboprophylaxis (Jochberger et al.,2005). Multiple factors affect the 
bioavailability of drugs in critically ill patients on ICU and careful pharmacokinetic 
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studies are needed to determine effective doses for such patients as data from non-
critically ill cohorts are unlikely to be representative. 
 
4.19.8 PaO2:FiO2 following administration of GM-CSF 
The administration of GM-CSF was not associated with any deterioration in gas 
exchange as measured by the PaO2:FiO2 and therefore there was no evidence to 
suggest the development or worsening of acute lung injury in these patients. 4 of the 
6 patients met the PaO2:FiO2 criteria for ALI on day 0, prior to administration of GM-
CSF, with 2 patients meeting the criteria for ARDS (Bernard et al.,1994). Median 
PaO2:FiO2 was 31kPa (range 16-70). There was a general trend towards an 
improvement in PaO2:FiO2 over the course of the study but this did not meet 
statistical significance. By day 9 median PaO2:FiO2 had risen to 40kPa (range 30-
100) with 3 patients meeting the criteria for ALI and no patients having ARDS. The 
concerns regarding the sequestration of neutrophils within the lungs leading to ALI 
were not apparent in this cohort of patients (Sanofi-Aventis., 2013). The data 
regarding the role of GM-CSF in the development of ALI in critically ill patients is 
conflicting with one recent randomised controlled trial investigating whether GM-CSF 
may in fact be useful as a therapy to treat patients with ARDS.  There was no 
difference seen in the primary outcome of ventilator free days seen (Paine et al., 
2012).  
 
4.19.8 Outcome of patients following administration of GM-CSF 
5 of the 6 patients survived to 30 days following administration of GM-CSF; 2 had 
been discharged home, one remained an inpatient on ICU and 2 remained hospital 
inpatients not on ICU. 1 patient was lost to follow-up at 30 days. As with the ACS this 
represents an expected outcome for critically ill patients. 
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4.20 Limitations of the dose finding study 
The dose finding study had several limitations which may have impacted on the 
interpretation of the results. 
 
4.20.1 Sample size 
The small sample size limits the strength of any findings and in particular lead to a 
significant impact of the missing phagocytosis data for patient R01 on day 2. A larger 
cohort of patients in each dosing sub-group would have offered greater confidence in 
the observed biological effect. 
  
4.20.2 Lack of control group 
A control group within each dosing cohort to run in parallel to the treatment group 
would have enabled analysis of the natural course of neutrophil phagocytic capacity 
during critical illness. As we did not have a control group for comparison and the 
literature lacks a description of the natural recovery of neutrophil phagocytic capacity 
in the course of critical illness, we were unable to assess the magnitude of the 
apparent biological response which we observed in our cohort of treated patients. It 
is possible therefore that we may have overestimated the contribution of the GM-CSF 
to the improvements seen in individual neutrophil phagocytic capacity. 
 
4.20.3 Absence of comparison with increased dose and duration of GM-CSF 
The decision to proceed directly to the RCT carrying forward low-dose, short-duration 
GM-CSF as the treatment intervention was made partly on the basis that low-dose, 
short-duration GM-CSF was deemed to be both safe and effective and partly due to 
pressures in relation to recruitment to, and progress of, the trial. Proceeding to the 
next stages of the DFS would have enabled comparison of both the increased dose 
(in particular, whether an increased biological effect may have been observed), and 
the more prolonged duration which may have shown evidence of a more sustained 
response in terms of mHLA-DR recovery suggesting a potentially increased benefit 
with a longer duration of therapy. 
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4.21 Conclusions 
The dose finding study demonstrated low-dose, short duration GM-CSF to be both 
safe and effective in terms of restoring neutrophil phagocytic capacity in critically ill 
patients with confirmed impairment. The absence of any deterioration in gas 
exchange confirmed that the RCT could safely proceed with open, unrestricted 
recruitment of patients without fear of harm. Finally, the opportunity to further analyse 
the inclusion and exclusion criteria enabled these criteria to be further modified to 
ensure recruitment of the target population of patients most likely to have the 
potential for benefit from the intervention being studied. 
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Chapter 5: Randomised Controlled Trial 
 
This chapter will outline the results of the randomised controlled trial. It will begin by 
stating the aim of the study and describing the primary and secondary outcomes and 
will go onto give a synopsis of the study conduct. The processes of screening, 
recruitment and consent will be revised prior to presenting the results. Finally, the 
conclusions and limitations of the study will be discussed. 
 
5.1 Aim of study 
The aim of the trial was to investigate the hypothesis that GM-CSF would restore 
effective neutrophil function in critically ill patients with known impaired neutrophil 
function. 
 
5.2 Study design 
The randomised controlled trial was designed to compare the outcome, in terms of 
neutrophil phagocytic capacity, of 2 matched groups of critically ill patients with 
impaired neutrophil function randomised to receive either subcutaneous GM-CSF or 
placebo over a period of 4 days following admission to ICU. Based on the previous 
work carried out by our collaborators (Conway Morris et al, 2009) we believed that an 
absolute increase in neutrophil phagocytic capacity of ≥ 15% from baseline to day 2 
would be clinically significant. On this basis we calculated that a sample size of 17 
per group would give a power of 90% to detect such a difference between the 
groups. To allow for loss of patients to follow-up during the study we planned to 
recruit 19 patients into each group (Trial protocol, appendix). 
 
Following completion of the Dose Finding Study it was recognised that some of the 
exclusion criteria were excluding patients within the target study population. As 
discussed in chapter 4 minor modifications to the inclusion and exclusion criteria 
were made and approved by the relevant regulatory bodies prior to commencing 
enrolment to the dose finding study; 
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I. The exclusion criterion ‘Patients with a history of cancer (unless curative 
resection or treatment performed)’ was removed 
II. The window for inclusion following admission to ICU was extended to 72 hours 
III. The inclusion requirement for organ support was amended to include any 
patient who had ‘required support of one or more organ systems (invasive 
ventilation, inotropes or haemofiltration) during current ICU stay’ 
 
 
5.3 Study outcomes 
 
5.3.1 Primary outcome 
The primary outcome of the trial was neutrophil phagocytic capacity, as measured by 
the percentage of neutrophils ingesting 2 or more zymosan particles at day 2 
following administration of the study drug or placebo. 
 
5.3.2 Secondary outcomes 
The study included several secondary outcomes which included both biological and 
clinical measures. 
 
5.3.2.1 Biological measures 
The following biological measures were assessed up to day 9: 
 
I. Sequential neutrophil phagocytic capacity to look for sustainability of any 
effect seen on day 2 following administration of GM-CSF 
II. Neutrophil superoxide generation following administration of GM-CSF 
III. Neutrophil chemotaxis following administration of GM-CSF 
IV. Neutrophil apoptosis following administration of GM-CSF 
V. Monocyte HLA-DR expression following administration of GM-CSF 
VI. Relative proportions of regulatory T cells following administration of GM-CS 
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5.3.2.2 Clinical measures 
 
I. Sequential organ failure assessment (SOFA) score to day 7 
II. Length of ICU and hospital stay 
III. The incidence of nosocomial infection (as defined by the HELICS criteria) 
IV. All-cause mortality at 30 days following randomisation 
V. PaO2:FiO2 following administration of GM-CSF to day 9 
VI. Duration of mechanical ventilation to day 30 
 
 
5.4 Study conduct 
Following completion of the DFS (including analysis of the data collected in relation 
to the effect of GM-CSF on PaO2:FiO2) the DMSC gave permission for recruitment to 
the RCT to take place in an unrestricted manner with recruitment commencing at all 
sites at the same time. 
 
5.5 Recruitment  
The randomised controlled trial commenced in November 2013 and ran until March 
2014. Patients were recruited from 5 different intensive care units across 3 different 
hospital Trusts in the North East of England namely, the Royal Victoria Infirmary 
(General and Neurosurgical ICUs) and the Freeman Hospital Critical Care Unit (all 
The Newcastle upon Tyne Hospitals NHS Foundation Trust), the Queen Elizabeth 
Hospital Gateshead Critical Care Unit, (Gateshead Health NHS Foundation Trust), 
and Sunderland Royal Hospital Integrated Critical Care Unit, City Hospitals 
Sunderland NHS Foundation Trust. 
 
All admissions to critical care were screened on a daily basis, from Monday to Friday, 
to identify eligible patients according to the inclusion and exclusion criteria below.   
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Eligibility criteria for RCT 
 
Inclusion criteria 
 
• Fulfil criteria for SIRS* (see Chapter 2, section 2.1.1.3, page 40) 
• Has required support of 1 or more organ systems (mechanical 
ventilation/inotropes/haemofiltration) during current ICU stay 
• Survival over next 48 hours most likely outcome 
• Consent obtained from patient, PerLR or ProfLR 
• Admitted to ICU within last 72 hours 
Final step in eligibility 
• Neutrophil phagocytosis < 50% 
 
 
Exclusion Criteria 
 
• Absence/refusal of informed consent 
• Current prescription of a colony stimulating factor 
• Any history of allergy/adverse reaction to GM-CSF 
• Total white cell count >30x109/litre at time of screening 
• Haemoglobin < 7.5g/dl at the time of screening 
• Age < 18 years 
• Pregnancy or lactation 
• Known in-born errors of neutrophil metabolism 
• Known haematological malignancy and/or known to have >10% peripheral 
blood blast cells   
• Known aplastic anaemia or pancytopaenia 
• Platelet count <50x109/litre 
• Chemotherapy or radiotherapy within the last 24 hours 
• Solid organ or bone marrow transplantation 
• Use of maintenance immunosuppressive drugs other than maintenance 
corticosteroids (allowed up to 10mg prednisolone/day or equivalent) 
• Known HIV infection 
• Active connective tissue disease (e.g. rheumatoid disease, systemic lupus 
erythematosus) requiring active pharmacological treatment. 
• ST-segment elevation myocardial infarction, acute pericarditis (by ECG 
criteria) or pulmonary embolism (radiographically confirmed) in previous 
week 
• Involvement in any study involving an investigational medicinal product in the 
previous 30 days 
 
 
Table 20: Eligibility criteria for randomised controlled trial 
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A total of 3634 patients were screened to recruit 38 patients to the RCT. The 
CONSORT (Consolidated standards of Reporting Trials) diagram (Figure 5.1) 
overleaf shows the process by which the 38 patients were enrolled into the study.  
As with the previous phases of the study consent was sought from the individual 
where possible (8/38, 21.1%). Of these participants 30 (78.9%) lacked capacity as a 
consequence of their critical illness and in these circumstances, as before, consent 
was sought from a personal (26/38, 68.4%) or professional (4/38, 10.5%) legal 
representative. 18 of the 30 (60%) participants who lacked capacity at the time of 
enrolment recovered capacity prior to end end of the trial. Of these 13 (13/18, 72) 
gave retrospective consent. Of the other 5 one had been withdrawn from the study 
immediately following randomisation and received no drug or further blood sampling 
and 2 were discharged from hospital prior to retrospective consent being sought. 
There were substantially more cases of declined consent in the RCT with 70 
episodes of out of 134 eligible patients (52%) compared to 7/24 (29%) in the DFS. 
 
5.6 Final eligibility 
As with the DFS neutrophil phagocytic capacity assessment was used as the final 
step for eligibility with only those patients found to have neutrophil phagocytic 
capacity < 50% proceeding to randomisation.  
 
5.7 Randomisation 
Once final eligibility was confirmed patients were randomised via an online 
programme and a randomisation number was generated. A prescription containing 
the randomisation number was then taken to the relevant clinical trials pharmacy 
where study drug/placebo was issued to a member of the unblinded research nursing 
team delegated with responsibility for administering the drug. Blinding of all other 
clinical and research staff was maintained during drug administration. 
21 patients were randomised to receive placebo with 17 patients being randomised 
to receive GM-CSF (see consort diagram, figure 5.1). The reason for the imbalance 
between groups was in part due to the randomisation being stratified by site in 
permuted blocks of variable length (Trial protocol, appendix 1) and part due to the 
effect of one patient who was randomised in error and was subsequently excluded 
from the study.  
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5.8 CONSORT diagram 
 
 
 
 
Figure 5.1: CONSORT Diagram of randomised controlled trial. For the two patients 
excluded from the trial following consent, on the basis of abnormal blood results, the results 
were found to have become abnormal on routine clinical testing after consent had been 
taken but prior to randomisation. ITT, intention to treat; ICUAI, ICU acquired infection.  
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5.9 Baseline demographic data 
 
Overall baseline demographic data were similar between the 2 groups (Table 17). 
There were more male patients and more patients with a surgical diagnosis in the 
placebo group compared to the GM-CSF group. 
 
 
  Placebo GM-CSF 
N 21 17 
Median age, years (range) 68 (31-80) 69 (28-89) 
Gender (male : female) 15:6 10:7 
Median weight, kg (range) 82 (45-144) 77 (49-103) 
% with surgical reason for admission to ICU 28.6 17.6 
Median APACHE II score (IQR) 21 (18-23) 19.5 (16-27.5) 
Sepsis at admission (n) 9 8 
Median SOFA Score on admission (IQR) 8 (6-10) 9 (4-11) 
Median lowest PaO2:FiO2 , kPa (IQR) 25 (17-38) 20 (16-26) 
Median lowest MAP, mmHg (IQR) 63 (61-67) 61 (59-65) 
Smoking status (current: ex: never: unknown) 
(%) 
19:33:19:29 35:35:24:6 
Neutrophil phagocytosis % 40.1 (8.2) 45.1 (4.6) 
Median white cell count [x109/L] (IQR) 11.9 (5.9-12.7) 14.5 (9.6-22.1)) 
Median neutrophil count [x109/L] (IQR) 9.5 (4.0-10.8) 13.1 (8.3-20.6) 
Median platelet count [x109/L] (IQR) 164 (101-236) 208 (94-257) 
Median creatinine [µmol/L] (IQR) 132 (72-155) 83 (54-159) 
Median ALT [U/L] (IQR) 27 (16-36) 27 (17-50) 
Median AST [U\L] (IQR) 34 (26-108) 71 (42-92) 
 
Table 21. Baseline demographic data for participants in randomised controlled trial. 
ALT, alanine aminotransferase; APACHE, acute physiology and chronic health evaluation; 
AST, aspartate aminotransferase; FiO2 inspired concentration of oxygen; ICU, intensive care 
unit; IQR, inter-quartile range; kg, kilogram; L, litre; MAP, mean arterial pressure; µmol, 
micromole; PaO2 partial pressure of oxygen; SOFA, sequential organ failure assessment 
score, s.d., standard deviation; U, unit.  
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There was a greater number of patients admitted following emergency surgery within 
the placebo group compared to the GM-CSF group (Table 18). Otherwise the source 
of admission was similar between the two groups.  
 
Allocation Arm Elective 
medical 
Elective 
surgical 
Emergency 
medical 
Emergency 
surgical 
Placebo 1 2 14 4 
GM-CSF 0 2 14 1 
Total 1 4 28 5 
 
Table 22: Case mix of patients in randomised controlled trial 
 
 
There were similar rates of co-morbid disease in both groups of patients. Increased 
rates of known heart disease (angina, congestive heart failure and myocardial 
infarction) were observed in the placebo group. 
 
 Placebo (Y:N) GM-CSF (Y/N) 
Arthritis 2 (11%) : 17 (89%) 4 (25%) : 12 (75%) 
Osteoporosis 0 (0%) : 19 (100%) 0 (0%) : 15 (100%) 
Asthma 1 (5%) : 18 (95%) 2 (13%) : 13 (87%) 
COPD/ARDS/Emphysema 5 (25%) : 15 (75%) 4 (24%) : 13 (76%) 
Angina 2 (21%) :15 (79%) 1 (6%) : 15 (94%) 
Congestive heart failure 4 (20%) : 16 (80%) 0 (0%) : 15 (100%) 
Myocardial infarction 5 (26%) : 14 (74%) 1 (7%) : 14 (93%) 
Neurological disease 0 (0%) : 19 (100%) 0 (0%) : 15 (100%) 
Cerebrovascular disease 3 (15%) : 17 (85%) 1 (7%) : 13 (93%) 
Peripheral vascular 
disease 
2 (11%) : 17 (89%) 1 (7%) : 13 (93%) 
Diabetes type 1 and 2 5 (26%) : 14 (74%) 3 (20%) : 12 (80%) 
Upper GI disease 2 (11%) : 17 (89%) 4 (25%) : 12 (75%) 
Depression 3 (20%) : 16 (84%) 3 (20%) : 12 (80%) 
Anxiety/panic disorders 0 (0%)  : 19 (100%) 2 (13%) : 13 (87%) 
Visual impairment 2 (11%) : 17 (89%) 0 (0%)  : 15 (100%) 
Hearing impairment 1 (5%) : 18 (95%) 0 (0%) : 15 (100%) 
Obesity and/ or BMI>30 3 (17%) : 15 (83%) 2 (13%) : 13 (87%) 
Degenerative disc disease 0 (0%) : 19 (100%) 0 (0%) : 15 (100%) 
 
Table 23: Co-morbid disease data 
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5.10 Study drug administration 
All patients in the RCT were intended to receive a daily injection of subcutaneous 
GM-CSF at a dose of 3 microgram/kg/day or an equivalent volume of normal saline 
until one of the study drug termination criteria was met (Chapter 2, section 2.11.5). 
As outlined in the trial methods (Chapter 2, section 2.11.3) the syringe and contents 
of the subcutaneous injections of GM-CSF and normal saline were identical in 
appearance and volume at the point of administration. 
The study drug had to be terminated in five patients prior to assessment of the 
primary outcome on day 2. In the cohort of patients randomised to receive placebo 
one patient triggered the study drug termination criteria on the morning of day 1 
(development of thrombocytopenia). As a result, this patient only received one dose 
of the study drug during the course of the trial. In the cohort of patients randomised to 
receive GM-CSF one patient triggered study drug termination criteria prior to 
receiving any study drug (the patient developed marked thrombocytosis, platelet 
count 1099 x109/L) and was discharged from ICU on day 1, with no further blood 
samples collected. A further three patients in the GM-CSF group triggered study drug 
termination criteria after only one dose (one patient died, one developed a significant 
transaminitis and the third developed thrombocytopenia). As a result, only 13 patients 
in the GM-CSF group received each daily dose of study drug up to and including the 
point of assessment of the primary outcome (i.e. at least 2 doses of GM-CSF) 
compared to 20 patients receiving placebo. 
Median weight in the GM-CSF group was 77 kg (range 49 – 103) and in the placebo 
group 82kg (range 45 – 144). The dose or volume of GM-CSF or placebo to be 
administered was prescribed according to weight ranges to the nearest 5kg. GM-CSF 
was dosed on actual body weight up to a maximum dose of 450 micrograms /1.8ml 
by volume (see table 20). Normal saline was prescribed by equivalent volume (see 
table 21). Corresponding doses or equivalent volumes of study drug ranged from 135 
micrograms (0.54ml) to 435 micrograms (1.75ml). In line with the size and graduation 
of the syringes used to administer the injections, doses above 1ml were rounded to 
the nearest 0.05mls due to the accuracy with which the dose could be drawn up. 
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Table 24: Dosing schedule for patients allocated to GM-CSF arm 
kg, kilogram, ml, millilitres. *In line with the size and graduation of the syringes used 
to administer the injections, doses above 1ml were rounded to the nearest 0.05mls 
due to the accuracy with which the dose could be drawn up. 
 
 
 
 
  
Patient Weight (kg) Dose of GM-CSF   to 
be administered per 
day (microgram) 
(3microgram/kg) 
Volume of GM-CSF 
to be administered 
subcutaneously  per 
day (ml) 
Number of 
vials 
required 
per day 
  40 (37.5 – 42.4 kg) 120 0.48 1 
  45 (42.5 – 47.4 kg) 135 0.54 1 
  50 (47.5 – 52.4 kg) 150 0.60 1 
  55 (52.5 – 57.4 kg) 165 0.66 1 
  60 (57.5 - 62.4 kg) 180 0.72 1 
  65 (62.5 – 67.4 kg) 195 0.78 1 
  70 (67.5 – 72.4 kg) 210 0.84 1 
  75 (72.5 – 77.4 kg) 225 0.90 1 
  80 (77.5 – 82.4 kg) 240 0.96 1 
  85 (82.5 – 87.4 kg) 255 1.0* 1 
  90 (87.5 – 92.4 kg) 270 1.1 2 
  95 (92.5 – 97.4 kg) 285 1.15 2 
100 (97.5 – 102.4 kg) 300 1.2 2 
105 (102.5 – 107.4 kg) 315 1.25 2 
110 (107.5 – 112.4 kg) 330 1.3 2 
115 (112.5 – 117.4 kg) 345 1.4 2 
120 (117.5 – 122.4 kg) 360 1.45 2 
125 (122.5 – 127.4 kg) 375 1.5 2 
130 (127.5 – 132.4 kg) 390 1.55 2 
135 (132.5 – 137.4 kg) 405 1.6 2 
140 (137.5 – 142.4 kg) 420 1.7 2 
145 (142.5 – 147.4 kg) 435 1.75 2 
150 (147.5 – 150 kg+) 450 1.8 2 
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Table 25: Dosing schedule for patients allocated to placebo arm 
kg, kilogram, ml, millilitres. *In line with the size and graduation of the syringes used 
to administer the injections, doses above 1ml were rounded to the nearest 0.05mls 
due to the accuracy with which the dose could be drawn up. 
 
 
 
  
Patient Weight (kg) Volume of 0.9 % sodium 
chloride to be administered 
subcutaneously 
  per day (ml) 
Number of 
ampoules 
required per day 
  40 (37.5 – 42.4 kg) 0.48 1 
  45 (42.5 – 47.4 kg) 0.54 1 
  50 (47.5 – 52.4 kg) 0.60 1 
  55 (52.5 – 57.4 kg) 0.66 1 
  60 (57.5 - 62.4 kg) 0.72 1 
  65 (62.5 – 67.4 kg) 0.78 1 
  70 (67.5 – 72.4 kg) 0.84 1 
  75 (72.5 – 77.4 kg) 0.90 1 
  80 (77.5 – 82.4 kg) 0.96 1 
  85 (82.5 – 87.4 kg) 1.0* 1 
  90 (87.5 – 92.4 kg) 1.1 1 
  95 (92.5 – 97.4 kg) 1.15 1 
100 (97.5 – 102.4 kg) 1.2 1 
105 (102.5 – 107.4 kg) 1.25 1 
110 (107.5 – 112.4 kg) 1.3 1 
115 (112.5 – 117.4 kg) 1.4 1 
120 (117.5 - 122.4 kg) 1.45 1 
125 (122.5 – 127.4 kg) 1.5 1 
130 (127.5 – 132.4 kg) 1.55 1 
135 (132.5 – 137.4 kg) 1.6 1 
140 (137.5 – 142.4 kg) 1.7 1 
145 (142.5 – 147.4 kg) 1.75 1 
150 (147.5 – 150kg +) 1.8 1 
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5.11 Blood sampling 
As described in chapter 2 (section 2.12), blood samples were collected from patients 
on alternate mornings for assessment of neutrophil function, monocyte and T 
lymphocyte analysis, and cytokine profiling. Samples for assessment of these 
biological outcomes were collected from all patients on day 0 and day 2 and then on 
day 4 or 5, day 6 or 7 and day 8 or 9 according to the availability of the researchers 
(see table 26). Blood for assessment of these parameters was not collected on 
weekend days when no researcher was available. As far as possible following 
discharge of patients from the intensive care unit blood samples continued to be 
collected at the required time points up until day 8/9 or the point of discharge from 
hospital, whichever came first. No blood samples were collected from patients 
following discharge from hospital. 
Blood was collected for the assessment of safety parameters on a daily basis, 
including weekends, as part of usual clinical care.  
Missing samples occurred in all data subsets (a) following patient death, (b) in some 
circumstances following discharge from the ICU, and (c) on weekend days when no 
researcher was available. In addition, there were some instances of failed assays. 
Table 22 summarises the completeness of neutrophil phagocytosis data for all 
patients from day 0 to day 9. Where there are omissions the reason for the omission 
is described. In circumstances where researcher availability was limited priority was 
given to completion of the neutrophil phagocytic capacity assay. As a consequence, 
some of the n values for other neutrophil functional assessments and flow cytometry 
analyses may be lower than the corresponding n value for the phagocytosis results 
for any given day. 
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Table 26: Study day blood sample analysis and missing data 
W/E-RNA, weekend-researcher not available; X, sample collected; dis, discharged; PNS, 
patient not sampled  
Patient 
study ID DO D2 D4/5 D6/7 D8/9 
F04 X X X X X 
F05 X X X X X 
F06 X X X X W/E-RNA 
F08 X X Died D4 
Q07 X X X X X 
Q12 X Discharged  ICU D1   PNS  
Q15 X X X X PNS 
Q20 X X X Died D5 
Q22 X X X X X 
Q23 X X X X W/E-RNA 
Q24 X X W/E-RNA X X 
Q25 X X W/E-RNA X X 
Q26 X X Died D3 
Q27 X X W/E-RNA X Dis hospital D8 
R11 X X W/E-RNA X X 
R13 X X X X X 
R14 X X X X X 
R15 X X X Discharged Hospital D6 
R16 X X X X X 
R18 X X X Died D4 
R21 X Died D1 
R22 X X X X Died D7 
R24 X X X X W/E-RNA 
R26 X X X Died D5 
R27 X X X X W/E-RNA 
R29 X X X X X 
R30 X X X X X 
R31 X X Discharged hospital  D1 
R33 X X X PNS W/E-RNA 
S01 X X X PNS X 
S02 X X X X X 
S03 X X X X X 
S04 X X X X X 
S06 X X X X X 
S07 X X X X X 
S11 X X X Discharged ICU D7 PNS 
S12 X X X X X 
S13 X X W/E-RNA X X 
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5.12 Clinical data collection 
Clinical data collection included the following parameters; SOFA score, length of ICU 
and hospital stay, mortality, duration of mechanical ventilation, PaO2:FiO2 ratio, body 
temperature and clinical blood results. These data were recorded on source data 
(ICU observation charts, hospital clinical notes, ICU blood result charts and electronic 
patient records) by members of the usual clinical team as part of routine clinical care. 
All members of the routine clinical team were fully blinded to patient allocation at all 
times. Members of the research nursing team were involved in the transcription of 
these data from source data to the electronic case report form. 
 
 
5.13 Blinding 
The study was designed to be a double blind randomised controlled trial with the 
participants, the research team and the usual clinical team all remaining blinded to 
the treatment allocation at all times. As discussed in Chapter 2 (section 2.10) 
complexities in relation to the drug stability following reconstitution and the operating 
procedures of the clinical trial pharmacies, alongside the absence of a custom made 
fully matched placebo, resulted in significant logistical challenges in implementing the 
blinding. A pool of unblinded research nursing staff were recruited and trained to 
reconstitute and administer the study drug. Reconstitution and administration of the 
study drug was the only unblinded task undertaken in the delivery of the trial. All 
other trial procedures were fully blinded at all times. Blinded and unblinded tasks 
could not be undertaken by the same member of the research nursing team for a 
given patient to ensure that there was no potential for bias within the results. 
Laboratory staff carrying out all laboratory assessments including neutrophil, 
monocyte, T lymphocyte and cytokine analysis for primary and secondary outcomes 
were fully blinded to sample treatment allocation at all times. 
Following completion of the study, during the processes of internal and external 
audits it became apparent that at two sites research nursing staff who had been 
involved in the unblinded reconstitution and administration of the study drug, had 
taken part in the blinded task of transfer of clinical data from source data to the 
electronic case report form for the same patient. As the clinical data were all 
recorded independently at source, by the clinical nursing team or hospital laboratory 
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as part of usual clinical care, the potential for bias (through the participation of an 
unblinded member of the research nursing team in this task) is considered to be 
negligible but could not be fully excluded. As a consequence, the Research Sponsor 
(Newcastle upon Tyne Hospitals NHS Foundation Trust) and the MHRA 
recommended that the study should be reported as a single blinded trial.  
  
 
 
Figure 5.2: Schematic diagram showing mechanisms of blinding and potential breach 
of blinding. The patient, research laboratory staff, hospital laboratory staff and hospital 
clinical staff remained fully blinded at all times. The study drug was administered by research 
nurses unblinded to the allocation for that particular patient. During audit processes it 
became apparent that research nursing staff, unblinded to the treatment allocation of an 
individual patient, had participated in the blinded task of transfer of source data to the e-CRF 
for the same patient. This potential breach had occurred in patients at two sites. * Source of 
potential breach of blinding - research nursing staff were found to have undertaken the 
blinded task of transfer of clinical data on patients in whom they had administered study drug 
even though it had been mandated that they should not. Solid black line signifies complete 
separation of participant / staff at all times. Dotted black line indicates staff working within 
same environment at certain times.  
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5.14 Results: Neutrophil phagocytic capacity 
 
As previously described in chapter 2 (section 2.16) neutrophils were extracted from 
whole blood by dextran sedimentation and percoll gradient separation technique. 
Following isolation neutrophils were pre-incubated with autologous serum and then 
incubated with zymosan particles for 30 minutes at 37°C in a 5% CO2 incubator. 
Neutrophil phagocytic capacity was assessed by light microscopy by counting the 
percentage of neutrophils ingesting 2 or more zymosan particles. 
 
5.14.1 Neutrophil phagocytic capacity at baseline 
There was an unexpected difference seen in neutrophil phagocytic capacity between 
the two groups at baseline with mean phagocytic capacity being 40.1 (s.d.+/- 8.2, 
n=21) in the group subsequently randomised to placebo group versus mean of 45.1 
(s.d. +/- 4.6, n=17) in the group randomised to receive GM-CSF. This difference was 
statistically significant (p=0.03). Where analyses have been found to be statistically 
significant adjustment for baseline will be carried out. 
 
 
 
Figure 5.3: Mean neutrophil phagocytic capacity at baseline. A statistically significant 
difference was seen at baseline between the two groups when analysed by 2-sample t-test. 
Mean placebo 40.1% (s.d.+/- 8.2, n= 21), mean GM-CSF 45.1% (s.d.+/- 4.6, n= 17), p=0.03. 
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5.14.2 Neutrophil phagocytic capacity on day 2 
A rise in neutrophil phagocytic capacity was seen between day 0 and day 2 (the day 
for assessment of the primary outcome) in both groups. Mean neutrophil phagocytic 
capacity in the placebo group was 49.8% (s.d.+/- 13.4) versus mean neutrophil 
phagocytic capacity in the GM-CSF group of 57.2% (s.d.+/- 13.2), p=0.11. The mean 
rise in GM-CSF treated patients was 11.9% (s.d. +/- 12.3%, n=15) versus 9.6% (s.d. 
+/- 10.8%, n=21) in the placebo group. There was no significant difference seen in 
neutrophil phagocytic capacity at day 2, however.   
 
 
 
Figure 5.4: Mean neutrophil phagocytic capacity at day 2. No significant difference was 
seen between the two groups on day 2 when analysed by 2-sample t-test. Mean placebo 
49.8% (s.d.+/- 13.4, n= 21), mean GM-CSF 57.2% (s.d.+/- 13.2, n= 15), p=0.11. 
 
 
 
 
5.14.3 Neutrophil phagocytic capacity on day 4/5 
There was a statistically significant difference seen in neutrophil phagocytic capacity 
between the 2 groups at day 4/5 -  mean in the GM-CSF group 62.3 %(+/- 15.7, 
n=12) versus mean placebo group 50.3% (+/- 14.3, n=16), p=0.046. This significance 
was lost however, when adjusted for site and baseline neutrophil phagocytic capacity 
(p=0.15). The mean rise in neutrophil phagocytic capacity was 17.2% (+/- 13.6) in the 
GM-CSF group versus 10.8% (+/- 14.1) in the placebo group. 
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Figure 5.5: Mean neutrophil phagocytic capacity at day 4/5. A statistically significant 
difference was seen between the two groups on day 4/5 when analysed by 2-sample t-test. 
Mean placebo 50.3% (s.d.+/- 14.3, n= 16), mean GM-CSF 62.3% (s.d.+/- 15.7, n= 12), 
p=0.046. 
 
 
 
 
 
5.14.4 Neutrophil phagocytic capacity on day 6/7 
Mean neutrophil phagocytic capacity was once again seen to be greater in the GM-
CSF treated group compared to the placebo group on day 6/7. However, this fell just 
outside statistical significance, p=0.05. Mean neutrophil phagocytic capacity was 
64% (+/- 11.4, n=10) in the GM-CSF group with mean capacity of 52.7% (+/- 15.0, 
n=16) in the placebo group. 
 
 
5.14.4 Neutrophil phagocytic capacity on day 8/9 
Finally, on day 8/9 there was no significant difference observed in neutrophil 
phagocytic capacity between the 2 groups. Mean neutrophil phagocytic capacity was 
57.2% (s.d. +/- 16.6, n=11) in the placebo group versus 68.3% (s.d.+/- 9.1, n=9) in 
the GM-CSF group (p=0.09). 
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Table 27: Summary statistics for neutrophil phagocytic capacity over study 
course 
  
Study Day Statistical 
indices 
Placebo GM-CSF 
Baseline : Day 
0 
N 
Mean 
S.D. 
Median 
Range 
IQR 
21 
40.1 
8.2 
41.3 
15.2 – 48.7 
36.3 – 47.3 
17 
45.1 
4.6 
46.6 
35.1 – 49.7 
42.4 – 48.7 
Day 2 N 
Mean 
S.D. 
Median 
Range 
IQR 
21 
49.8 
13.4 
48.8 
23 – 77.1 
41.7 – 59.6 
15 
57.2 
13.2 
60.8 
22.4 – 76.3 
51.9 – 76.3 
Day 4/5 N 
Mean 
S.D. 
Median 
Range 
IQR 
16 
50.3 
14.3 
47.1 
33.9 – 86 
40.1 – 56.8 
12 
62.3 
15.7 
63.2 
29.6 – 86.1 
49.5 – 74.8 
Day 6/7 N 
Mean 
S.D. 
Median 
Range 
IQR 
16 
52.7 
15.0 
48.9 
34.6 – 88.3 
40.9 – 62.2 
10 
64.0 
11.4 
63.5 
51.5 – 86.2 
52.9 – 71.5 
Day 8/9 N 
Mean 
S.D. 
Median 
Range 
IQR 
11 
57.2 
16.6 
59.2 
32 - 83.2 
44.2 – 72.7 
9 
68.3 
9.1 
66.7 
53.2 
84.9 
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5.14.5 Proportion of patients with adequate neutrophil phagocytic capacity 
There was a statistically significant difference seen in the proportion of patients with 
adequate neutrophil phagocytic capacity (i.e. ≥ 50% of neutrophils ingesting 2 or 
more zymosan particles following a zymosan “meal”) in the GM-CSF group 
compared with the placebo group on day 2 (42.9% versus 80%, p=0.041) and day 
6/7 (43.8% versus 100%, p=0.004). On day 4/5 and day 8/9, although there was a 
greater proportion of patients with adequate neutrophil phagocytic capacity, this did 
not reach statistical significance (day 4/5 placebo 43.8% versus GM-CSF 75%, 
p=0.13, day 8/9 placebo 63.6% versus GM-CSF 100%, p=0.09). 
 
 
 
5.14.5.1 Proportion of patients with adequate neutrophil phagocytic capacity 
on day 2 
 
 
 
 
Figure 5.6: Proportion of patients with neutrophil phagocytic capacity ≥50% or 
<50%on day 2. There was a significant difference was seen between the two groups on day 
2 when analysed by Fisher’s exact test. % with adequate neutrophil phagocytic capacity (≥ 
50%) placebo 42.9% (9 of 21 patients) versus GM-CSF 80% (12 of 15 patients) (p=0.041). 
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5.14.5.2 Proportion of patients with adequate neutrophil phagocytic capacity 
on day 4/5 
 
 
 
 
 
 
Figure 5.7: Proportion of patients with neutrophil phagocytic capacity ≥50% or 
<50%on day 4/5. There was no significant difference seen between the two groups on day 
4/5 when analysed by Fisher’s exact test. % of patients with adequate neutrophil phagocytic 
capacity (i.e. ≥ 50%) placebo 43.8% (7 of 16 patients) versus GM-CSF 75% (9 of 12 
patients) (p=0.14). 
 
 
 
5.14.5.3 Proportion of patients with adequate neutrophil phagocytic capacity 
on day 6/7 
 
 
 
 
 
Figure 5.8: Proportion of patients with neutrophil phagocytic capacity ≥50% or 
<50%on day 6/7. There was a significant difference seen between the two groups on day 
6/7 when analysed by Fisher’s exact test. % of patients with adequate neutrophil phagocytic 
capacity (i.e. ≥ 50%) placebo 43.8% (7 of 16 patients) versus GM-CSF 100% (10 of 10 
patients) (p=0.004). 
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5.14.5.4 Proportion of patients with adequate neutrophil phagocytic capacity 
on day 8/9 
 
 
 
 
Figure 5.9 Proportion of patients with neutrophil phagocytic capacity ≥50% or <50%on 
day 8/9. There was no significant difference seen between the two groups on day 8/9 when 
analysed by Fisher’s exact test. Patients with adequate neutrophil phagocytic capacity (≥ 
50%) placebo 63.6% (7 of 11 patients) versus GM-CSF 100% (9 of 9 patients) (p=0.09). 
 
 
5.14.6 Area under the curve for neutrophil phagocytic capacity up to day 8/9 
There was a statistically significant difference in the area under the curve between 
D0 and D8/9 between the two groups, p=0.011. When adjusted for baseline 
phagocytosis and site, however, this significance was lost, p =0.14. The curves were 
seen to diverge in particular up to day 4/5. 
 
 
 
 
Figure 5.10: Area under the curve for neutrophil phagocytic capacity up to day 8/9. A 
significant difference was seen between the area under the curve for the two groups up to 
day 8/9. GM-CSF mean 553.9 (+/- 73.5, n=9) versus placebo mean 451.9 (+/- 85.2, n= 11) 
when analysed by 2 sample t-test. p=0.011. Symbol = mean, whiskers = S.E.M. 
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5.14.7 Neutrophil superoxide release 
As described in chapter 2 (section 2.16.6) following isolation from whole blood 
neutrophils were re-suspended in HBSS+, primed with PAF and incubated at 37ºC in 
a shaking water bath. Following stimulation with fMLF, in the presence of superoxide 
dismutase and cytochrome C, the generation of superoxide anion (O2-) was 
calculated by determining the amount of superoxide dismutase-inihibitable reduction 
of cytochrome C. Results were expressed as nanomoles of superoxide anions 
generated per million neutrophils (nmolO2-/106 neuts) 
 
 
5.14.7.1 Neutrophil superoxide release at baseline  
There was no significant difference in neutrophil superoxide release at baseline 
between the two groups. Mean superoxide release in the placebo group was 2.15 
nmol O2-/106 neuts (s.e.m. +/- 0.45) versus 1.98 nmol O2-/106 neuts (s.e.m, +/- 0.39) 
in the GM-CSF group (p=0.78). 
 
 
 
 
 
Figure 5.11: Mean neutrophil superoxide release at baseline. There was no significant 
difference seen between the two groups at baseline when analysed by 2 sample t-test. 
Placebo mean 2.15 nmol O2-/106 neuts (s.e.m. +/- 0.45, n= 19), GM-CSF mean 1.98 nmol 
O2-/106 neuts (s.e.m +/- 0.39, n=15) (p=0.78).  
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5.14.7.2 Neutrophil superoxide release on day 2 
There was no significant difference in neutrophil superoxide release between the two 
groups on day 2 following administration of the study drug. Mean superoxide release 
in the placebo group was 2.05 nmol O2-/106 neuts (s.e.m. +/- 0.34) versus 2.49 nmol 
O2-/106 neuts (s.e.m, +/- 0.38) in the GM-CSF group (p=0.39). 
 
 
 
 
Figure 5.12: Mean neutrophil superoxide release on day 2. There was no significant 
difference seen between the two groups on day 2 when analysed by 2 sample t-test. 
Placebo mean 2.05 nmol O2-/106 neuts (s.e.m. +/- 0.34, n=17), GM-CSF mean 2.49 nmol O2-
/106 neuts (+/- 0.38, n=15) (p=0.39). 
 
 
 
5.14.7.3 Neutrophil superoxide release on day 4/5, day 6/7, day 8/9 
There was no significant difference in neutrophil superoxide release between the two 
groups on any other day following administration of the study drug. Mean superoxide 
release on day 4/5 in the placebo group was 1.51 nmol O2-/106 neuts (s.e.m. +/- 
0.34) versus 2.63 nmol O2-/106 neuts (s.e.m, +/- 0.80) in the GM-CSF group 
(p=0.20). Equivalent values on day 6/7 were 2.23 nmol O2-/106 neuts (s.e.m. +/- 
0.44) in the placebo group versus 2.29 nmol O2-/106 neuts (s.e.m, +/- 0.42) in the 
GM-CSF group (p=0.92), while on day 8/9 they were 0.68 nmol O2-/106 neuts (s.e.m. 
+/- 0.14) in the placebo group versus 1.35 nmol O2-/106 neuts (s.e.m, +/- 0.43) in the 
GM-CSF group (p=0.13) 
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5.14.8 Neutrophil chemotaxis 
As described in chapter 2 (section 2.16.7) following isolation from whole blood 
neutrophils were re-suspended at 25x106/ml in IMDM containing 1% autologous 
serum. They were placed in a central well on an agarose-coated slide. 
Chemoattractant in the form of fMLF was placed in an adjacent well with IMDM being 
placed in a control well equidistant on the other side. Following incubation at 37ºC/ 
5%CO2 the slides were fixed and stained and the neutrophil migration distance was 
assessed by computer imaging. 
 
 
5.14.8.1 Neutrophil chemotaxis at baseline  
There was no significant difference in the migratory distance to chemoattractant 
seen between the two groups at baseline.  
 
 
 
 
Figure 5.13: Neutrophil chemotaxis at baseline. There was no significant difference seen 
in the migration distance between the two groups at baseline. Median migratory distance 
placebo group was 420µm (IQR 0-630, n=15), GM-CSF group was 391µm (IQR 146-689, 
n=12), p=0.75, Mann Whitney U test.  
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5.14.8.2 Neutrophil chemotaxis on day 2 
There was no significant difference in the migratory distance to chemo attractant 
seen between the two groups on day 2 following the administration of the study drug. 
 
 
 
 
 
Figure 5.14: Neutrophil chemotaxis on day 2. There was no significant difference seen in 
the migration distance between the two groups on day 2. Median migration distance placebo 
group was 374µm (IQR 116-588, n=14), GM-CSF group 487 (IQR 185-580, n=12), p= 0.56, 
Mann Whitney U test.  
 
 
 
 
5.14.8.3 Neutrophil chemotaxis day 4/5, day 6/7, day 8/9 
There was no significant difference in the migratory distance to chemo attractant 
fMLF seen between the two groups on any other study day. Day 4/5, placebo n=9, 
GM-CSF n=10, p= 0.66, day 6/7 placebo n=8, GM-CSF n=6, p= 0.56, day 8/9 
placebo n=4, GM-CSF n=3 p= 0.23, Mann Whitney U test.  
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5.14.9 Neutrophil apoptosis 
As described in chapter 2 (section 2.16.8) following isolation from whole blood 
neutrophils were re-suspended in HBSS+ washed once and re-suspended in 
Annexin V buffer solution. The cells were incubated with Annexin V and 
subsequently with propidium iodide (PI) in the dark at room temperature. Following 
incubation cells were washed and re-suspended in Annexin V buffer and analysed 
by flow cytometry. The proportion of cells showing evidence of early and late 
apoptosis by Annexin V / PI analysis was calculated. 
 
 
5.14.9.1 Neutrophil apoptosis at baseline  
There was no significant difference seen in the early and late apoptosis rates 
between the two groups at baseline. 
 
 
 
 
 
Figure 5.15: Mean neutrophil apoptosis rates at baseline. There was no significant 
difference seen in the apoptotic rates between the two groups at baseline when analysed by 
2-sample t test. Early apoptosis placebo 16.9% (s.e.m +/- 3, n=17) GM-CSF 16.1% (s.e.m. 
+/- 3.3, n=16) p= 0.88; late apoptosis placebo 7.4% (s.e.m. +/- 1.3, n=17) GM-CSF 12.0% 
(s.e.m. +/- 2.7, n=16) p = 0.13. 
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5.14.9.2 Neutrophil apoptosis on day 2 
There was no significant difference in the neutrophil apoptotic rate seen between the 
two groups on day 2 following the administration of the study drug. 
 
 
 
 
Figure 5.16: Mean neutrophil apoptosis rates on day 2. There was no significant 
difference seen in the apoptotic rates between the two groups on day 2 when analysed by 2-
sample t test. Early apoptosis placebo 16.6% (s.e.m +/- 2, n=17) GM-CSF 15.1% (s.e.m. +/- 
2.4, n=15) p= 0.64; late apoptosis placebo 10.1% (s.e.m. +/- 1.8, n=17) GM-CSF 7.9% 
(s.e.m. +/- 2.1, n=15) p = 0.42. 
 
 
5.14.9.3 Neutrophil apoptosis day 4/5, day 6/7, day 8/9 
There was no significant difference in the neutrophil apoptotic rate seen between the 
two groups on any other study day, when analysed by 2-sample t test. Day 4/5 - 
early apoptosis placebo 16.3% (s.e.m. +/- 4.6, n=13) GM-CSF 13.8% (s.e.m. +/- 2.8, 
n=9) p= 0.67; late apoptosis placebo 6.6% (s.e.m. +/- 1.2, n=13) GM-CSF 5.1% 
(s.e.m +/- 1.0, n=9) p = 0.37.  Day 6/7 early apoptosis placebo 17.6% (s.e.m +/- 3.4, 
n=15) GM-CSF 15.8% (s.e.m +/- 3.3, n=10) p= 0.72; late apoptosis placebo 7.4% 
(s.e.m +/- 1.6, n=15) GM-CSF 8.9% (s.e.m. +/- 2.5, n=10) p = 0.61. Day 8/9 early 
apoptosis placebo 13.8% (s.e.m. +/- 3.8, n=8) GM-CSF 24.1% (s.e.m. +/- 4.5, n=8) 
p= 0.10; late apoptosis placebo 7.0% (s.e.m. +/- 2.1, n=8) GM-CSF 6.7% (s.e.m. +/- 
1.3, n=8) p = 0.92.  
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5.14.10 Neutrophil CD88 expression 
As described in chapter 2 (section 2.16.4) samples of whole blood were collected for 
flow cytometry analysis including assessment of neutrophil CD88 expression. Whole 
blood was incubated with phycoerythrin-conjugated antibody or isotype control at 
4ºC in the dark. Following incubation red cell lysis was performed with Pharmlyse 
solution and the cells were washed prior to analysis by flow cytometry. Neutrophils 
were identified by forward scatter and side scatter characteristics, gated accordingly 
and CD88 expression was measured in arbitrary units. 
  
5.14.10.1 Baseline neutrophil CD88 expression at baseline 
There was no significant difference seen in the neutrophil CD88 expression between 
the two groups at baseline. Median neutrophil CD88 expression in the placebo group 
was 559 (IQR 463-914) arbitrary units compared to median of 714 (IQR 541-868) in 
the group allocated to GM-CSF (p=0.71). 
 
 
 
 
 
Figure 5.17: Neutrophil CD88 expression at baseline. There was no significant difference 
seen in the neutrophil CD88 expression between the two groups at baseline when analysed 
by Mann Whitney U test. Placebo median 559 (IQR 463-914, n=19) versus GM-CSF median 
714 (IQR 541-868, n=15) arbitrary units, p= 0.71.  
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5.14.10.2 Neutrophil CD88 expression on day 2 
There was no significant difference seen in neutrophil CD88 expression between the 
two groups on day 2 following the administration of the study drug. Median neutrophil 
CD88 expression in the placebo group was 953 (IQR 544-1334) arbitrary units 
compared to median of 885 (IQR 483-1013) in the group allocated to GM-CSF 
(p=0.52). 
 
 
 
 
 
Figure 5.18: Neutrophil CD88 expression on day 2. There was no significant difference 
seen in the neutrophil CD88 expression between the two groups on day 2 when analysed by 
Mann Whitney U test. Placebo median 953 (IQR 544-1334, n=18) versus GM-CSF median 
885 (IQR 483-1013, n=12) arbitrary units, p= 0.52.  
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5.14.10.3 Neutrophil CD88 expression day 4/5, day 6/7, day 8/9 
There was no significant difference in the neutrophil CD88 expression seen between 
the two groups on any other study day. 
 
 
 
 
 
Figure 5.19: Neutrophil CD88 expression over study period. There was no significant 
difference seen in the neutrophil CD88 expression between the two groups on any other 
study day. Day 4/5 placebo median 1072 (IQR 830-1671, n=14) versus GM-CSF median 
764 (IQR 389-1038, n=8) arbitrary units, p= 0.07. Day 6/7 placebo median 1119 (IQR 864-
1932, n=15) versus GM-CSF mean 1178 (IQR 516-1612, n=9) arbitrary units, p= 0.41. Day 
8/9 placebo median 1415 (IQR 1227-1785, n=11) versus GM-CSF median 1478 (IQR 648-
2086, n=8) arbitrary units, p= 0.97. Mann Whitney U test. 
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5.14.10.5 Correlation between baseline neutrophil CD88 and neutrophil 
phagocytic capacity 
Contrary to previous findings there was no significant correlation observed between 
neutrophil CD88 expression and neutrophil phagocytic capacity at baseline. 
 
 
 
Figure 5.20: Correlation between neutrophil CD88 expression and neutrophil 
phagocytic capacity at baseline. Spearman’s r = - 0.09 (p= 0.622, n=34, pooled data for 
placebo and GM-CSF groups). 
 
 
 
There was a weak correlation seen between neutrophil phagocytic capacity and 
neutrophil CD88 expression over the course of the study. 
 
 
Figure 5.21: Correlation between neutrophil CD88 expression and neutrophil 
phagocytic capacity over the course of the study. Spearman’s r = 0.26 (p= 0.012, n=92, 
pooled data for placebo and GM-CSF groups). 
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5.14.11 Monocyte HLA-DR expression 
As described in chapter 2 (section 12.15.5) samples of whole blood were collected 
for flow cytometry analysis including assessment of monocyte HLA-DR expression. 
Whole blood was incubated with QuantiBRITETM PE-conjugated antibody at room 
temperature in the dark. Following incubation red cell lysis was performed with 
Pharmlyse solution and the cells were washed prior to analysis by flow cytometry. 
Monocytes were initially identified by forward scatter and side scatter characteristics 
and then by CD14/ CD64 positivity. The number of antibodies bound per cell 
(Ab/cell) was calculated. 
 
 
5.14.11.1 Baseline monocyte HLA-DR expression 
There was no significant difference seen in the mean monocyte HLA-DR expression 
between the two groups at baseline. Mean monocyte HLA-DR expression in the 
placebo group was 6382 (s.d. +/- 5149) arbitrary units compared to mean of 6179 
(s.d. +/- 4146) in the group allocated to GM-CSF (p=0.90). 
 
 
 
 
Figure 2.22: Mean monocyte HLA-DR expression at baseline. There was no significant 
difference seen in monocyte HLA-DR expression between the two groups at baseline when 
analysed by 2-sample t test. Placebo mean 6382 (s.d.+/- 5149, n=18) versus GM-CSF mean 
6179 (s.d. +/- 4146, n=16) arbitrary units, p= 0.90. 
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5.14.11.2 Monocyte HLA-DR expression day 2 
There was a statistically significant difference seen in monocyte HLA-DR expression 
between the two groups on day 2 following the administration of the study drug. 
Mean HLA-DR expression in the placebo group was 6097Ab/cell (s.d +/- 4501, n=18) 
compared with mean HLA-DR expression 54999 Ab/cell (s.d. +/- 31239, n=13) in the 
GM-CSF group (p<0.0001). The mean rise in mHLA-DR expression in the placebo 
group was -285.3 Ab/cell (s.d. +/- 2529) compared with a mean rise of 48949 Ab/cell 
(s.d. +/- 29381) in the GM-CSF group. 
 
 
 
 
 
Figure 5.23: Mean monocyte HLA-DR expression on day 2. There was a statistically 
significant difference seen in absolute monocyte HLA-DR expression seen between the two 
groups on day 2 when analysed by 2-sample t test. Placebo mean 6097 (s.d.+/- 4501, n=18) 
versus GM-CSF mean 54999 (s.d. +/- 31239, n=13), p< 0.0001. 
 
 
 
5.14.11.3 Monocyte HLA-DR expression over study course 
A statistically significant difference in monocyte HLA-DR expression continued to be 
seen between the two groups at day 4/5 - mean mHLA-DR in the placebo group 
5807 Ab/cell (s.d. +/- 5303, n=14) versus mean mHLA-DR 30706 Ab/cell (+/- s.d. 
34484, n=8) in the GM-CSF group, p=0.01. Following the completion of study drug 
administration on day 3 the levels of mHLA-DR expression were seen to fall in the 
GM-CSF group reaching the pre-treatment baseline levels by day 6/7. 
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Figure 5.24: Mean monocyte HLA-DR expression over study course. A statistically 
significant difference continued to be seen in absolute monocyte HLA-DR expression on day 
4/5 (placebo 5807 Ab/cell (s.d.+/- 5303, n=14) versus GM-CSF 30706 Ab/cell (s.d.+/- 34484, 
n=8), p= 0.01). Following this mHLA-DR expression in the GM-CSF group was seen to fall to 
baseline levels. Day 6/7 p= 0.77 (placebo n= 15, GM-CSF = 9), day 8/9 p= 0.79 (placebo 
n=12, GM-CSF n=8). 
 
 
 
5.14.12 T cell analysis 
 
As described in chapter 2 (section 2.16.9) T cell analysis was performed by flow 
cytometry to determine regulatory T cell (Treg) proportion as a percentage of CD4+ 
cells. Whole blood was incubated with the antibody panels described (section 2.16.9) 
at 4ºC in the dark. Following incubation red cell lysis was performed with Pharmlyse 
solution and the cells were washed prior to analysis by flow cytometry. Tregs were 
identified by CD4+, CD25+, CD127low characteristics. Differentiation of memory and 
naïve cells was performed by CD45RA/CD45RO analysis. 
 
5.14.12.1 Proportion of regulatory T cells at baseline 
There was no significant difference seen in the mean Treg proportion between the 
two groups at baseline, when analysed by two-sample t-test. Mean Treg proportion 
in the placebo group was 16.6% (s.d. +/- 4.1, range 7.8-22.9%, n=15) compared to 
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mean of 17.6% (s.d. +/-5.7,range 10.4-27.9%, n=13) in the group allocated to GM-
CSF, p=0.62. 
 
 
 
 
Figure 2.25: Proportion of regulatory T cells (Tregs) at baseline. There was no 
significant difference seen in the proportion of Tregs between the two groups at baseline 
when analysed by 2-sample t test. Placebo mean 16.6% (s.d.+/- 4.1, n=15) versus GM-CSF 
mean 17.6% (s.d. +/- 5.7, n=16), p= 0.62. 
 
 
5.14.12.2 Proportion of regulatory T cells on day 2 
 
There was no significant difference seen in the mean Treg proportion between the 
two groups on day 2, when analysed by two-sample t-test. 
 
 
 
 
Figure 2.26: Proportion of regulatory T cells (Tregs) on day 2. There was no significant 
difference seen in the mean Treg proportion between the two groups on day 2, when 
analysed by two-sample t-test. Mean Treg proportion in the placebo group was 17.7% (s.d. 
+/- 7.1, range 8-35%, n=14) compared to mean of 17.7% (s.d. +/-7.5, range 5.1-32%, n=11) 
in the group allocated to GM-CSF, p=0.99. 
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5.14.12.3 Proportion of regulatory T cells over study course 
There was no significant difference in the T reg proportion seen between the two 
groups on any other study day, when analysed by 2-sample t test. Day 4/5 placebo 
mean was 18.8% (s.d. +/- 9.2, n=7) compared to GM-CSF 16.9% (s.d. +/- 7.7, n=6). 
Day 6/7 placebo mean was 19.7% (s.d. +/- 7.7, n=12) compared to 20.5% (s.d. +/- 
5.0, n=7). Day 8/9 Placebo mean was 19.1% (s.d. +/- 7.8, n=9) compared to 19.5% 
(s.d. +/- 5.6, n=6). 
 
5.14.12.4 Differentiation of regulatory T cells  
There was no significant difference seen in the differentiation of T cells at baseline or 
day 2 when analysed by two-sample t-test. Mean proportion of memory cells 
(CD45RA+RO-) at baseline was 35.3% in the placebo group (s.d. +/-12.8, n=17)  and 
36.5% (s.d. +/- 12.8%, n=15) in the GM-CSF group. On day 2 mean proportion of 
memory cells was 34.7% in the placebo group (s.d. +/-14.5, n=15)  and 35.6% (s.d. 
+/- 12.2%, n=12) in the GM-CSF group. Mean proportion of naïve cells (CD45RA-
RO+) at baseline was 48.8% in the placebo group (s.d. +/-15.3, n=17)  and 48.1% 
(s.d. +/- 12.7%, n=15) in the GM-CSF group. On day 2 mean proportion of naïve 
cells was 48.3% in the placebo group (s.d. +/-17.5, n=15)  and 49.6% (s.d. +/- 
13.9%, n=12) in the GM-CSF group 
 
 
 
5.15 Per-protocol analyses 
 
The number of patients who triggered study drug termination criteria prior to 
assessment of the primary outcome was greater than had been anticipated. As 
described in section 5.10 a total of 5 (5/38, 13.2%) patients received less than 2 
doses of study drug prior to assessment of neutrophil phagocytic capacity on day 2 
(1 in placebo group, 4 in GM-CSF group).  A per protocol analysis was carried out to 
investigate whether there were differences in primary outcome in the cohort of 
patients who had received at least 2 doses of GM-CSF or placebo. 
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5.15.1 Per-protocol analysis neutrophil phagocytic capacity on day 2  
There was a significant difference in neutrophil phagocytic capacity seen at day 2 
between the 2 groups when analysed per-protocol (p=0.048). This significance was 
lost when adjusted for baseline neutrophil phagocytic capacity and site (p=0.497).  
 
 
 
 
 
Figure 5.27: Per-protocol analysis of mean neutrophil phagocytic capacity at day 2. A 
significant difference was seen between the two groups on day 2 when analysed by 2-
sample t-test. Mean placebo 50.1% (s.d.+/- 13.7, n= 20), mean GM-CSF 59.1% (s.d.+/- 9.4, 
n= 13), p=0.048. 
 
Mean neutrophil phagocytic capacity on day 2 in the patients receiving less than 2 
doses GM-CSF was 45.3% (s.d. 32.3%, n=2). Results from 2 patients receiving less 
than 2 doses of GM-CSF were not available on day 2; one patient had died on day 1, 
and one patient met study drug termination criteria prior to receiving any drug (and 
was not sampled further following baseline assessment). 
 
 
5.15.2 Per-protocol analysis of neutrophil phagocytic capacity area under the 
curve 
There was a significant difference between the 2 groups when neutrophil phagocytic 
capacity area under the curve to day 9 was analysed per-protocol (p=0.011). This 
significance was lost when adjusted for baseline neutrophil phagocytic capacity and 
site (p=0.14). The curves were seen to diverge in particular up to day 4/5. 
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Figure 5.28: Per-protocol analysis of neutrophil phagocytic capacity area under the 
curve to day 8/9. A significant difference was seen between the two groups when area 
under the curve to day 9 was analysed by 2-sample t-test. Mean AUC placebo 451.9 (s.d.+/- 
85.2, n= 11), mean AUC GM-CSF 553.9 (s.d.+/- 73.5, n= 13), p=0.011. 
 
5.15.3. Per-protocol analysis of proportion of patients with adequate 
phagocytic capacity on day 2  
 
There was a significant difference seen in the proportion of patients with adequate 
neutrophil phagocytic capacity, between the two groups, on day 2 when analysed 
per-protocol for those receiving at least 2 doses of study drug (placebo 45%, GM-
CSF 85%, p =0.032). 
 
 
 
 
Fig 5.29: Per-protocol analysis of the proportion of patients with neutrophil 
phagocytic capacity ≥50% or <50%on day 2. There was a significant difference seen 
between the 2 groups with regard to the proportion of patient with adequate neutrophil 
phagocytic capacity (i.e. ≥ 50%) on day 2 when analysed per-protocol by Fisher’s exact test 
- placebo =45% (9 of 20 patients) versus GM-CSF 85% (11 of 13 patients), p=0.032. 
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5.15.3.1 Per-protocol analysis of the proportion of patients with adequate 
phagocytic capacity on day 4/5, day 6/7, day 8/9 
 
A significant difference was also seen in the proportion of patients, in each group, 
with adequate neutrophil phagocytic capacity on day 4/5 and day 6/7, when 
analysing per-protocol for those receiving at least 2 doses of study drug. On day 4/5 
46.7% (7 of 15 patients) of the placebo group had adequate phagocytic capacity 
compared to 90% (9 of 10 patients) of the GM-CSF group, p= 0.04. On day 6/7 
46.7% (7 of 15 patients) of the placebo group had adequate phagocytic capacity 
compared with 100% (9 of 9 patients) in the GM-CSF group, p= 0.009. There was no 
significant difference seen between the 2 groups on day 8/9 when analysed per-
protocol when 63.6% (7 of 11 patients) in the placebo group had adequate 
phagocytic capacity compared to 100% (8 of 8 patients) in the GM-CSF group, p= 
0.103. 
 
5.15.4 Per-protocol analysis of neutrophil superoxide release on day 2 
There was no significant difference in neutrophil superoxide release between the two 
groups on day 2 following administration of the study drug when analysed per-
protocol. Mean superoxide release in the placebo group was 1.95 nmol O2-/106 neuts 
(s.e.m. +/- 0.35, n=16) versus 2.65 nmol O2-/106 neuts (s.e.m, +/- 0.41, n=13) in the 
GM-CSF group, p=0.20. 
 
 
 
Figure 5.30: Per-protocol analysis of mean neutrophil superoxide release on day 2. 
There was no significant difference seen between the two groups on day 2 when analysed 
per-protocol by 2-sample t-test. Placebo mean 1.95 nmol O2-/106 neuts (s.e.m. +/- 0.35, 
n=16), GM-CSF mean 2.65 nmol O2-/106 neuts (+/- s.e.m. 0.41, n=13), p=0.20. 
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5.15.5 Per-protocol analysis of neutrophil chemotaxis on day 2 
There was no significant difference seen in neutrophil chemotaxis, between the two 
groups, on day 2 when analysed per-protocol for those receiving at least 2 doses of 
study drug.  Mean migration distance in the placebo group was 381.4 µm (+/- 278.6) 
compared to a mean of 405.4 µm (+/- 239.2) in the GM-CSF group, p=0.82. 
 
 
  
 
Figure 5.31: Per-protocol analysis of neutrophil chemotaxis on day 2. There was no 
significant difference seen in neutrophil chemotaxis, between the two groups of patients, on 
day 2 when analysed per-protocol by 2-sample t-test. Distance migrated on chemotaxis 
assay (µm) placebo 381.4 (s.d +/- 278.6, n= 10), GM-CSF 405.4 (s.d. +/- 239.2, n=11), 
p=0.82. 
 
 
5.15.6 Per-protocol analysis of neutrophil apoptosis on day 2 
There was no significant difference seen in neutrophil apoptosis on day 2.  
 
 
 
 
Figure 5.32: Per-protocol analysis of neutrophil apoptosis on day 2. There was no 
significant difference seen in neutrophil apoptosis, between the two groups of patients, on 
day 2 when analysed per-protocol by 2-sample t-test. Mean early apoptosis - placebo 16.6% 
(s.e.m. +/- 2.1, n=16), GM-CSF 15.1% (s.e.m. +/- 2.6, n=13), p= 0.65; mean late apoptosis - 
placebo 9.9% (s.e.m. +/- 1.9, n=16) GM-CSF 8.4% (s.e.m +/- 2.3, n=13), p= 0.62. 
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5.16 Clinical Outcomes 
 
 
5.16.1 Sequential organ failure assessment (SOFA) score  
The change in SOFA score between baseline and day 7 was assessed. As the 
SOFA score represents ordinal data analysis was performed by Mann Whitney test. 
There was no significant difference in change in SOFA score seen between the two 
groups, median change in the placebo group was 4 (IQR -0.25 to 8.25) compared to 
median change in SOFA score in GM-CSF group of 2.5 (IQR 0 to 4.5), p=0.59. 
 
 
 
 
 
Figure 5.33: Change in sequential organ failure assessment (SOFA) score between 
day 0 and day 7. There was no significant difference seen in the change in SOFA score 
from day 0 to day 7 between the two groups when analysed by Mann Whitney U test. 
Median change in SOFA score in the placebo group 4 (IQR -0.25 to 8.25, n=18) versus 
median change in the GM-CSF group 2.5 (IQR 0 to 4.5, n=10), p=0.59. 
 
 
 
 
5.16.2 Duration of mechanical ventilation 
There was no significant difference seen, between the two groups, in the duration of 
mechanical ventilation in those patients surviving to 30 days. Median duration of 
mechanical ventilation in the placebo group was 8 days (IQR 2 to 23) compared to 
median duration of 9 days in the GM-CSF group (IQR 2.5 to24), p=0.99. 
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Figure 5.34: Duration of mechanical ventilation in patients surviving to day 30. Median 
in the placebo group 8 days (IQR 2-23, n=15), compared to median in the GM-CSF group of 
9 days (IQR 2.5-24, n=13), p=0.99 Mann Whitney U test. 
 
 
 
5.16.3 Duration of ICU stay 
There was no significant difference seen, between the two groups, in the duration of 
ICU stay in those patients surviving to 30 days. Median duration of ICU stay in the 
placebo group was 17 days (IQR 5 to 30) compared to median duration of 19 days in 
the GM-CSF group (IQR 7.5-30), p=0.75. 
 
 
 
Figure 5.35: Length of ICU stay in patients surviving to day 30. There was no significant 
difference seen in duration of ICU stay when analysed by Mann Whitney test. Median 
placebo group 17 (IQR 5-30, n=15), median GM-CSF group 19 (IQR 7.5-30, n=13), p=0.75 
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5.16.4 Status of patients alive at day 30 
 
There was no significant difference seen, between the two groups, when comparing 
the status of patients alive at day 30. Of the 15 patients in the placebo group who 
were alive at day 30, 5 had been discharged home and 10 remained as inpatients (6 
on a general ward and 4 on ICU). This compared with the 13 patients in the GM-CSF 
group where 5 had been discharged home and a further 8 remained as inpatients (4 
on a general ward and 4 on ICU). 
 
 
 
 
Figure 5.36: Status of patients surviving to day 30. There was no significant difference 
seen in the status of patients surviving to day 30 when analysed by Chi Squared test. p=0.78 
 
 
 
 
5.16.5 All-cause mortality, day 30 
There were 10 deaths during the course of the study up to day 30. 6 deaths occurred 
in patients in the placebo group (6/21, 28.6%) and 4 in patients in the GM-CSF group 
(4/17, 23.5%). 9 of the deaths occurred while participants were still an inpatient on 
ICU. One death occurred following discharge to the ward. When examining deaths in 
the sub-group of patients who received at least 2 doses of study drug all-cause 
mortality was 7.7% (1/13) in the GM-CSF group compared to 30% (6/20) in the 
placebo group. 
There was no significant difference in all-cause mortality between the two groups 
when analysed by log-rank test, p=0.73. 
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Figure 5.37: Survival curve up to day 30. There was no significant difference in all-cause 
mortality between the two groups at day 30. Log-rank test, p=0.76. 
 
 
 
 
 
 
 
Treatment 
allocation 
Time from 
randomisation 
to death (days) 
Cause of death 
Placebo 14 Multi-organ failure 
Placebo 4 Refractory septic shock 
Placebo 7 Sepsis secondary to small bowel perforation 
Placebo 29 Long-term post-operative complications of 
emergency nephrectomy 
Placebo 2 Sepsis, stroke, type II respiratory failure 
Placebo 3 Pneumonia and cardiac failure 
GM-CSF* 10 Pneumonia, multiple comorbidities 
GM-CSF** 1 Large bowel obstruction, multiple comorbidities 
GM-CSF 5 Chronic obstructive pulmonary disease, type II 
respiratory failure, acute kidney injury 
GM-CSF*** 5 Biliary sepsis 
 
Table 28: Cause and timing of death for patients in RCT according to treatment 
allocation. *, only 1 dose of GM-CSF administered due to transaminitis on day 1; ** only 1 
dose administered; *** only 1 dose administered due to thrombocytopaenia. 
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5.16.5 Incidence of ICUAI 
As described in chapter 2 incidence of ICUAI was assessed according to the 
HELICS criteria (HELICS Protocol 6.1, 2004). Over the course of the study there 
were 22 confirmed episodes of ICUAI.  
Between day 0 and day 9, 13 cases of ICUAI were reported in 10 unique patients. 
Six cases occurred in the GM-CSF group and 7 in the placebo group.  
 
 Incidence of ICU-acquired infection (ICUAI) 
Arm D0 D1 D2 D3 D4 D5 D6 D7 D8 D9 
GM-CSF 1 0 3 0 2 0 0 0 0 0 
Placebo 0 0 2 0 2 0 0 0 2 1 
 
Table 29: Incidence of ICU-AI from study day 0 to study day 9. D, day 
 
 
From day 10 to day 30 a further 9 cases of ICUAI were reported in 6 patients (3 
episodes in 3 patients within the GM-CSF group and 6 episodes in 3 patients within 
the placebo group). When the data were analysed per protocol according to the 
number of patients who had received at least 2 doses of GM-CSF/ placebo the 
number of cases of ICUAI was unchanged.   
 
 Incidence of ICU-acquired infection (ICUAI) 
Arm D10 D14 D15 D20 D22 D24 D30 
GM-CSF  1   1 1  
Placebo 1  2 1   2 
 
Table 30: Incidence of ICU-AI from study day 10 to study day 30. D, day 
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5.17 Safety data 
 
5.17.1 Blood monitoring 
 
5.17.1.1 White blood cells 
GM-CSF was seen to be associated with a rise in total white cell count and a rise in 
neutrophil count. Both parameters were seen to rise in the GM-CSF group until day 3 
following which there was a slight fall before a relatively stable course was followed. 
Maximum total white cell count seen in any patient was 43.8 x109/L seen on day 4 in 
a patient in the GM-CSF group. The corresponding neutrophil count was 36.5 x109/L. 
Median total white cell count and neutrophil count remained elevated in the GM-CSF 
group compared to the placebo group up to day 9. No patient triggered study drug 
termination criteria on account of their total white cell count. 
 
 
 
Figure 5.38: Total white cell count over study course. 
 
 
 
 
 
 
Figure 5.39: Total neutrophil count over study course.  
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5.17.1.2 Haemoglobin 
A gradual fall in haemoglobin level was observed in both groups over the course of 
the study.  
 
 
 
 
Figure 5.40: Haemoglobin level g/dL over study course. 
 
 
 
 
5.17.1.3 Platelet count 
Baseline platelet count was observed to be higher in the GM-CSF group. Platelet 
count was seen to rise slowly from day 5 in both groups.  
 
 
 
Figure 5.41: Platelet count over study course.  
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5.17.1.4 Serum creatinine 
Baseline creatinine was observed to be higher in the placebo group at baseline, but 
in both groups serum creatinine appeared to follow a stable course over the10-day 
sampling period.  
 
 
 
 
Figure 5.42: Serum creatinine over study course.  
 
 
 
5.17.1.5 Liver function tests 
Alanine aminotransferase (ALT) levels were similar at baseline between the groups. 
ALT was seen to rise in the GM-CSF group until day 4 following which it followed a 
stable course. ALT was seen to follow a stable course in the placebo group. 
Aspartate aminotransferase levels were seen to follow a stable course in both 
groups. 
 
 
 
 
Figure 5.43: Serum alanine aminotransferase over study course.  
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Figure 5.44: Serum aspartate aminotransferase over study course.  
 
 
 
 
5.17.2 PaO2:FiO2 
As described previously, due to concerns related to the potential for GM-CSF to 
induce or accelerate acute lung injury, highest and lowest PaO2:FiO2 were recorded 
on a daily basis for each patient whilst on ICU. 
 
 
 
 
Figure 5.45: PaO2:FiO2 over course of study. Mean daily lowest PaO2:FiO2 (kPa) over 
course of study. No significant difference was seen between the lowest recorded PaO2:FiO2 
on any study day. P>0.05 on all days. Mean +/- s.d.  
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Study  Placebo GM-CSF 
Day  Lowest ratio Highest ratio Lowest ratio Highest ratio 
0 n 
mean (s.d.) 
range 
20 
27.4 (13.2) 
(7.6, 54.5) 
20 
38.3 (17.7) 
(11.4, 65.0) 
16 
23.0 (11.0) 
(9.9, 49.5) 
15 
33.9 (14.9) 
(13.2, 59.1) 
1 n 
mean (s.d.) 
range 
20 
28.5 (13.5) 
(7.9, 52.8) 
20 
42.5 (19.4) 
(9.2, 91.3) 
16 
21.4 (10.8) 
(8.3, 52.4) 
16 
38.3 (14.3) 
(18.0, 65.5) 
2 n 
mean (s.d.) 
range 
20 
27.3 (12.7) 
(6.7, 50.0) 
20 
38.8 (15.6) 
(10.6, 61.4) 
14 
27.6 (9.7) 
(10.9, 43.8) 
14 
37.0 (15.3) 
(16.5, 68.5) 
3 n 
mean (s.d.) 
range 
19 
26.3 (13.5) 
(6.4, 51.0) 
19 
44.2 (18.5) 
(10.9, 69.0) 
13 
28.5 (12.9) 
(10.9, 47.6) 
13 
38.7 (16.7) 
(12.6, 65.0) 
4 n 
mean (s.d.) 
range 
19 
31.9 (17.1) 
(8.8, 70.8) 
17 
41.5 (21.6) 
(12.2, 92.1) 
12 
25.4 (10.5) 
(9.2, 42.6) 
12 
37.5 (21.4) 
(10.4, 92.1) 
5 n 
mean (s.d.) 
range 
14 
28.7 (15.6) 
(8.9, 51.9) 
14 
39.7 (16.5) 
(15.6, 63.5) 
12 
26.1 (13.0) 
(9.0, 50.6) 
12 
38.5 (16.3) 
(20.8, 71.5) 
6 n 
mean (s.d.) 
range 
12 
28.1 (15.7) 
(7.4, 52.6) 
13 
39.3 (18.0) 
(11.3, 66.0) 
10 
28.8 (14.1) 
(7.8, 50.2) 
10 
39.1 (15.8) 
(9.9, 63.0) 
7 n 
mean (s.d.) 
range 
10 
28.3 (21.1) 
(8.1, 71.1) 
10 
40.1 (31.2) 
(10.4, 92.1) 
10 
29.0 (12.0) 
(9.8, 46.3) 
10 
37.1 (17.0) 
(11.2, 60.9) 
8 n 
mean (s.d.) 
range 
11 
26.2 (20.3) 
(6.2, 54.6) 
11 
42.8 (31.3) 
(12.1, 92.1) 
10 
27.3 (14.1) 
(9.0, 50.2) 
10 
36.5 (14.2) 
(12.9, 54.6) 
9 n 
mean (s.d.) 
range 
11 
30.1 (20.1) 
(8.8, 60.7) 
11 
40.4 (26.1) 
(11.8, 92.1) 
9 
28.5 (14.0) 
(9.9, 54.6) 
9 
41.4 (19.5) 
(12.4, 64.4) 
 
Table 31: Mean daily PaO2:FiO2 ratio, kPa 
 
There was no significant difference observed in the PaO2:FiO2 between the two 
groups on any study day.  
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5.17.3 Adverse event reporting 
 
5.17.3.1 Adverse events 
Adverse events were classified on their seriousness, their expectedness and their 
severity. The severity of an adverse event was graded on a three-point scale as mild, 
moderate or severe. 
 
Study 
day 
No of 
episodes 
 
Mild 
GM-CSF 
Moderate 
 
Severe 
 
Mild 
Placebo 
Moderate 
 
Severe 
D0 1 0 0 0 1 0 0 
D1 4 1 2 0 1 0 0 
D2 2 2 0 0 0 0 0 
D3 3 3 0 0 0 0 0 
D4 1 1 0 0 0 0 0 
D5 0 0 0 0 0 0 0 
D6 2 0 0 0 1 1 0 
D7 1 1 0 0 0 0 0 
D8 0 0 0 0 0 0 0 
D9 1 1 0 0 0 0 0 
 
Table 32: Adverse events 
 
There were a total of 15 adverse events reported. 12 of these adverse events were 
classified as mild with a further 3 being classified as moderate. There were no 
severe adverse events reported. 
All 3 moderate adverse events were felt to be unlikely to be related to the study drug. 
2 of the moderate adverse events were reported in the GM-CSF group (1 patient 
developed progressive thrombocytopaenia and 1 patient developed a rise in 
ALT/AST) both occurring on day 1. In the placebo group one patient developed 
increased oxygen requirements on day 6 on a background of presumed necrotising 
pneumonia.  
Of the 12 mild adverse events 4 were related to the development of a pyrexia (all 
within the GM-CSF group), 3 related to changes in platelet count (1 patient within 
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each group developed thrombocytopaenia, 1 patient in the GM-CSF group 
developed thrombocytosis), 2 related to the finding of internal jugular vein 
thrombosis (1 within each group), 2 related to abnormal LFTs (both within the GM-
CSF group) and one related to episodes of hypoglycaemia. 
In summary within the GM-CSF group there were a total of 11 adverse events; 2 
moderate and 9 mild of which 3 were felt to be unlikely to be related and 8 possibly 
related to the study drug. In the placebo group 1 moderate and 3 mild adverse 
events were observed; 2 felt to be unrelated and 2 unlikely to be related to the study 
drug. 
 
5.17.3.2 Serious adverse events 
There were a total of 3 serious adverse events reported during the course of the 
study. One of these events related to a patient in the GM-CSF group occurring on 
day 1. The patient died following emergency surgery for bowel obstruction and this 
was thought to be unrelated to the study drug. Of the two serious adverse events 
occurring in patients within the placebo group, one developed sudden oxygen 
desaturation on day 3 whilst ventilated and was found to have a 
pneumomediastinum. This was felt to be unlikely to be related to the study drug. The 
second patient developed a sudden deterioration with type II respiratory failure 
requiring treatment with NIV on day 4 following discharge from ICU. This was 
thought to be due to decompensated obstructive sleep apnoea (OSA) but was 
reported as being possibly related to the study drug. 
 
5.17.3.3 Suspected unexpected serious adverse events 
There were no SUSARs reported during the course of the study in either group.
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5.18 Discussion 
 
The randomised controlled trial was designed to test the hypothesis that GM-CSF 
would restore effective neutrophil phagocytosis in critically ill patients with confirmed 
neutrophil dysfunction. In addition, it aimed to explore the effect of subcutaneous 
GM-CSF on other elements of neutrophil function, neutrophil receptor expression, 
monocyte HLA-DR expression and various clinical outcomes (especially safety). 
 
5.18.1 Effect of subcutaneous GM-SCF on neutrophil phagocytic function 
Compared to normal saline placebo GM-CSF was not seen to produce a statistically 
significant difference in neutrophil phagocytic capacity on day 2 following daily sub-
cutaneous administration. On examining sequential neutrophil phagocytic capacity 
on day 4/5 there was a statistically significant difference seen between the two 
groups, however, this effect was lost when corrected for baseline neutrophil 
phagocytic capacity and site. No significant difference was seen on day 6/7 or day 
8/9. The statistically significant difference in the area under the curve for neutrophil 
phagocytic capacity up to day 9 and the divergence of the curves in particular up to 
day 4/5 does suggest some evidence for a biological effect of GM-CSF on neutrophil 
phagocytic function. However again this effect was lost when correcting for baseline 
neutrophil phagocytic capacity and site. The unexpected and statistically significant 
difference in baseline neutrophil phagocytic capacity between the two groups is likely 
to have had a significant impact on the power of the study to demonstrate an effect 
in a cohort of this size. All significant results have been adjusted for baseline 
phagocytic capacity and site. In addition, during the RCT, the placebo group of 
patients was observed to have a natural recovery of neutrophil function over time. 
This recovery was greater than we had anticipated (chapter 2, section 2.18.3, page 
83). As discussed in chapter 4 there have not, to my knowledge, been any published 
studies examining the natural course of recovery in neutrophil function during critical 
illness and this study provides some evidence to show that neutrophil recovery does 
occur to some degree even during these relatively early stages of critical illness. 
However, despite this, other evidence of immune dysfunction is seen to persist. With 
this new observation applied to our previous calculations a larger cohort of patients 
would be required to power the study to demonstrate a biological effect of GM-CSF. 
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5.18.2 Timing of assessment of primary outcome 
The choice of timing of assessment of the primary outcome may arguably have been 
more appropriately placed on day 4 following administration of all 4 doses of the 
study drug when the maximal biological effect could have been evaluated. The 
rationale for our original decision regarding assessment of the primary outcome on 
day 2 was that, in view of the fact that ICUAI is defined as any infection occurring 
after 48 hours of admission to ICU (World Health Organization., 2002) we hoped that 
we could demonstrate a potentially protective biological effect of GM-CSF within this 
time window. It is likely however that the maximal impact of GM-CSF had not yet 
been achieved and that the power of the study to demonstrate benefit was 
weakened as a result. 
 
5.18.3 Adequacy of primary outcome in assessing the biological effect under 
investigation 
As we were investigating the biological effect of GM-CSF on neutrophil function, as a 
proof of concept study to inform a larger trial to assess whether GM-CSF may 
reduce ICU-acquired infection, the impact on the proportion of patients having 
‘adequate neutrophil function’ may have had greater relevance. As discussed, 
previous work has shown that a neutrophil phagocytic capacity < 50% is associated 
with an increased risk of ICUAI (Conway Morris et al 2009) and that neutrophil 
phagocytic capacity ≥50% may confer some form of protection. The fact that a 
statistically significant difference was seen in the proportion of patients with 
adequate neutrophil function in the GM-CSF group on all study days up to and 
including day 6/7 could be of greater clinical importance than the mean difference in 
absolute phagocytic capacity on each those days. On reflection our choice of primary 
outcome may not enable the most sensitive or rigorous assessment of the potential 
for GM-CSF to affect neutrophil function in a manner that would afford protection 
against ICUAI. 
The observation that by day 8/9 the significant difference seen in the proportion of 
patients with adequate neutrophil function had been lost may suggest that GM-CSF 
speeds the rate of recovery of neutrophil phagocytic capacity while over time the 
natural rate of recovery seen in the placebo group catches up. As ICUAI can develop 
at any time after 48 hours of admission to the ICU (World Health Organization., 
2002) the ability to restore adequate neutrophil function earlier in the course of a 
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patient’s admission may potentially offer significant clinical benefit with improvement 
in outcomes related to both morbidity and mortality. 
 
5.18.4 Loss of follow up of laboratory data due to patient recovery or death 
Unfortunately, due to the logistics of the trial, in some cases it was not possible to 
collect blood samples from patients for analysis of neutrophil functional outcomes 
after they had been discharged from ICU to another location within the hospital 
(n=2). Collection of blood samples was not continued after a patient had been 
discharged from hospital during the sampling follow-up period day 0 to day 9 (n=3). 
In addition, the study cohort was affected by the deaths of seven patients 
(7/38,18.4%) between day 0 and day 9, further diminishing the sample size in both 
groups. This unavoidable loss in potential data on each sampling day during the 
RCT will undoubtedly have had an effect on the power of the study as the numbers 
remaining in each group, in particular the GM-CSF group, at day 2 fell below the 
number required to ensure the power of the study to assess the primary outcome 
(n=17, chapter 2, section 2.18.3). In addition, there is the potential for these data 
omissions to have skewed the remaining data. It could be postulated that patients 
with an increased severity of critical illness may be both at higher risk of death and 
have a poorer rate of recovery of their neutrophil phagocytic capacity up to the point 
of their death (negatively skewed results) while patients with a lower severity of 
critical illness may follow a rapid trajectory to recovery, leading to discharge from the 
ICU, and have a greater rate of recovery of neutrophil phagocytic capacity following 
discharge from ICU (positively skewed results) reflecting their clinical improvement. 
Data for 3 patients were lost from the GM-CSF group due to recovery (compared to 
1 from the placebo group), while data from 3 patients were lost from the GM-CSF 
group due to death (compared to 4 from the placebo group). Given the small sample 
size the potential exists for the remaining data to be skewed by the absence of these 
data. 
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5.18.5 Per-protocol analysis of data 
There was a greater than expected number of patients triggering study drug 
termination criteria prior to receiving 2 doses of GM-CSF/placebo, which was the 
number of doses intended to be administered prior to assessment of the primary 
outcome. In addition, there was an imbalance between the groups in those patients 
affected, with a greater number of patients triggering study drug termination criteria 
within the GM-CSF group. When a planned per-protocol analysis was carried out a 
statistically significant difference was seen in the primary outcome, however this 
effect was lost when adjusted for the unexpected difference in baseline neutrophil 
phagocytic capacity. As with the intention-to-treat analysis there was a significant 
difference in the area under the curve up to day 8/9, with divergence of the curves up 
to day 4/5. However, once again the significance was lost when adjusted for baseline 
differences. The impact of these missing patients on both intention-to-treat and per-
protocol analysis will have affected the power of the study.  
 
5.18.6 Effect of subcutaneous GM-CSF on monocyte HLA-DR expression 
In keeping with the DFS it was once again observed that GM-CSF administration 
was associated with a significant rise in the levels of mHLA-DR expression, but that 
this effect was lost shortly after all 4 doses had been completed. Extensive evidence 
exists to demonstrate that mHLA-DR is a reliable marker of immunosuppression and 
immunoparesis (Monneret et al., 2006, Cheron et al., 2010, ) and that restoration of 
HLA-DR expression on the surface of monocytes has been associated with faster 
recovery from critical illness (Cheron et al., 2010, Tschaikowsky et al, 2006).The fall 
in mHLA-DR expression on cessation of the daily GM-CSF injections may indicate 
that the duration of therapy was inadequate to sustain the response to GM-CSF and 
that the risk of ICUAI may increase again at this point. Previous studies of the effect 
of GM-CSF on mHLA-DR expression have not made any attempt to quantify whether 
the restoration of mHLA-DR levels to the healthy range is associated with any 
improvement in the functional capacity of monocytes in particular with respect to 
their contribution to immunocompetence. Meisel’s study (Meisel et al., 2009) 
previously showed that when GM-CSF was administered for 10 days the effects in 
terms of recovery of mHLA-DR persisted over this time course.  They did not, 
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however, carry out any analysis of the course of mHLA-DR expression once the drug 
had been stopped. 
 
5.18.7 Effect of subcutaneous GM-CSF on neutrophil CD88 expression 
GM-CSF was not seen to have any effect on neutrophil CD88 expression over the 
course of the study. In addition, there was no correlation seen between neutrophil 
phagocytic capacity and neutrophil CD88 expression at baseline in the RCT. This 
supported our previous decision not to use neutrophil CD88 expression as a 
surrogate marker for phagocytic capacity when determining final eligibility for entry 
into the study. 
As a significant correlation has previously been identified between neutrophil 
phagocytic capacity and neutrophil CD88 expression (Conway Morris et al.,2009, 
Conway Morris et al., 2011 ), and as we ourselves demonstrated a moderate 
correlation within the cohorts of patients studied in the ACS (chapter 3, section 3.6), 
and DFS (chapter 4, section 4.13.3)  , we felt that further validation of the possible 
role of CD88 expression as a surrogate marker for phagocytosis was warranted 
during the RCT. In our hands, there is no consistent evidence to confirm a significant 
correlation between these two parameters. 
 
5.18.8 Effect of subcutaneous GM-CSF on other elements of neutrophil 
function 
Previous studies have shown GM-CSF to have an effect on other neutrophil 
functions including; enhancing neutrophil superoxide release when administered 
both ex-vivo (Lopez et al., 1986, Cebon et al., 1990, Weisbart et al., 1987) and in-
vivo (Presneill et al., 2002); delaying neutrophil apoptosis (Lopez et al., 1986, Brach 
et al., 1992) and reducing neutrophil chemotaxis (Lieschke et al., 1992). Within this 
patient cohort, when administered at this dose, GM-CSF was not seen to have any 
effect on neutrophil superoxide release, apoptosis or chemotaxis when assessed by 
either intention-to-treat or per-protocol analysis at any time over the course of the 
study. 
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5.18.9 Effect of subcutaneous GM-CSF on regulatory T cell proportions 
As has been observed in previous studies of sepsis and critical illness an increased 
proportion of regulatory T cells, as a proportion of CD4+ cells, was seen in our 
cohort of patients (Monneret et al.,2003, Venet et al., 2009). In a healthy population 
the proportion of Tregs is usually between 5-10% (Tatura et al., 2012) while in our 
group at baseline overall mean was 17.1% Similar proportions, and indeed higher 
levels, have been seen in previously studied cohorts of patients with a rise in the 
proportion of Tregs being seen within the first few days of sepsis onset (Monneret et 
al., 2003, Venet et al., 2009). Mean Treg proportion continued to be elevated in both 
groups at day 9 and high levels at this stage in the course of illness have been 
associated with poor survival however out study was not powered to examine this. 
 
5.18.10 Effect of subcutaneous GM-CSF on clinical outcomes 
The study was not powered to examine the secondary clinical outcomes and there 
was no significant difference seen between the two groups in any of the secondary 
clinical endpoints including length of stay on ICU and in hospital, duration of 
mechanical ventilation, change in SOFA score and change in PaO2:FiO2. Analysis of 
these outcomes would need to be studied in a much larger cohort of patients to look 
for differences in outcome. These outcomes are, however, those which are of most 
importance to patients and the clinical teams responsible for their care. 
 
5.18.11 Effect of subcutaneous GM-CSF on patient outcome 
As with other clinical outcomes this study was not powered to look at differences in 
patient outcome in terms of mortality. Overall ICU mortality rate was 23.7% (9/38) 
while in hospital mortality rate was 26.3% (10/38). This mortality rate is in the 
expected range for this cohort of critically ill patients where median APACHE II score 
was 20 (19.5 GM-CSF group, 21 placebo group). Predicted in hospital mortality for a 
patient with an APACHE II score of 20 admitted to ICU with sepsis is 38.1%, rising to 
50% for a patient admitted with sepsis post emergency surgery. Although mortality 
rates were similar in each group when analysed on an intention to treat basis the 
absolute difference in mortality rate seen in those patients receiving at least 2 doses 
of study drug was 22% (8%(1/13) GM-CSF group compared to 30%(6/20) placebo 
group).There was no difference seen in the status of patients surviving to day 30 with 
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33% of the placebo group and 38% of the GM-CSF group having been discharged 
home while the rest of patients in each group remained inpatients within the hospital 
with similar numbers in each group still on ICU. 
 
5.18.12 Observed safety profile of subcutaneous GM-CSF 
Administered at this dose and for this duration subcutaneous GM-CSF appears to be 
safe when administered to critically ill patients. As expected GM-CSF was seen to be 
associated with a rise in total white cell count and a rise in neutrophil count with 
median total white cell count and neutrophil count remaining elevated in the GM-CSF 
group compared to the placebo group up to day 9. No patient developed a rise in 
total white blood cell count such that study drug termination criteria were triggered 
and no complications were seen in relation to leucocytosis.  The gradual fall in 
haemoglobin level observed was similar in both groups and is in keeping with the 
observed response to critical illness (Nguyen et al., 2003). Prior to commencing the 
study, we discussed the impact of the trial blood sampling procedures with an 
independent haematologist who felt that there was no risk of inducing anaemia as a 
consequence of the sample volumes collected. Baseline platelet count was observed 
to be higher in the GM-CSF group with platelet count being seen to rise slowly from 
day 5 in both groups. This may have reflected some degree of recovery from the 
critical illness insult (Hui et al., 2011). There have been previous reports of 
elevations in serum creatinine following administration of GM-CSF (Sanofi-Aventis, 
2013). Alternate week serum monitoring is advised within the product SmPC 
suggesting that this may be a longer term effect of GM-CSF administration. Baseline 
creatinine was observed to be higher in the placebo group but in both groups serum 
creatinine appeared to follow a stable course over the10 day sampling period. 
Elevations in liver enzymes have also been reported previously in patients following 
administration of GM-CSF (Leischke et al., 1992, Honkoop et al., 1996). Alanine 
aminotransferase (ALT) levels were similar at baseline between the groups however, 
ALT was seen to rise in the GM-CSF group until day 4 following which it followed a 
stable course. Despite the rise in ALT median levels remained within the normal 
range. ALT was seen to follow a stable course in the placebo group. Aspartate 
aminotransferase levels were seen to follow a stable course in both groups. 
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With respect to adverse events there were an acceptable number of adverse events 
reported none of which were deemed to be severe in nature. Of the 3 adverse 
events of moderate severity all were considered to be unlikely to be related to the 
study drug. Although there was a greater number of adverse events seen in the GM-
CSF group (11) versus the placebo group (4) the majority of these were considered 
to be mild. Of the three serious adverse events reported during the study only one of 
these was thought to be possibly related to the study drug. Following unblinding it 
was confirmed that this patient had received placebo. 
As had been observed in the DFS there was no difference seen in the PaO2:FiO2 
following administration of GM-CSF. Despite the theorectical concerns and 
previously reported data (Goodman et al., 1999) regarding the risk of ALI with GM-
CSF our results add to the more recent data suggesting that GM-CSF is not 
associated with an increased risk of ALI (Presneill et al., 2002, Paine et al., 2012). 
The favourable safety profile of GM-CSF observed suggests that in future studies 
our strict exclusion criteria may be able to be relaxed to enable recruitment of a 
broader range of patients who may potentially benefit from the drug. 
 
5.18.13 Blinding issues 
As discussed previously there were significant logistical challenges in implementing 
blinding for the study. These were overcome by identifying unblinded research 
nurses to be involved in the reconstitution and administration of the study drug at all 
research sites. As discussed in section 5.13, at two sites a possible breach of 
blinding was retrospectively identified during the processes of both internal and 
external audit. The potential breach related to research nurses having been involved 
in the transposition of clinical data from source data to the e-CRF in patients to 
whom they had administered IMP. Concerns were raised that this could have led to 
bias within these data. There was no evidence for a breach of blinding at any other 
study site or in any other trial process or procedure. As discussed in section 5.13 all 
clinical data were recorded independently at source, by the clinical nursing team or 
hospital laboratory as part of usual clinical care. We therefore believe that the 
potential for bias (through the participation of an unblinded member of the research 
nursing team in the transposition of clinical data) is considered to be negligible but 
could not be fully excluded. There was no evidence to suggest that this potential 
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breach could have had any effect on the research laboratory outcomes which were 
analysed by blinded staff in a research laboratory location which was geographically 
distinct from the clinical areas where the administration of study drug and the 
transfer of clinical data took place. As a consequence of this potential breach, 
however, the study has been reported as a single-blind study. 
 
 
5.19 Limitations of the study 
 
5.19.1 Effect of sample size on the power of the study 
As has been discussed the power of this study was limited by the unexpected 
imbalance in neutrophil phagocytic capacity at baseline and an unexpected rate of 
study drug termination prior to assessment of the primary endpoint. Therefore, while 
the study provided some evidence to suggest a biological effect of GM-CSF on 
neutrophil phagocytic capacity the power of the study to confirm this effect may have 
been lost. This was also impacted upon to some degree by the imbalance in the two 
allocation groups following randomisation which arose as a result of the 
randomisation occurring in permutable blocks of variable length, stratified by site. 
This degree of complexity in the randomisation schedule was designed to minimise 
the risk of breach of concealment but ultimately led to an imbalance between the 
groups, given the small sample size. 
 
5.19.2 Uncertainty regarding optimum dose and duration of GM-CSF 
Although the dose finding study served to confirm that GM-CSF, at a dose of 
3µgm/kg/day for 4 days, appeared to be safe and to be associated with the desired 
biological effect in terms of improvement in neutrophil function, the lack of 
comparison treatment arms meant that it did not answer the question as to the 
optimum dose and duration of GM-CSF. An increase in both the dose and duration 
of GM-CSF used in the RCT may have resulted in a more significant improvement in 
neutrophil phagocytic capacity in the treated group. Analysis of the area under the 
curve data shows an increased rate of rise in neutrophil phagocytic capacity between 
day 0 and day 4/5 in the GM-CSF group with divergence of the curves up to this 
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point. Between day 4/5 and day 6/7 mean neutrophil phagocytic capacity is seen to 
fall slightly in the GM-CSF group before rising again at a slower rate in parallel with 
the placebo group. This may suggest that after completion of the administration of 
GM-CSF on day 3 the beneficial effect of GM-CSF on phagocytic function was lost 
and from that point the natural rate of recovery, seen in the placebo group, was 
counting for the slower rate of rise in each group. In addition, the data showing that 
GM-CSF increased mHLA-DR expression to immunocompetent levels initially, 
followed by a fall to levels associated with immunosuppression on cessation of the 
drug, do raise the question of whether short duration GM-CSF was inadequate to 
ensure a sustained response. In addition, it is recognised that the bioavailability of 
many drugs (in particular subcutaneously administered drugs) is reduced by a 
variety of factors affecting critically illness (Smith et al., 2012, Dorffler-Melly et al., 
2002). Within our patient cohort a significant number of patients received treatment 
with vasopressor drugs or CVVH during the study drug administration period and 
both of these factors may have had a significant affect on the bioavailability of the 
study drug. 
 
5.19.3 Lack of prior evidence regarding the natural course of recovery of 
neutrophil phagocytic capacity in critical illness 
 
The lack of prior available evidence regarding the natural course of recovery of 
impaired neutrophil phagocytic capacity in critical illness led to the unexpected 
finding of a higher rate of recovery in neutrophil phagocytic function among patients 
randomised to receive placebo than we had anticipated. The impact of this on our 
power calculation may have led to the study being underpowered to demonstrate a 
beneficial effect of GM-CSF over placebo. The results in the placebo group within 
this study are, to our knowledge, the first results to show that recovery in terms of 
neutrophil phagocytic capacity begins fairly early in the course of the critical illness. 
Further study in this area is required. Interventions to speed up the rate of recovery 
may still be of significant benefit but an alternative approach to measuring this may 
be required. 
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5.19.4 Effect of logistical challenges on the delivery of the study 
This study was recruiting critically ill patients early in the course of their admission to 
ICU and consequently recruitment was both unpredictable and time critical. In 
addition, the intervention was required to be delivered seven days a week, 
necessitating availability of research staff on all days including weekends and bank 
holidays. For a non-commercial clinical trial operating with limited resources in terms 
of staffing and finance, timely and successful completion of the trial was a significant 
challenge. Current local clinical research networks are not set up to enable the 
sharing of research staff and resources across multiple clinical research sites, and 
seeking to attain this in the future is likely to contribute to the improved successful 
completion of similar studies. 
 
5.19.5 Effect of blinding mechanisms on the study 
The logistical issues outlined in terms of delivering the trial successfully and in a 
timely manner also influenced the mechanisms for blinding of this study. As 
discussed this unfortunately led to the discovery (after the trial had completed) of a 
potential breach of blinding at two sites. Although we feel confident that no breach of 
blinding actually occurred and that the potential for bias is negligible we have been 
unable to publish the study as a double blinded trial and this will undoubtedly have 
an effect on the scientific impact of the trial and may negatively affect future research 
in this area. 
 
5.19.6 Effect of sample size on the analysis of clinical outcomes 
The study was not powered to assess the effect of GM-CSF on any of the clinical 
outcomes and results in relation to clinical outcomes are provided by descriptive 
statistics only. While the biological effects of drugs determine their efficacy the 
impact on clinical outcomes are of most importance to patients and clinicians. Much 
larger studies would be required to explore these potential clinical effects in more 
detail in particular the potential for GM-CSF to prevent the development of ICUAI. 
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5.20 Future work 
Future work in this area should focus on establishing robust pharmacokinetic and 
pharmacodynamic data in a larger cohort of critically ill patients to establish the 
optimum dose and duration of GM-CSF which might lead to a beneficial response in 
terms of neutrophil phagocytic function.  Once the optimum dose and duration has 
been established a large scale multi-centre trial would be required to answer both 
the biological question of whether or not GM-CSF can speed the rate of recovery of 
neutrophil phagocytic capacity and the clinical question of whether or not, therefore, 
GM-CSF could have an impact on the development of ICUAI in such patients. In 
order to adequately power such studies a deeper understanding of the natural 
course of neutrophil phagocytic dysfunction in critically ill patients is required. The 
importance of mHLA-DR expression as a biomarker of immune dysfunction has 
already been established and this study adds to the data which show that 
administration of GM-CSF can restore mHLA-DR expression to normal levels. 
Further work exploring the functional impact of both low mHLA-DR expression and 
restoration to normal levels following administration of GM-CSF would provide 
valuable information in terms of further developing targeted therapy 
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5.21 Conclusion 
 
The results of this study suggest that low dose, short duration treatment with GM-
CSF has a small but real biological effect in restoring neutrophil phagocytic capacity 
in critically ill patients. To our knowledge this is the first demonstration of such an 
effect in adult critically ill patients with confirmed neutrophil dysfunction. While many 
previous similar studies have focused on immune cell dysfunction in patients with 
sepsis we sought to include patients with a wide range of critical illness insults in our 
population demonstrating the potential relevance across the ICU population. We 
acknowledge that no single factor is responsible for the immunosuppressed state 
seen to affect patients during critical illness, and in targeting neutrophil phagocytic 
function were attempting to impact on one crucial element of host defence in the 
search for improved clinical outcomes. It is increasingly recognised that the future for 
improvements in patient care needs to be focussed on delivering personalised 
medicine. By stratifying patients on the basis of their baseline neutrophil function and 
targeting those at increased risk this study was seeking to deliver exactly that. To 
deliver personalised medicine it must be accepted that large numbers of patients 
may need to be screened in order to identify the target population for a particular 
drug. While in the past a high screening to recruitment ratio has been viewed as a 
negative finding (suggesting that the results of studies may not be applicable to the 
broad population) in the modern era of personalised medicine this will become an 
expected task. The key to the delivery of such targeted medical care will therefore be 
to ensure the development of rapid diagnostic screening tests to enable prompt 
delivery of therapy where it is indicated.  
The results of the study suggest that further work is needed to establish whether (a) 
an increased dose and or duration of GM-CSF might produce a greater biological 
effect while maintaining the favourable safety profile seen at this dose, and (b) 
whether ultimately GM-CSF could be effective in reducing the risk of ICUAI in 
critically ill patients with confirmed neutrophil dysfunction. 
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1. STUDY SUMMARY 
 
 
1.1 Lay Summary 
 
Despite the introduction of multiple preventative measures rates of hospital-acquired 
infection (HAI) in the intensive care unit (ICU) remain high. New approaches to tackling this 
problem are required. The neutrophil (a type of white blood cell) is the key cell fighting 
bacterial and fungal infection in the body. This study group has shown that the majority of 
patients on intensive care have neutrophils which don't eat germs effectively and are 
therefore less able to fight off infection. These patients, whose white blood cells don't work 
properly in this way, are much more likely to develop a second infection whilst in hospital 
(HAI). These patients can be identified by measuring the levels of a specific receptor on the 
surface of the neutrophils by a simple blood test. 
 
Previous work carried out by this research group has also shown that adding a drug called 
granulocyte macrophage-colony stimulating factor (GM-CSF) to a sample of blood from such 
patients in the laboratory, it is possible to restore the ability of the neutrophils to eat bacteria 
and fight infection. 
 
This study, therefore, will test whether it is possible to restore the eating ability of critically ill 
patients' white blood cells, in real life, by giving them GM-CSF as an injection while they are 
on intensive care. 
 
The study will involve 2 distinct components. The first component will aim to establish the 
optimal dose of GM-CSF that should be administered in order to improve the function of 
neutrophils in critically ill patients. Patients with faulty neutrophils who are enrolled into this 
part of the study will receive a dose of either 3 or 6 microgram/kilogram/day of GM-CSF for 4 
or 7 days. We will measure the eating capacity of their neutrophils before and after the 
injections to see which dose is the most effective in improving their function. At the same 
time we will monitor the patients’ blood tests and clinical condition to look for any unwanted 
side effects of treatment. The optimal dose (i.e. the one which produces the greatest benefit 
without significant side effects) will be selected for use in the Randomised Controlled Trial 
(RCT) that will follow. 
 
The second component of the study, the RCT, will again enrol patients on intensive care 
whose white blood cells don’t work properly in this way. Patients who take part in this 
component of the study will either receive an injection of the drug (GM-CSF) or an injection 
of a solution which will have no effect (placebo or dummy drug). We will then compare 
whether those patients who have received the GM-CSF injection have an improvement in the 
function of their neutrophils compared to those who don't.  
 
As well as looking at whether or not the white blood cells work properly we will also study 
whether there is a difference in the rates of infection picked up in hospital between the two 
groups and also whether there is any difference in their clinical outcomes e.g. length of stay 
in hospital, time on a ventilator and survival. 
 
If the RCT demonstrates a clear effect for GM-CSF in improving the function of patients’ 
neutrophils, the way would be paved for future studies determining whether GM-CSF can 
prevent HAI in future, larger studies. Currently, no good drug treatments preventing HAI in 
the ICU are available. 
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1.2 Professional Summary 
 
Despite the introduction of multiple preventative measures, nosocomial infection rates remain 
unacceptably high, particularly in the ICU where 20-40% of patients acquire new nosocomial 
infections. Novel strategies are therefore urgently required. The neutrophil is the key cellular 
effector for clearance of bacterial and fungal pathogens. We have demonstrated that: 
impaired neutrophil phagocytosis is common in ICU patients; patients with impaired 
neutrophil phagocytosis in ICU are at significantly increased risk of nosocomial infection; and 
granulocyte macrophage – colony stimulating factor (GM-CSF) applied to patients’ impaired 
neutrophils ex vivo restores effective phagocytosis. If subcutaneous (s/c) GM-CSF, targeted 
to high risk patients with proven neutrophil dysfunction, also restored effective phagocytosis, 
GM-CSF would be well positioned for comprehensive assessment and development as a 
novel measure to prevent nosocomial infection in the ICU. GM-CSF has never been 
evaluated as a therapy specifically targeted to critically ill patients with neutrophil dysfunction 
in the ICU. 
 
We therefore propose a) to initially carry out a dose finding study to determine the optimal 
dose/duration of GM-CSF in this specific setting in order b) to perform the first proof of 
concept, double blind randomised controlled trial (RCT) of s/c GM-CSF specifically targeting 
critically ill patients with proven neutrophil dysfunction, and therefore at high risk of 
nosocomial infection. The primary endpoint will be neutrophil phagocyte capacity. A proven 
beneficial effect for GM-CSF would rapidly pave the way for larger studies assessing its 
capacity to prevent nosocomial infections in ICU. 
 
 
1.3 Hypothesis 
 
GM-CSF targeted to critically ill patients with known neutrophil dysfunction restores effective 
neutrophil phagocytosis. 
 
 
1.4 Study Aims and Objectives 
 
To test whether clinical administration of GM-CSF replicates the effects seen ex vivo, in the 
blood of critically ill patients, by restoring neutrophil phagocytosis.  
 
 
1.5 Patient Population 
 
Critically ill patients with evidence of impaired neutrophil phagocytosis. Levels of neutrophil 
surface CD88 expression correlate with phagocytic capacity and will be used to identify such 
patients. 
 
 
1.6 Study Setting 
 
General adult ICUs (Royal Victoria Infirmary (RVI) and Freeman Hospital (FRH), Newcastle 
upon Tyne, Queen Elizabeth Hospital (QEH), Gateshead) and Sunderland Royal Hospital 
(SRH). 
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1.7 Study Intervention 
 
1.7.1 Dose-finding Study 
 
Leukine (Sargramostim, recombinant, yeast derived GM-CSF) 3µg/kg/day OR 6µg/kg/day, 
administered subcutaneously, for 4 OR 7 days. 
 
Patient Enrolment Number Dose of Leukine (Sargramostim, rhu GM-CSF) 
1-6 3 µg/kg/day for 4 days 
7-12 3 µg/kg/day for 7 days 
13-18 6 µg/kg/day for 4 days 
19-24 6 µg/kg/day for 7 days 
 
 
1.7.2 Randomised Controlled Trial 
 
Leukine (Sargramostim, rhu GM-CSF) 3 or 6* µg/kg/day OR placebo administered 
subcutaneously for 4 or 7* days. *Dose and duration to be decided on basis of dose-finding 
study. 
 
 
1.8 Sample size 
 
We plan to recruit a maximum of 24 patients (6 patients x 4 dosing regimens) to the dose-
finding study. Sample sizes for the dose finding study were derived pragmatically. Equivalent 
numbers have provided comprehensive data in similar settings. A sample size of n=6 per 
group (24 in total) provides 80% power to detect an effect size of 1.8 at a significance level of 
0.05 between any 2 groups using the 2 sample t-test. 
 
Based on our previous data (with SD of 13% for primary outcome) our power calculation 
estimates that for the RCT, a sample size of 17 in each group gives power of 90% to detect a 
difference (absolute difference in mean phagocytosis of 15%) between the groups at 2 days 
with a significance level of 0.05 using the 2-sample t-test.4 To allow for an attrition rate of 
approximately 10% we would intend to recruit 38 patients (19 per group). This is equivalent 
to an effect size of 1.15. 
 
 
1.9 Method of Participant Assignment 
 
Patients entered into the RCT will be individually randomised after informed consent has 
been obtained and final eligibility confirmed. 
 
 
1.10 Examination points 
 
A screening blood test for neutrophil dysfunction will take place as a final step for eligibility of 
entry into both the dose-finding study and the RCT after consent for entry into the study has 
been received. 
 
Subcutaneous GM-CSF or placebo injection will be administered on day 0 and at the same 
time on each subsequent study day thereafter up to day 3 or day 6 of both the dose finding 
study and randomised controlled trial. (The total duration of administration in the RCT will be 
determined by the results of the dose finding study.) 
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1.10.1 Dose finding study 
 
During the dose finding study blood will be collected daily for GM-CSF concentration 
measurement, neutrophil phagocytosis, neutrophil CD88 and monocyte HLA-DR expression, 
and safety analysis. Urine will be collected daily for GM-CSF concentration measurement.  
The schedule of study events for the dose finding study is illustrated in the table below. 
 
Table 1. Schedule of events for dose finding study 
 
      Day      
 -1 0 1 2 3 4 5 6 7 8 9 
Eligibility assessment X           
Informed Consent X           
Neutrophil CD88 
Quantification 
X           
Study drug  X X X X X* X* X*    
Blood sampling      
(safety  ≤10mls) 
 X X X X X X X X X X 
Blood sampling 
(phagocytosis ≤ 20mls) 
 X X X X X X X X X X 
Neutrophil CD88 
/monocyte HLA-DR 
expression/ GM-CSF 
concentration/ 
neutralising antibodies to 
GM-CSF (≤5mls) 
 X X X X X X X X X X 
Urine for GM-CSF 
concentration  
 X X X X X X X X X X 
Adverse events  X X X X X X X X X X 
 *Whether study drug is given on these days depends on dosing scheduled assigned to patient 
 
 
 
 
1.10.2 Randomised controlled trial 
 
During the RCT blood will be drawn for phagocytosis, neutrophil functional assays, monocyte 
HLA-DR expression and other tests of inflammation (20mls) on alternate study days up to 
day 8. Blood will be drawn for safety assessments (<10mls) on a daily basis (these samples 
will form part of usual clinical care).  
 
The schedule of study events for the RCT is illustrated on the table below. 
 
 
Table 2. Schedule of study events for RCT 
 
       Day      
 -1 0 1 2 3 4 5 6 7 8 9 10-30 
Eligibility assessment X            
Informed consent X            
Neutrophil CD88 
quantification 
X            
Randomisation  X           
Study drug 
administration 
 X X X X X* X* X*     
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Blood sampling 
(safety ≤10ml) 
 X X X X X X X X X X  
Blood sampling  
(phagocytosis ≤ 20ml) 
 X  X**  X**  X**  X**   
SOFA score  X X X X X X X X X X X 
ICU status (i.e. 
whether still in ICU) 
 X X X X X X X X X X X 
Adverse events  X X X X X X X X X X  
Survival analysis  X X X X X X X X X X X 
ICUAI (by HELICS 
criteria) 
 X X X X X X X X X X X 
Neutrophil functional 
assays, neutralising 
antibodies to GM-
CSF, monocyte HLA-
DR expression ≤5mls 
 X  X**  X**  X**  X**   
 
*Whether study drug is given on these days will be determined by the dose finding study 
** If no trained researcher available to complete analysis blood may be collected the following day  
 
 
1.11 Primary Outcomes 
 
The primary outcome for the study will be neutrophil phagocytic capacity 2 days after GM-
CSF injection. 
 
1.12 Secondary Outcomes 
 
The secondary outcomes of the study will include a) sequential neutrophil phagocytic 
capacity; b) sequential organ failure assessment score (SOFA); c) length of ICU stay; d) 
incidence of ICUAIs; e) 30 day mortality; f) other measures of neutrophil function; g) safety; 
h) duration of mechanical ventilation. 
 
1.13 Assessments 
 
Neutrophil CD88 expression and monocyte HLA-DR expression will be determined by flow 
cytometry using whole blood. 
 
GM-CSF concentration will be measured in serum and urine by ELISA. 
 
Neutrophil functional assays will be determined following isolation of neutrophils from whole 
blood by dextran sedimentation and techniques such as percoll gradient separation. 
Phagocytosis will be determined by techniques such as zymosan ingestion, ROS generation 
by techniques such as superoxide dismutase inhibitable cytochrome C reduction and 
neutrophil migration by techniques such as the ‘under agarose’ method. 
 
1.14 Weekend Blood Sampling 
 
Blood samples for safety analysis will be collected and analysed daily including Saturday and 
Sunday for all patients. These samples form part of the patient’s usual care and will be 
processed in the hospital lab. Blood samples for neutrophil CD88, neutrophil functional 
assays and GM-CSF concentration require processing by a trained member of the research 
group. These samples will only be collected on a Saturday or Sunday when such a person is 
available or when this represents the day for assessment of the primary outcome (2 days 
after GM-CSF injection). 
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2. STUDY TEAM 
 
Chief Investigator 
(CI) 
Prof John Simpson, Professor of Respiratory Medicine, Institute 
of Cellular Medicine, 4th Floor, William Leech Building, Medical 
School, Newcastle University, Framlington Place, Newcastle 
upon Tyne NE2 4HH 
Principal 
Investigators (PIs) 
at Study Sites 
 
 
 
 
 
 
 
 
 
 
 
Local Investigator  
at Study Site 
Dr Simon Baudouin, Senior Lecturer in Intensive Care Medicine, 
Dept of Anaesthesia, Leazes Wing, Royal Victoria Infirmary 
(RVI), Queen Victoria Road, Newcastle upon Tyne NE1 4LP (PI 
for RVI and FRH – Newcastle upon Tyne Hospitals Foundation 
Trust.) 
 
Dr Vanessa Linnett, Consultant Anaesthesia and Intensive Care 
Medicine, Dept of Anaesthesia, Queen Elizabeth Hospital, 
Gateshead, NE9 6SX.(PI for QEH) 
 
Dr Alistair Roy, Consultant Anaesthesia and Intensive Care, 
Sunderland Royal Hospital, Anaesthetics Dept, Sunderland 
Royal Hospital, Kayll Road, Sunderland, SR4 7TP. (PI for SRH) 
 
Dr Stephen Wright, Consultant Anaesthesia and Intensive Care 
Medicine, Freeman Hospital (FRH), Freeman Road, Newcastle 
upon Tyne, NE7 7DN (Newcastle upon Tyne Hospitals 
Foundation Trust) 
 
Clinical Research 
Fellow 
Dr Emma Browne, Clinical Research Associate, Institute of 
Cellular Medicine, Medical School, Newcastle University, 
Framlington Place, Newcastle Upon Tyne NE2 4HH 
Study Research 
Nurse 
To be appointed 
Study Statistician Dr Tom Chadwick, The Institute of Health and Society, 
Newcastle University,Baddiley-Clark Building, Richardson Road, 
Newcastle upon Tyne  NE2 4AX. 
Study 
Management 
Ms Melinda Jeffels (Trial Manager), Newcastle Clinical Trials 
Unit, Institute of Health & Society, Medical School, Newcastle 
University, Framlington Place, Newcastle upon Tyne NE2 4HH 
 
Prof Elaine McColl, Director, Newcastle Clinical Trials Unit, 
Institute of Health & Society, Medical School, Newcastle 
University, Framlington Place, Newcastle upon Tyne NE2 4HH 
 
Technology 
Transfer and 
Commercialisation 
Dr Marie Labus, Business Development Manager, Enterprise 
Team, Research and Enterprise Services, Faculty of Medical 
Sciences, Medical School, Newcastle University, Framlington 
Place, Newcastle upon Tyne NE2 4HH 
 
Study Sponsor Newcastle upon Tyne Hospitals Foundation NHS Trust (contact 
Ms Amanda Tortice) 
Joint Research Office 
Royal Victoria Infirmary 
Queen Victoria Road 
Newcastle upon Tyne NE1 4LP 
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3. BACKGROUND 
 
3.1 Background information 
 
Hospital-acquired infection (HAI) is a major concern for the public, health policy makers and 
governments.1 It typically arises in approximately 6% of all hospitalised patients2, 3 but this 
figure rises to 20-40% in intensive care units.4, 5 
 
A significant effort has been made to address the rates of ICU-acquired infection (ICUAI) in 
recent years including the introduction of care bundles and improved hand hygiene.6-8 
Despite these measures the overall rate of ICUAI has not significantly improved and 
continues to be associated with significantly increased morbidity, mortality and cost.9 In 
addition ICUAI leads directly to an increased use of antibiotics, in turn promoting the 
emergence of antibiotic-resistant pathogens which commonly cause ICUAI. Novel 
approaches to target the problem are required. 
 
Specific pharmacological interventions for the prevention of ICUAI have attracted relatively 
little attention. This has been due in part to the lack of a unifying model to explain 
pathophysiology across the range of HAIs. In parallel, redundancy among the many potential 
molecular mediators of susceptibility to infection has hampered the identification of logical 
pharmacological targets. This position could be altered significantly if therapies to boost 
cellular innate immune function were reliably identified. 
 
 
3.2 Rationale for Study 
 
Dysfunctional Neutrophil Phagocytosis Occurs in Critically Ill Patients 
 
The significant majority of HAIs are caused by bacterial pathogens, though fungi contribute 
an increasing proportion of cases.10 In health the circulating blood neutrophil makes by far 
the greatest contribution to the rapid elimination of bacteria and fungi.11 
 
Neutrophil function is significantly impaired in critically ill patients in the ICU.12 We previously 
demonstrated that neutrophils from critically ill patients have markedly reduced capacity to 
phagocytose microbiological particles.13,14 The problem is compounded by the fact that 
patients’ neutrophils are less capable of generating bactericidal reactive oxygen species 
(ROS) and have an increased tendency to promote the release of cytotoxic mediators.13 
 
 
Dysfunctional Neutrophil Phagocytosis is Associated with Increased risk of ICUAI 
 
We recently made the important observation that neutrophil phagocytic dysfunction is largely 
driven by systemic generation of C5a (activated complement factor 5, which acts as an 
anaphylotoxin).13 We also showed that CD88 (the receptor for C5a on human neutrophils) is 
an effective biomarker for neutrophil phagocytic capacity with low CD88 levels correlating 
directly with neutrophil phagocytic dysfunction.13,14 We went on to demonstrate that 53% of 
ICU patients with neutrophil dysfunction developed an ICUAI, as compared with 9% of those 
patients with good neutrophil function (high neutrophil CD88 expression).14 These findings 
are consistent with the increasing recognition that nosocomial infection is associated with a 
state of ‘immune paresis’. 
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GM-CSF Can Restore Neutrophil Phagocytic Capacity when Applied to Dysfunctional 
Cells ex vivo 
 
Crucially, we have demonstrated that treating patients’ dysfunctional neutrophils with 
granulocyte-macrophage colony stimulating factor (GM-CSF) in vitro reproducibly restores 
phagoctyic function.13,14 Indeed, in every one of 24 critically ill patients studied, phagocytic 
function was improved by ex vivo application of GM-CSF.14 The clear association between 
phagocytic dysfunction and ICUAI, and the restoration of phagocytosis by GM-CSF, suggest 
that GM-CSF may be able to prevent ICUAI in patients with demonstrable impairment of 
phagocytosis. 
 
The Intervention has an Acceptable Safety Profile 
 
GM-CSF boosts granulopoiesis and production of monocytes.15 This has led to GM-CSF 
being studied and applied in a wide range of clinical settings, with a good safety profile. 
However remarkably few studies have tested the place of GM-CSF in non-neutropaenic 
critically ill adult patients, 16-19 and none have specifically studied ICU patients in whom 
neutrophils have been proven to be dysfunctional prior to administration. 
 
GM-CSF is an FDA-approved drug licensed for use in the treatment of patients following 
chemotherapy for acute myeloid leukaemia and post bone marrow transplant. The doses 
selected for use in this trial are within the recommended doses for use within these 
indications. 
 
3.3 Local Confirmation of Neutrophil CD88 Expression Flow Cytometry Assay 
 
Our work illustrating the correlation of neutrophil surface CD88 expression with phagocytic 
capacity was carried out in a laboratory in Edinburgh. This study will be completed in 
Newcastle upon Tyne using the flow cytometry facilities at Newcastle Medical School. 
 
In order to ensure that we are selecting the correct, at risk, patient group we will carry out a 
pre-study local confirmation of the neutrophil CD88 assay in our current laboratory by 
comparing CD88 expression with phagocytic capacity in a group of 30 critically ill patients 
who would meet the criteria for entry into the clinical trial.  
 
Consent will be gained from all patients (or from a personal or professional legal 
representative where the patient is deemed to be lacking in capacity) prior to entry into this 
section of the study. Where consent is obtained for participation a single 20ml blood sample 
will be taken from the patient. Where possible the blood sample will be collected from an in-
dwelling line in order to minimise discomfort to the patient. If no in-dwelling lines are in situ 
the blood will be collected from a peripheral vein. 18mls of the blood collected will be used to 
isolate neutrophils for assessment of phagocytic capacity and 2 mls will be used to perform a 
CD88 flow cytometry assay. The results will be plotted against each other to determine the 
level of CD88 expression correlating with impaired neutrophil phagocytic capacity (<50% 
neutrophils ingesting 2 or more zymosan particles). 
 
All samples collected will be labelled with a unique anonymous study number. Only the age 
and sex of the patients will be recorded. No other data will be collected on these patients. 
Their involvement in the study will cease following the collection of the single 20 ml blood 
sample. There will be no alterations in their usual clinical care. Patients entered in other non-
pharmacological intervention studies may be included. 
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4. AIMS AND OBJECTIVES 
 
4.1 Primary aim 
 
• This is a non-commercial study. The study’s primary aim, as a proof of concept 
application, is to test the hypothesis that GM-CSF targeted to critically ill patients, with 
known neutrophil dysfunction, restores effective neutrophil phagocytosis. 
 
 
4.2 Secondary aims and objectives 
 
• To establish the optimum dose/duration of GM-CSF needed to restore dysfunctional 
neutrophil phagocytosis in critically ill patients and to establish the sustainability of 
any effect. 
• To assess the effect of GM-CSF on other elements of neutrophil function (which may 
include but not be limited to superoxide generation, transmigration and apoptosis). 
• To assess whether GM-CSF has beneficial effects in terms of length of ICU stay, 
duration of mechanical ventilation and 30-day mortality. 
• To assess whether GM-CSF administration is associated with a lower incidence of 
ICUAI in those patients who are randomised to receive it. 
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5. STUDY DESIGN 
 
5.1 Design of Study 
 
The study involves two distinct components. The first component is an open labelled dose 
finding study. The second component is a prospective, randomised parallel group, double-
blind, placebo controlled trial. 
 
5.2.1 Schematic Diagram for Dose-finding Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening for eligibility on ICU 
• Fulfil criteria for SIRS* (see appendix 1) 
• Require support of 1 or more organ 
systems  (MV/ inotropes/haemofiltration) 
• Predicted to require support for at least a 
further 48 hrs (survival most likely) 
• Consent obtained from patient, PerLR or 
ProfLR 
• Admitted to ICU within last 48 hours 
 
Excluded 
Not suitable for 
enrolment into study 
 
Neutrophil phagocytic 
capacity as final 
eligibility check 
 
Excluded 
  Phagocytic capacity > 
50 % 
 
Patient 1-6 
GM-CSF 3μg/kg/day 
for 4 days 
 
Patient 7-12** 
GM-CSF 3μg/kg/day 
for 7 days 
 
Patient 13-18** 
GM-CSF 6μg/kg/day 
for 4 days 
 
Patient 19-24** 
GM-CSF 6μg/kg/day 
for 7 days 
 
• Blood sampling for neutrophil functional assays 
• Blood /urine sampling for GM-CSF concentration 
• Blood sampling for safety 
 
Patients regaining capacity will 
be asked for consent 
 
Excluded 
Patients declining 
retrospective consent 
*on admission to ICU 
 
** if low dose, short 
duration GM-CSF is 
found to be safe and 
effective the trial may 
proceed directly to 
RCT without dose 
escalation 
Protocol'number:'AJSEB001''''''''''''''''Version'8.0:'''09/10/2013' Page'16'
 
5.2.2 Schematic diagram for RCT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening for eligibility on ICU 
• Fulfil criteria for SIRS* (see appendix 1) 
• Has required support of 1 or more organ 
systems  (MV/inotropes/haemofiltration) 
during current ICU stay 
• Survival over next 48 hrs most likely outcome 
• Consent obtained from patient,  PerLR or 
ProfLR 
• Admitted to ICU within last 72 hours 
 
Excluded 
Not suitable for 
enrolment into study 
 
Neutrophil phagocytic 
capacity as final 
eligibility check 
 
Excluded 
Phagocytic capacity > 
50% 
 
Randomisation 
Daily placebo 
injection 
 
Daily GM-CSF injection 
(Dose/duration confirmed by 
dose-finding study) 
• Blood sampling for neutrophil functional assays 
• Blood sampling for safety 
• Clinical data collection until day 30 
 
Patients regaining capacity 
will be asked for consent 
Excluded 
Patients declining 
retrospective consent 
*on admission to ICU 
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5.3 Study sites 
 
Patients will be screened in 4 ICUs in England, the Royal Victoria Infirmary (RVI) and the 
Freeman Hospital (FRH), Newcastle upon Tyne, the Queen Elizabeth Hospital (QEH), 
Gateshead and Sunderland Royal Hospital (SRH). Two sites (RVI and FRH) are large 
teaching hospitals, the other sites (QEH & SRH) are district general hospitals. Involvement of 
all four sites will increase the relevance of study data to the general ICU population. The RVI 
and FRH are located within 2 miles of each other and are part of the same trust and 
therefore Dr Baudouin will act as PI for both sites. 
 
5.4 Study Patients 
 
5.4.1 Inclusion criteria 
 
Patients fulfilling all of the following criteria will be eligible for entry into the study. 
 
• Fulfil criteria for systemic inflammatory response syndrome on admission to ICU (see 
appendix 1)  
• Has required support of one or more organ systems (invasive ventilation, inotropes or 
haemofiltration) during current ICU stay 
• Survival over next 48 hours deemed most likely outcome by responsible ICU clinician 
• Admitted to ICU within last 72 hours 
• Neutrophil phagocytic capacity <50%  
 
 
5.4.2 Exclusion criteria 
 
The presence of any of the following criteria will exclude entry to the study 
• Absence/refusal of informed consent 
• Current prescription of a colony stimulating factor 
• Any history of allergy/adverse reaction to GM-CSF 
• Total white cell count >30x109/litre at time of screening 
• Haemoglobin < 7.5g/dl at the time of screening 
• Age < 18 years 
• Pregnancy or lactation 
• Known in-born errors of neutrophil metabolism 
• Known haematological malignancy and/or known to have >10% peripheral blood 
blast cells   
• Known aplastic anaemia or pancytopaenia 
• Platelet count <50x109/litre 
• Chemotherapy or radiotherapy within the last 24 hours 
• Solid organ or bone marrow transplantation 
• Use of maintenance immunosuppressive drugs other than maintenance 
corticosteroids (allowed up to 10mg prednisolone/day or equivalent) 
• Known HIV infection 
• Active connective tissue disease (e.g. rheumatoid disease, systemic lupus 
erythematosus) requiring active pharmacological treatment. 
• ST-segment elevation myocardial infarction, acute pericarditis (by ECG criteria) or 
pulmonary embolism (radiographically confirmed) in previous week 
• Involvement in any study involving an investigational medicinal product in the 
previous 30 days 
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5.5 Duration of Study 
 
For the dose finding study a maximum of 24 patients, completing a full dosing regimen, will 
be recruited over approximately 6 months. During the randomised controlled trial 38 patients 
will be recruited over approximately 10 months. Following randomisation patients will 
participate actively in the dose finding study and randomised controlled trial for up to 9 days, 
including daily contact with the trial team. Retrospective consent will be sought from patients 
once they have recovered capacity. Clinical follow up data for patients in the RCT will be 
collected at 30 days but no contact will be made with the patient at this time point. 
 
5.6 Trial Interventions 
 
5.6.1 Dose-finding study 
 
Patients in the dose finding study will receive a daily dose of subcutaneous Leukine 
(Sargramostim, rhu GM-CSF) as detailed below for 4 or 7 days. 
 
Patient Enrolment Number Dose of Leukine (Sargramostim, rhu GM-CSF) 
1-6 3 µg/kg/day for 4 days 
7-12 3 µg/kg/day for 7 days 
13-18 6 µg/kg/day for 4 days 
19-24 6 µg/kg/day for 7 days 
 
5.6.1.1 Dose-escalation scheme 
 
6 patients will be recruited to each dosing schedule. Screening will take place on each unit 
on a daily basis and those patients who meet the eligibility criteria and consent to 
participation in the study (or whose PerLR/ProfLR consent) will be recruited consecutively. 
We expect recruitment to be proportional across the sites. Within each dose cohort the first 
patient recruited will be treated and observed for 3 days after the initial injection of Leukine 
prior to the entry of the next patient. Following this patients 2,3,4,5 and 6 may be entered. 
The safety and tolerability data collected during the treatment and observation period for all 
six patients in the cohort (up to day 9 following initial injection of leukine) will be evaluated 
prior to dose-escalation. The data will be sent to the Data Monitoring and Safety Committee 
(DMSC) 5-10 days after the last dose of Leukine (Sargramostim, rhu GM-CSF) is 
administered to patient 6 within the cohort. If 2 of the 6 patients in a cohort experience a 
dose-limiting toxicity (see section 5.6.1.2) during the treatment period dose-escalation will not 
take place.The decision to dose-escalate or not will be made by the DMSC. Minutes will be 
recorded at the dose-escalation decision meetings and circulated for final approval before 
being placed on file. The same procedure will be followed for each subsequent dosing 
schedule. The minimum time interval between dosing schedules (ie dosing of the last patient 
in one cohort and the first patient in the next will be 7 days).  
 
If low dose, short duration (3ug/kg/day for 4 days) GM-CSF is demonstrated to be effective 
(ie we observe a phagocytosis rate on day 2 that is protective against infection (≥50% in all 
patients) and if there is no toxicity observed, then we will proceed directly to RCT at that 
dose. Higher doses would then seem unlikely to further reduce infection risk significantly, 
while carrying an increased risk of toxicity. 
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5.6.1.2 Dose-limiting toxicity 
 
A dose-limiting toxicity will be considered as any serious adverse event which is judged to be 
probably or definitely related to the administration of Leukine (Sargramostim, rhu GM-CSF). 
 
5.6.1.3 Selection of optimum dose for the randomised controlled trial 
 
The dose selected for use in the randomised controlled trial will be that which is shown to be 
effective ie produces a demonstrable increase in phagocytosis and in which <2 of the 6 
patients in the cohort experience a dose-limiting toxicity. 
 
5.6.2 Randomised controlled trial 
 
Patients enrolled in the RCT will be randomised to receive a daily subcutaneous injection of 
Leukine (Sargramostim, rhu GM-CSF) 3 or 6 µg/kg/day OR placebo for 4 or 7 days. The final 
dose and duration of study drug or placebo will be decided following the outcome of the 
dose-finding study. 
 
5.7 Outcome Measures 
 
5.7.1 Primary Outcome Measure 
 
The primary outcome measure is neutrophil phagocytic capacity 2 days after administration 
of GM-CSF/placebo (as measured by the percentage of neutrophils ingesting ≥ 2 zymosan 
particles ex vivo).  
 
5.7.2 Secondary Outcome Measures 
 
There are a number of secondary outcomes based on biological, clinical and safety 
measures. 
 
5.7.2.1 Biological measures 
 
• Sequential neutrophil phagocytic capacity on alternate study days (to determine 
sustainability of any observed effects in the primary endpoint) 
• Neutrophil phagocytic capacity measured, for example, as ‘area under the curve’ over 
the study period 
• Other assessments of neutrophil function which may include, but are not limited to, 
ROS generation, migratory capacity and apoptotic rate 
• Monocyte HLA-DR expression on alternate study days 
• Serum measures of inflammatory response which may include, but not be limited to, 
cytokine levels 
 
5.7.2.2 Clinical Measures  
 
In addition to baseline clinical and demographic measurements the following data will be 
recorded: 
• Sequential organ failure assessment (SOFA) score 
• Length of stay in ICU 
• The incidence of ICUAIs (as defined by Hospitals in Europe Link for Infection Control 
Surveillance (HELICS) criteria – see appendix 4) 
• All cause mortality 30 days post randomisation 
• Number of days of mechanical ventilation 
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5.7.2.3 Safety measures 
 
Safety measurement will be made in relation to effect on: 
 
• Full blood count – including haemoglobin level and platelet count 
• White cell count including neutrophil, monocyte, eosinophil and lymphocyte counts 
• U&Es and LFTs 
• Development of neutralising antibodies to GM-CSF 
 
Serious adverse events (SAEs) and occurrence of suspected unexpected serious adverse 
reactions (SUSARs) as defined in section 11 will be recorded. 
 
 
 
6. INVESTIGATIONAL MEDICINAL PRODUCT (including Product information leaflet/ 
SmPC equivalent & Product Monograph – appendix 2 & 3) 
 
6.1 General Description 
 
GM-CSF is one of a group of growth factors termed colony stimulating factors. It acts by 
stimulating the differentiation and division of progenitor cells in the granulocyte-monocyte 
pathway.15 This includes neutrophils, the key cell in bacterial and fungal pathogen defence 
and the focus of study in this trial. 
  
Recombinant human GM-CSF is clinically available in 2 forms 
 
i) a glycosylated compound derived from a yeast based system 
ii) a non-glycosylated compound prepared in an E. coli based system. 
 
The effects of the two compounds on granulopoiesis are broadly comparable20 but the yeast-
derived product has a superior safety profile and has therefore been selected for use in this 
trial.21 
 
 
 
6.2 License and Indications  
 
The investigational medicinal product to be used in this study is the recombinant human GM-
CSF, Leukine (Sargramostim, rhu GM-CSF). It is a glycosylated compound derived from a 
yeast based system. It is owned by Genzyme (a subsidiary of Sanofi-Aventis) and is an FDA-
approved drug for the treatment of patients post chemotherapy or bone marrow transplant 
where it aids the recovery of the myeloid cells and reduces the incidence of serious 
infection..22   
 
6.3 Manufacture and Supply 
 
Sargramostim is manufactured in the U.S., to GMP requirements, by Bayer, under the trade 
name Leukine. It is produced by recombinant DNA technology in a Saccharomyces 
cerevisiae-based system. It is a glycoprotein of 127 amino acids characterized by three 
primary molecular species having molecular masses of 19,500, 16,800 and 15,500 daltons. 
The amino acid sequence of Leukine differs from natural human GM-CSF by a substitution of 
leucine at position 23. 
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The drug will be imported by Mawdsley Brooks and Co., Quest 22, Quest Park, Silk Road, 
Off Wheatley Hall Road, Doncaster, DN2 4LT. They will provide certification by a Qualified 
Person (QP) that the manufacturing site works in compliance with GMP. The will also provide 
a copy of the importers manufacturing authorization as required by the MHRA. 
 
 
6.4 Preparation and Storage 
 
Sargramostim is presented as a liquid or a lyophilized white powder for reconstitution with 
sterile water for injection and is suitable for both subcutaneous and intravenous injection. 
The lyophilized powder form will be used in this trial. It should be stored in a refrigerator 
between 2-8◦C. It will be reconstituted with sterile water for injections from a licensed UK 
market source. When reconstituted with sterile water the lyophilized form must be used 
within 6 hours. If reconstituted with bacteriostatic water the lyophilized form may be stored for 
up to 20 days The reconstituted product appears as a clear, colourless liquid. Sub-cutaneous 
administration appears to result in a more gradual accumulation and decline in serum 
concentrations and has been selected as the route of administration for use in this trial.23, 24 
 
 
6.5 Clinical Pharmacology 
 
Leukine has species-specific biological effects. In vitro studies using human bone marrow 
cells have shown a dose-dependent response in terms of progenitor cell proliferation, 25 and 
an increase in chemotaxis and anti-fungal and anti-parasitic activities of neutrophils and 
monocytes.26 Concentrations ranging from 1-100ng/ml have been studied. 
Pharmacological and toxicological studies carried out on monkeys showed no major visceral 
organ pathology following either single dose or daily dosing up to one month by either 
intravenous or subcutaneous preparations using doses up to 200 micrograms/kg/day. As 
with in vitro human studies dose dependent responses were seen in terms of leucocyte 
proliferation, with counts recovering to baseline within 1 -2 weeks.27 
Pharmacokinetic studies have shown that when Leukine was administered s/c to healthy 
volunteers GM-CSF was detectable in the blood at 15 minutes, peak concentrations occurred 
between 1 and 3 hours and Leukine remained detectable for up to 6 hours post injection.27 
 
 
6.6 Clinical Experience  
 
Acute myeloid leukaemia (AML) 
 
Leukine is used in the treatment of older (55-70 years) neutropaenic patients with AML post 
chemotherapy where it shortens neutrophil recovery and reduces the incidence of, and death 
rate from, serious infections.28 
 
 
Bone Marrow Transplantation 
 
Studies of GM-CSF in the treatment of patients post autologous and allogenic bone marrow 
transplant show significant improvements in the rate of myeloid engraftment duration of 
hospital stay and frequency of infections. A shorter duration of antibiotic therapy was also 
seen in those patients receiving Leukine post bone marrow transplant. It is used widely in 
this context in the U.S.27, 29-31 
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Sepsis 
 
The largest area of literature in the use of GM-CSF in sepsis relates to the care of 
neutropaenic premature babies where it enhances neutrophil recovery and possibly reduces 
nosocomial infection rates but has no impact on survival.32-35 
Few studies have looked at the use of GM-CSF in the treatment of non-neutropaenic septic 
adults, however some recently published studies have shown effects in terms of various 
parameters of sepsis-related immune dysfunction in addition to non-significant benefits in 
terms of length of stay, duration of mechanical ventilation and FiO2:PaO2.16-19 No published 
trials have studied the use of GM-CSF in patients with demonstrated neutrophil dysfunction. 
 
Other Indications 
 
Immunomodulatory properties of GM-CSF have shown varying degrees of promise in 
prostate cancer, Crohn’s disease, human immunodeficiency virus (HIV) infection, childhood 
neuroblastoma and vaccination strategies.36-41 Promising topical use of GM-CSF has been 
described for burns, cervical intraepithelial neoplasia and pulmonary alveolar proteinosis.42-45 
However, with the possible exception of prostate cancer, so far there is insufficient evidence 
to recommend widespread application of GM-CSF in these settings. 
 
 
6.7 Contraindications  
  
Leukine is contraindicated in the following patients (see Product Information Leaflet /SmPC 
equivalent, and Product monograph appendix 2 & 3) 
 
i) any patient with known hypersensitivity to GM-CSF or yeast derived products 
 
ii) any patient with >10% blast cells in the bone marrow or peripheral blood 
 
iii) any patient who has received chemotherapy or radiotherapy in the previous 24 
hours 
 
 Such patients have been excluded from entry into the study to minimise risk of harm. 
 
 
6.8 Side Effects / Toxicity Profile. 
 
 
6.8.1 IMP clinical trial literature relevant to the study population 
 
The dose of GM-CSF used in research and in clinical practice tends to be in the range of 3-
10 μg/kg/day. In reported studies in critically ill non-neutropaenic adults, doses have ranged 
between 3μg/kg/day for 3 days through to 4" μg/kg/day for 8 days.16-19 The emerging 
consensus is that GM-CSF has a dose-dependent adverse event profile, with low toxicity 
rates if doses less than 10" μg/kg/day are used.50 Published data does not suggest 
detrimental effects in terms of organ function. 
 
A study by Meisel et all looking at the effects of GM-CSF on sepsis induced monocyte 
function included 38 critically ill patients treated with doses of 4 mcg/kg/day GM-CSF for 8 
days. They reported that no adverse effects were seen, even in a sub-group of patients 
whose doses were increased to 8mcg/kg/day following a lack of improvement in monocyte 
HLA-DR expression.19 In relation to organ dysfunction and disease severity; duration of 
mechanical ventilation, length of ICU stay and length of intra-hospital stay were all shorter in 
patients receiving GM-CSF. Despite patients in the GM-CSF group having higher 
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vasopressor support at baseline noradrenaline requirements were lower in this group after 
the intervention interval. In addition there were no differences seen in the need for renal 
replacement therapy between the two groups. Baseline mean APACHE II and SOFA scores 
were higher in the control group, however, scores fell in both groups over the treatment 
period with greater improvements seen in the GM-CSF group.19 
 
Similarly a study by Presneill et al of 10 critically ill patients with respiratory compromise on 
ICU treated with 3mcgm/kg/day of GM-CSF for 5 days reported only 1 adverse event relating 
to an elderly gentleman with sepsis-related renal dysfunction who developed transient 
oliguria following administration of the 3rd dose. The drug was discontinued after the 4th dose 
and his renal function recovered.18 The authors found no other evidence of worsening organ 
dysfunction in the GM-CSF group during the study and reported an improvement in 
oxygenation in the treated patients.18 
 
A third study of adult non-neutropaenic patients with abdominal sepsis recorded 3 adverse 
events in 28 patients treated with 3mcg/kg/day of E. coli-derived GM-CSF for 4 days. This 
included 1 episode of thrombocytopaenia, 1 rash and 1 patient treated for nausea.16 
 
 
 
 
6.8.2 IMP clinical trial literature related to common indications (including Product 
Information Sheet/SmPC equivalent & Product Monograph appendix 2 & 3) 
 
Over all Leukine is generally well tolerated. Recognised associated adverse events include 
fever, chills, bone pain, myalgia, headache and erythema at the injection site. Large 
uncontrolled studies involving more than 200 patients recorded these adverse effects as 
being mild to moderate in nature and reversed by the use of simple analgesics such as 
paracetamol.28 
 
In placebo controlled studies involving more than 150 bone marrow transplant patients 
similar rates of side effects were experienced by those receiving Leukine as those receiving 
placebo. In addition studies involving patients with AML found the only significant difference 
in the rate of adverse events was an increase in skin-associated events in those receiving 
Leukine. 28 
Genzyme includes several warnings in their product literature for potentially serious adverse 
events reported with the use of the product. They advise caution in the following situations: 28 
 
 
Pre-existing renal/hepatic disease - A rise in serum creatinine, bilirubin and hepatic 
enzymes has been seen in some patients with pre-existing hepatic or renal disease enrolled 
in uncontrolled trials. Ceasing treatment with Leukine or reducing the dose has resulted in 
values returning to pre-treatment levels. In controlled trials, however, the incidences of renal 
and hepatic dysfunction were comparable between Leukine and placebo treated patients. 
Product literature suggests monitoring of renal and hepatic function at least every other week 
during Leukine administration. All patients enrolled in the study will have daily U&E and LFT 
monitoring. 
 
 
Fluid retention - Oedema, capillary leak and pleural/pericardial effusions have been 
observed in patients treated with GM-CSF and it is thought that it may aggravate fluid 
retention in those with pre-existing disease. In 156 patients enrolled in placebo controlled 
studies incidences of such symptoms were as follows (Leukine vs placebo) peripheral 
oedema 11% vs 7%, pleural effusion 1% vs 0%, pericardial effusion 4% vs 1%. Capillary leak 
syndrome was not observed in these studies but based on other uncontrolled studies and 
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reports from users of marketed Leukine, the incidence is estimated to be less than 1%. Again 
it has been observed to be reversible with interruption or reduction in dose. 
 
Cardiovascular disease – There are some reports of occasional transient supra-ventricular 
tachycardia, particularly in patients with pre-existing cardiac arrhythmias. Caution in such 
patients is advised. All patients on ICU will be on a cardiac monitor for the duration of the 
study as part of their usual care. 
 
Respiratory complications have been noted among patients treated with intravenous 
infusions of Leukine. Dyspnoea and sequestration of granulocytes have occasionally been 
observed. The lack of such reports in recent studies on critically ill patients with s/c GM-CSF 
may be related to the method of administration with more gradual rises in peak 
concentration. Subcutaneous administration of GM-CSF will be used throughout this study. 
The majority of patients in this study are likely to be invasively ventilated and all will have 
saturation and regular blood gas monitoring throughout. 
 
 
 
6.8.3 IMP clinical trial literature related to other Indications 
 
In an RCT of GM-CSF using 6"μg/kg/day s/c for 56 days in Crohn’s disease, overall adverse 
events were similar in treatment and placebo arms. Bone pain and injection site reaction 
were more common (but injection site haematoma less common) with GM-CSF treatment.37 
Allergic reactions have been described.46 Serious adverse events such as pericarditis and 
thrombosis have only been described with doses in excess of 20"μg/kg/day.24  
  
 
 
6.8.4 First Dose Syndrome 
 
It is recognised that a syndrome characterised by flushing, tachycardia, dyspnoea, 
hypotension and respiratory distress can be seen following the first administration of Leukine 
in a cycle. The features have resolved with symptomatic treatment and are not seen to recur 
with further administration.28 
 
 
6.8.5 Antibody formation 
 
The development of neutralising antibodies to GM-CSF is known to occur particularly in the 
context of prolonged administration.  Two large studies found rates of 2.3% (n=214) and 
1.3% (n=75).  The clinical relevance of these antibodies is not known at present. Patients in 
both components of the trial will be screened on alternate days for the development of 
neutralising antibodies.28 
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6.9 Placebo 
 
The placebo study drug will be normal saline for subcutaneous injection. All normal saline 
used in the trial will be from a licensed UK market source. The drug/placebo will be prepared 
in a blinded fashion and the final appearance of the drug and syringes will be identical in 
terms of volume, labelling and appearance of the solution. 
 
6.10 Labelling of IMP 
 
The labelling of the IMP will be performed by Mawdsley Brooks and Co. in compliance with 
the applicable regulatory requirements including annex 13. 
 
6.11 Prescription of IMP 
 
Trial delegation logs will specify the names of physicians authorised to prescribe the IMP for 
this study 
 
6.12 Disposal and Accountability 
 
The relevant hospital pharmacy will keep an accurate record of the dates and amounts of 
study drug dispensed. Where a dose of study drug is not administered it will be returned to 
the relevant hospital pharmacy. At the end of the study unallocated and unused study drug 
will be destroyed with permission from the Sponsors and in accordance with the site 
pharmacy procedure for destruction of an IMP. A record of the destruction will be maintained. 
 
6.13 Study drug provision at the end of the study 
 
The study drug is being investigated for use as a short term intervention during critical 
illness. The study drug will therefore not be provided beyond the clinical trial. Usual clinical 
care will resume on completion of the study drug. 
 
 
7. STUDY PROCEDURES 
 
7.1 Screening Procedure 
 
Patients will be prospectively screened on ICU, on the basis of the inclusion/exclusion criteria 
as specified in this protocol (section 5.4.1-5.4.2, page 16). The screening procedure will be 
identical for both the dose finding study and RCT. Screening may be performed by any 
qualified individual(s) designated by the local PI and listed on the delegation log as having 
responsibility for this aspect of the study.  
 
Each site PI will be responsible for maintaining a screening log. Entries may be made by any 
qualified individual(s) designated by the local PI. If a screened patient is not recruited the 
reason for not being enrolled must be recorded on the screening log. The study includes 
some time-dependent issues. The pattern of neutrophil function/dysfunction in critically ill 
patients appears to be established within the first 48 hours after admission to ICU. The 
previous work defining the independent predictive risk of cellular biomarkers in this clinical 
scenario used this time point for entry into studies.13, 14 To allow for recruitment of all such at 
risk patients, including those admitted at weekends and those in whom the need for organ 
support is delayed, we have placed a limit on screening to occur within the first 72 hours of 
admission to ICU. 
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7.2 Informed Consent Procedure 
 
The study will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki. Eligible patients may only be included in the trial after obtaining 
written informed consent. Informed consent must be obtained prior to conducting any trial 
specific procedures and the process for obtaining informed consent must be documented in 
the patient’s medical records.  
 
Patient information sheets and informed consent forms approved by the Research Ethics 
Committee (REC) will be provided to each study site. The incapacitating nature of the 
condition precludes obtaining prospective informed consent from all, or nearly all, 
participants. In this situation informed consent will be sought from a Personal Legal 
Representative (PerLR), or from a Professional Legal Representative (ProfLR) should no 
PerLR be available. The PI is responsible for ensuring that informed consent for study 
participation is given by each patient or a legal personal or professional representative. 
 
The time dependent factors discussed above in relation to screening (section 7.1, page 21) 
will be explained to the patient, PerLR or ProfLR. They will be given up to 24 hours to make a 
decision regarding consent but will be asked to provide a decision within 6 hours if they feel 
able. 
 
In cases where the patient or PerLR may not adequately understand verbal explanations or 
written information given in English the relevant hospital’s translation service will be called 
upon to provide all necessary oral and/or written translation. 
 
An appropriately trained doctor or nurse may take consent.  If no approved form of consent is 
obtained a patient cannot enter/be randomised into the study. 
 
 
 
7.2.1 Personal Legal Representative Consent 
 
If the patient is unable to give informed consent, consent may be sought from a patient’s 
PerLR who may be a relative, partner, carer or close friend. The PerLR will be informed 
about the trial by the responsible clinician or a member of the research team and they will be 
provided with a copy of the Covering Statement for the PerLR with an attached Participant 
Information Sheet (PIS) and asked to give an opinion as to whether the patient would object 
to taking part in such medical research. If the PerLR decides that the patient would have no 
objection to participating in the study then they will be asked to sign 2 copies of the PerLR 
Consent Form, which will then be countersigned by the person taking consent. A copy of the 
signed consent form and the PIS will be placed in the patient’s medical records, whilst the 
originals will be retained by the PerLR and by the PI in the Investigator Site File (ISF).A copy 
will also be retained to be given to the patient once they have regained capacity. 
 
 
7.2.2 Professional Legal Representative Consent 
 
If the patient is unable to give informed consent and no PerLR is available a doctor who is 
not directly connected with the conduct of the trial (i.e. not named in section 2 page 11) may 
act as a ProfLR. The doctor will be informed about the trial by the responsible clinician or a 
member of the research team and given a copy of the (PIS) If the doctor decides that the 
patient is suitable for entry into the trial then they will be asked to sign 2 copies of the ProfLR 
Consent Form. A copy of the signed consent form and the PIS will be placed in the patient’s 
medical records, whilst the originals will be retained by the ProfLR and by the PI in the ISF.A 
copy will also be retained to be given to the patient once they have regained capacity. 
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7.2.3 Retrospective Patient Consent 
 
Patients will be informed of their participation in the study by the responsible clinician or a 
member of the research team once they regain capacity to understand the details of the 
study. The decision as to whether capacity has returned will rest with the medical team 
caring for the patient. The responsible clinician or a member of the research team with 
delegated responsibility (as per delegation log) will discuss the study with the patient and 
he/she will be given a copy of the Patient Information Sheet to keep. The patient will be 
asked for consent to participate in the study and to sign two copies of the retrospective 
consent form. A copy of the signed retrospective consent form will be placed in the patient’s 
medical records whilst the originals will be retained by the patient and by the PI in the ISF. If 
the patient refuses consent no further data will be collected about or from the patient. The 
patient will then be asked to consent to whether or not data collected up to that point in the 
study can be entered into the analysis.  
 
 
7.3 Withdrawal of Consent 
 
Patients may withdraw or be withdrawn (by PerLR or ProfLR) from the study at any time 
without prejudice. Data recorded up to the point of withdrawal will be included in the study 
analysis, unless consent to use data already collected has also been withdrawn. 
 
 
 
 
7.4 Patient registration and randomisation procedure 
 
7.4.1 Dose finding study 
 
After informed consent has been received, patients with confirmed low neutrophil phagocytic 
capacity will commence treatment with daily s/c GM-CSF. The dose and duration of 
treatment will be determined by the sequence of entry into the study as outlined in section 
5.6.1, page 17. 
 
 
7.4.2 Randomised controlled trial 
 
After informed consent has been received, patients with confirmed low phagocytic capacity 
will be randomised to receive daily s/c GM-CSF or placebo. Randomisation will be in a 1:1 
ratio, with stratification by site, using a web-based randomisation service in NCTU. The 
randomised allocation schedule will be generated by a statistician with no other involvement 
in the study to ensure independence and concealment of allocation. Permuted blocks of 
variable length will be used to reduce the risk of breach of concealment of allocation. A 
treatment number will be generated for each participant that links to the corresponding 
allocated study drug/placebo. The treatment number will be clearly documented by the 
investigator on the trial prescription to ensure the study pharmacist dispenses the correct 
study medication.  
 
Contact details for randomisation: http://apps.ncl.ac.uk/random/ (available 24hrs) 
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7.5 Administration of Investigational Medicinal Product/Placebo Injections 
 
As previously described the yeast-derived form of rhu GM-CSF, Leukine (Sargramostim) will 
be used in both the dose-finding study and RCT (section 6, page 18). It will be provided as a 
lyophilised powder which will be reconstituted in sterile water for injection from a licensed UK 
market source. Once reconstituted, the drug will be administered within 6 hours. The placebo 
drug will be normal saline from a licensed UK market source. 
 
The first dose of the study drug (Leukine (Sargramostim, rhu GM-CSF) or placebo) will be 
given, on the morning of entry into the study, after final eligibility has been confirmed by 
phagocytic capacity assessment. Subsequent doses will be given at the same time each day 
thereafter. If for any reason a dose is not administered at the intended time, it may be 
administered subsequently but not more than 6 hours after the intended time of 
administration. Administration of GM-CSF/placebo injections will be carried out by any 
trained clinical member of the research or usual care team according to the product 
administration guidelines contained in the Product Information Leaflet (SmPC equivalent/ 
product monograph Appendix 2&3). 
 
The dose of GM-CSF for the RCT will be decided on the basis of the dose finding study as 
described in section 5.6. 
 
 
 
7.6 Study Drug Termination Criteria 
 
The study drug (Leukine (Sargramostim, rhu GM-CSF).) will be continued until one of the 
following conditions is met (whichever comes first): 
 
• maximum treatment period (to be defined in the dose finding study for RCT) 
• study drug-related SAR 
• discharge from a critical care environment 
• death 
• discontinuation of active medical treatment 
• the patient, PerLR or ProfLR requests withdrawal from the study 
• decision by the attending clinician that the study drug should be discontinued on 
safety grounds. 
 
In the following situations consideration will be given to either discontinuing the study drug or 
reducing the dose by half to minimise the risk of complications 
 
• WCC > 50,000 cells/mm3 
• Platelet count > 500,000 cells/mm3 
 
 
 
7.7 Blood sampling 
 
Up to 20ml of blood will be drawn from existing lines (≤ 20mls for phagocytosis assays, 
≤10mls for safety analysis, ≤5mls for flow cytometry/ELISA assays). Where possible this will 
be from arterial lines. Where arterial lines are inaccessible, venous lines may be used (and 
this information recorded). In the event that all indwelling vascular access devices are 
removed prior to completion of the study blood will be drawn by venesection no more than 
once per day in addition to the patient’s usual care. 
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7.8 Clinical Management of Patients in the Study 
 
Administration of either GM-CSF or a placebo injection will be outside of usual clinical care 
for all patients entered into the study. 
 
Blood drawn for assessment of phagocytosis, other elements of neutrophil function, 
monocyte HLA-DR expression and cytokine multiplex will be outside of usual clinical care for 
patients entering into the study. 
Blood drawn for safety assessment including full blood count (FBC), urea and electrolytes 
(U&E) and liver function tests (LFTs) would be included in usual patient care for all patients 
on ICU even if they were not included in the study. 
 
All other aspects of usual patient care will be delivered to patients prior to, during and after 
completion of the study. 
 
 
7.9 Study Procedures for Unblinding 
 
Each participant will be randomly allocated to receive either study drug or placebo. As a 
placebo controlled, double-blind trial, patients, clinicians and the PIs will be blinded to each 
patient's allocation. All trial drugs, whether GM-CSF or placebo, will be packaged identically 
at the point of administration and identified only by a unique trial identifier.  Either PI may 
request emergency unblinding on grounds of safety. Emergency unblinding will be performed 
by the use of sealed code-break envelopes which will be held within the hospital pharmacy at 
the relevant study site. The envelopes will be available for access 24 hours a day. 
 
Where the PI at the relevant site is not available the CI should be contacted to authorise 
unblinding. In an emergency situation where no contact can be made with the CI or PI (e.g. 
out of hours) unblinding should proceed and the CI should be informed at the first available 
opportunity. 
 
To arrange unblinding the duty or on-call pharmacist should be contacted via the relevant 
hospital switchboard.  
 
 
 
 
 
8. STUDY ASSESSMENTS 
 
8.1 Clinical Assessments  
 
In addition to the outcome measurements described in Section 5.7.2.2 (page 18) the 
following baseline details will be recorded on the appropriate Case Report Forms (CRFs): 
age; date of (and reason for) admission to hospital; date of (and reason for) admission to 
ICU; Acute Physiology and Chronic Health Evaluation) APACHE II score at admission; 
medications; co-morbidities; sequential organ failure assessment (SOFA) score; BP; 
PaO2:FiO2 ratio (FiO2/Sats if no arterial line); full blood count; urea and electrolytes; liver 
function tests; and blood glucose. These data will also be recorded on each study day up to 
day 10 and then at days 20 and 30 when the study data will be completed for each patient. 
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8.1.1 Dose finding study 
 
The schedule of study events for the dose finding study is illustrated on the table below. 
 
Table 1. Schedule of events for dose-finding study 
 
      Day      
 -1 0 1 2 3 4 5 6 7 8 9 
Eligibility assessment X           
Informed Consent X           
Neutrophil CD88 
Quantification 
X           
Study drug  X X X X X* X* X*    
Blood sampling      
(safety  ≤10mls) 
 X X X X X X X X X X 
Blood sampling 
(phagocytosis ≤20mls) 
 X X X X X X X X X X 
Neutrophil CD88 
/monocyte HLA-DR 
expression/ GM-CSF 
concentration/neutralising 
antibodies (5≤mls) 
 X X X X X X X X X X 
Urine for GM-CSF 
concentration  
 X X X X X X X X X X 
Adverse events  X X X X X X X X X X 
 *Whether study drug is given on these days depends on dosing scheduled assigned to patient 
 
 
 
8.1.2 Randomised controlled trial 
 
During the RCT blood will be drawn for phagocytosis, neutrophil functional assays, monocyte 
HLA-DR expression and other tests of inflammation (20mls) on alternate study days up to 
day 8. Blood will be drawn for safety assessments (<10mls) on a daily basis (these samples 
will form part of usual clinical care).  
 
The schedule of study events for the RCT is illustrated on the table below.  
 
Table 2. Schedule of study events for RCT 
 
       Day      
 -1 0 1 2 3 4 5 6 7 8 9 10-30 
Eligibility assessment X            
Informed consent X            
Neutrophil CD88 
quantification 
X            
Randomisation  X           
Study drug 
administration 
 X X X X X* X* X*     
Blood sampling 
(safety ≤10ml) 
 X X X X X X X X X X  
Blood sampling  
(phagocytosis ≤ 20ml) 
 X  X**  X**  X**  X**   
SOFA score  X X X X X X X X X X X 
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ICU status (i.e. 
whether still in ICU) 
 X X X X X X X X X X X 
Adverse events  X X X X X X X X X X  
Survival analysis  X X X X X X X X X X X 
ICUAI (by HELICS 
criteria) 
 X X X X X X X X X X X 
Neutrophil functional 
assays, neutralising 
antibodies to GM-
CSF, monocyte HLA-
DR expression ≤5mls 
 X  X**  X**  X**  X**   
 
*Whether study drug is given on these days will be determined by the dose finding study 
** If no trained researcher available to complete analysis blood may be collected the following day  
 
 
 
8.2 Blood 
 
Blood samples will be collected as described in section 7.9, page 23. Blood samples for 
neutrophil CD88, neutrophil functional assays and GM-CSF concentration require processing 
by a trained member of the research group. These samples will only be collected on a 
Saturday or Sunday when such a person is available or when this represents the day for 
assessment of the primary outcome (2 days after GM-CSF injection). 
 
8.2.1 Preparation of Neutrophils from Whole Blood 
 
Neutrophils will be separated from whole blood by recognised techniques such as dextran 
sedimentation and percoll gradient technique. 
 
8.2.2 Neutrophil Phagocytosis Assay 
 
Neutrophil phagocytosis will be determined by recognised techniques such as zymosan 
ingestion. The percentage of neutrophils ingesting 2 or more zymosan particles will be 
recorded by microscopic analysis of 4 fields of neutrophils each containing at least 100 cells. 
 
8.2.3 Neutrophil CD88 Expression 
 
Neutrophil CD88 expression will be determined in whole blood, using flow cytometry. 
 
8.2.4 Monocyte HLA-DR Expression 
 
Monocyte HLA-DR expression will be determined in whole blood, using flow cytometry. 
 
8.2.5 GM-CSF Concentration 
 
GM-CSF concentration in serum will be measured by recognised techniques such as ELISA. 
 
8.2.6 GM-CSF Neutralising Antibodies 
 
GM-CSF neutralising antibodies will be assayed by recognised techniques such as ELISA. 
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8.2.7 Neutrophil Reactive Oxygen Species Production 
 
Neutrophil reactive oxygen species production will be measured by recognised techniques 
such as superoxide dismutase inhibitable cytochrome C reduction. 
 
 
8.2.8 Neutrophil migration 
 
Neutrophil migration will be assessed by recognised techniques such as the under agarose 
method. 
 
 
8.2.9 Other Analyses 
 
Serum will be frozen at temperatures of at least -20°C for later analyses such as assessment 
of cytokines and other assays of inflammation/infection as appropriate. 
 
8.3 Urine 
 
Urine will be collected from an indwelling urinary catheter in a universal container. 
 
8.3.1 Urine GM-CSF Concentration 
 
Urine GM-CSF concentration will be measured by recognised techniques such as ELISA. 
 
 
 
 
 
9. COLLECTION AND STORAGE OF DATA  
 
 
9.1 Recording of data 
 
All data for an individual patient will be collected by each PI or their delegated nominees and 
recorded in the case report form (CRF) for the study. Patient identification on the CRF will be 
through a unique study identifier number. A record linking the patient’s name to the unique 
study identifier number will be held only in a locked drawer at the study site, and is the 
responsibility of the PI. As such, patients cannot be identified from CRFs. Copies of CRFs 
will be made – one will be kept in the ISF and the other will be retained by the Newcastle 
Clinical Trials Unit (NCTU). The NCTU will continually audit completeness and quality of data 
recording in CRFs and will correspond regularly with site PIs (or their delegated assistants) 
with the aim of capturing any missing data where possible, and ensuring continuous high 
quality of data.  
 
Data will be collected and recorded on the CRF by site research teams from the time the 
patient is considered for entry into the study through to the completion of outcome data. In 
the event that a patient is transferred to another hospital, the site research team will liaise 
with the receiving hospital to ensure complete data collection. 
 
Clinical information will not be released without the written permission of the participant, 
except as necessary for monitoring and auditing by the Sponsor, its designee, Regulatory 
Authorities, the Data Monitoring and Safety Committee (DMSC) or the REC. Secure 
anonymised electronic data may however be released to the Study Statistician for analysis. 
The PI and study site staff involved with this study may not disclose or use for any purpose 
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other than performance of the study, any data, record, or other unpublished, confidential 
information disclosed to those individuals for the purpose of the study. Prior written 
agreement from the Sponsor or its designee must be obtained for the disclosure of any said 
confidential information to other parties. 
 
 
9.2 Data Management 
 
Data received at NCTU will be processed as per the CTU SOPs, including entering the data 
into a secure central database. Responsibility for maintenance of the database will rest with 
the study manager. 
 
 
9.3 End of Study 
 
Up to a maximum of 24 patients, completing one of the four dosing regimens, will be 
recruited to the dose finding study. Dose escalation may stop prior to completion of all four 
dosing regimens if a satisfactory dose response is seen at one of the lower doses or if 
unacceptable side effects are observed. Recruitment will cease after 38 patients have 
entered the RCT. For regulatory and ethical reporting purposes, end of study is defined as 
when follow-up outcome data (30 days) is collected for the last patient. 
 
The study will stop sooner than this if: 
• mandated by the relevant REC 
• mandated by the MHRA 
• mandated by the Sponsor (for example on the advice of the DMSC) 
• funding was withdrawn. 
 
 
 
 
10. STORAGE OF SAMPLES 
 
Samples of serum and plasma will be labelled with the unique study identifier number and 
stored frozen. As described above the patient’s identity cannot be determined from the 
unique study identifier number alone. Samples will be processed and stored in Newcastle, 
where they will be kept in a locked freezer in the CI’s research facility. Samples will be stored 
for up to 15 years after completion of the study. Consent will be obtained for sample storage. 
 
Flow cytometry samples will be discarded after use. Cytospins will be performed, and the 
glass slides (labelled using only the unique study identifier number) will be stored in the CI’s 
lab for up to 15 years after completion of the study. 
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11. PHARMACOVIGILANCE 
 
Timely, accurate and complete reporting and analysis of safety information from clinical trials 
is crucial for the protection of patients and is mandated by regulatory agencies. 
 
 
11.1 Definitions 
 
Term Definition 
Adverse Event (AE) Any untoward medical occurrence in a patient or 
clinical trial subject administered a medicinal 
product and which does not necessarily have a 
causal relationship with this treatment. 
Adverse Reaction (AR) All untoward and unintended responses to an 
investigational medicinal product related to any 
dose administered 
Unexpected Adverse Reaction 
(UAR) 
An adverse reaction the nature or severity of 
which is not consistent with the applicable 
product information (e.g. investigator’s brochure 
for an unauthorised investigational product or 
SmPC for an authorised product). 
Serious Adverse Event (SAE) 
 
Serious Adverse Reaction 
(SAR) 
 
Suspected Unexpected Serious 
Adverse Reaction (SUSAR) 
Respectively, any adverse event, adverse 
reaction or unexpected adverse reaction that: 
 
a)results in death ; b)is life-threatening (i.e. the 
subject was at risk of death at the time of the 
event; it does not refer to an event which might 
have caused death if it were more severe); 
c)requires hospitalisation or prolongation of 
existing hospitalisation; d)results in persistent or 
significant disability or incapacity; e)is a 
congenital anomaly or birth defect; f)is any other 
important medical event(s) that carries a real, not 
hypothetical, risk of one of the above outcomes 
 
 
 
 
11.2 Assessment of Causality 
 
Each AE should be clinically assessed for causality based on the information available, i.e. 
the relationship of the AE to the study drug should be established. The assignment of the 
causality should be made by the principal investigator responsible for the care of the 
participant using the definitions in the table below.  All adverse events judged as having a 
reasonable suspected causal relationship to the study drug (i.e. definitely, probably or 
possibly related) are considered to be adverse reactions.  If any doubt about the causality 
exists, the local Principal Investigator should consult the Chief Investigator.  In the case of 
discrepant views on causality between the Principal Investigator and others, all parties will 
discuss the case and will refer as necessary to the DMSC.  In the event that no agreement is 
reached the main REC and other bodies will be informed of both points of view.  
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Relationship Description  
Unrelated There is no evidence of any causal relationship. The clinical event has an 
incompatible time relationship to the study drug administration, and could 
be explained by underlying disease, or other drugs or chemicals. 
Unlikely There is little evidence to suggest there is a causal relationship (e.g. the 
event did not occur within a reasonable time after study drug 
administration). There is another reasonable explanation for the event 
(e.g. the participant’s clinical condition). 
Possible There is some evidence to suggest a causal relationship (e.g. the event 
occurs within a reasonable time after the study drug administration). 
However the influence of other factors may have contributed to the event 
(e.g. the participant’s clinical condition). 
Probable  There is evidence to suggest a causal relationship, including a reasonable 
time relationship with the study drug administration, and the influence of 
other factors is unlikely. 
Definitely There is clear evidence to suggest a causal relationship and other possible 
contributing factors can be ruled out. 
Not 
assessable 
There is insufficient or incomplete evidence to make a clinical judgement 
of the casual relationship. 
 
 
 
 
11.3 Adverse Event Reporting Period 
 
The AE reporting period for this trial begins upon enrolment into the trial and ends 28 days 
following administration of the study drug. All AEs assessed by the PI as possibly related to 
the study drug and all SAEs that occur during this time will be followed until they are resolved 
or are clearly determined to be due to a patient’s stable or chronic condition or intercurrent 
illness(es). 
 
 
 
 
11.4 Adverse Event Reporting Requirements 
 
AEs should be reported and documented on the relevant pages of the CRF, in accordance 
with the procedures outlined below. The PI, or a delegated nominee, at each site will 
evaluate all AEs for expectedness in addition to causality. 
 
 
11.5 Expected Adverse Events  
 
Most adverse events that occur in this study, whether they are serious or not will be 
expected, treatment-related toxicities due to the study drugs, or non-treatment related due to 
the underlying critical illness. A full list of expected undesirable side effects of Leukine, 
Sargramostim, are outlined above (sections 6.8.1.- 6.8.5, page 21) and in the Product 
Information Leaflet. (SmPC equivalent/Product monograph Appendix 2&3) 
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11.6 Reporting AEs 
 
Because this trial is recruiting a population that is, by definition, already in a life-threatening 
situation, it is expected that many of the participants will experience AEs. Events that are 
expected in this population (i.e. events in keeping with the patient’s underlying medical 
condition) should not be reported as AEs. An adverse reaction (AR) is an AE which is related 
to the administration of the study drug. If any AEs are related to the study drug (i.e. are ARs) 
they must be reported on the AE form within the CRF. Adverse events occurring within 1 
hour of administration of the study drug should be considered related. It is the responsibility 
of the PI to record all relevant information in the CRF. 
 
The following are ARs which are expected and must be reported on the AE form within the 
CRF: 
 
• skin reaction at the site of injection 
• fever up to 38◦ C 
• elevated  WCC > 50,000 cells/mm3 
• bone pain 
• myalgia 
• antibody formation 
• ‘first dose syndrome’ (as described in section 6.8.5, page 22) 
 
 
An unexpected adverse reaction (UAR) is an AE which is related to the administration of the 
study drug and that is unexpected, in that it has not been previously reported in the current 
Product Information Leaflet. All UARs must be reported on the AE form within the CRF. 
 
Unexpected adverse events will be included as part of the safety analysis for the trial and do 
not need to be reported separately to the CTU.  
 
 
 
11.7 Reporting Serious Adverse Events  
 
 
Because this study is recruiting a population that is already in a life-threatening situation, it is 
expected that many of the participants will experience SAEs. Events that are expected in this 
population (i.e. events in keeping with the patient’s underlying medical condition) and that are 
collected as outcomes of the trial, including death and organ failure, should not be reported 
as SAEs. Other SAEs must be reported. A serious adverse reaction (SAR) is an SAE which 
is related to the administration of the study drug. These must be reported to the CTU. 
 
Suspected unexpected serious adverse reactions (SUSARs) are SAEs that are considered to 
be caused by the study drug and are unexpected i.e. their nature and severity is not 
consistent with the SmPC. 
 
If an SAR occurs, reporting will follow the regulatory requirements as appropriate and all 
SUSARs will be the subject of expedited reporting. SAEs will be evaluated by the PI for 
causality (i.e. their relationship to the study drug) and expectedness. Once the PI becomes 
aware that an SAR has occurred in a study patient, they must complete the SAE form in the 
CRF and report the information to the NCTU within 24 hours.  The SAE form must be 
completed as thoroughly as possible with all available details of the event, signed by the PI 
or designee.  If the PI does not have all information regarding an SAE, they will not wait for 
this additional information before notifying NCTU.  The form can be updated when the 
additional information is received. Follow up information should include whether the event 
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has resolved, if and how it was treated and whether the patient continues in the study or has 
been withdrawn from treatment. 
 
The SAE form should be transmitted by fax to the NCTU on 0191 2228901.  
 
The NCTU is responsible for reporting SUSARs (i.e. SAEs that are considered to be related 
and unexpected) to the Sponsors, the REC, and the MHRA within 15 days of becoming 
aware of the event using the NRES Reporting of SAE Form. In the event of a fatal or life 
threatening SUSAR reporting to the relevant regulatory authorities should take place within 7 
days. 
 
The Co-ordinator of the main REC should acknowledge receipt of related, unexpected safety 
report within 30 days. 
 
 
 
11.8 Reporting SAEs to Data Monitoring and Safety Committee 
 
SAEs will be reported to the DMSC within the same timelines as for Regulatory reporting. A 
copy of each report will be sent to the DMSC. 
 
 
 
11.9 Pregnancy 
 
It is not known whether Sargramostim can cause foetal harm if administered to pregnant 
women.28 All pregnant women will be excluded from entry into the study. A pregnancy test 
will be performed on all women of child-bearing potential prior to final confirmation of 
eligibility and those with a positive pregnancy test will be excluded. In the unlikely event, that 
it is subsequently confirmed, that a participant was pregnant at the time of the study despite 
a negative pregnancy test, then follow up will continue until completion of the pregnancy. 
 
 
 
 
12. STATISTICAL CONSIDERATIONS 
 
12.1 Sample Size  
 
Sample sizes for the dose finding study were derived pragmatically. Equivalent numbers 
have provided comprehensive data in similar settings. A sample size of n=6 per group (24 in 
total) provides 80% power to detect an effect size of 1.8 at a significance level of 0.05 
between any 2 groups using the 2 sample t-test. 
 
The sample size for the RCT was calculated based on our previous data studying the effects 
of GM-CSF on ex-vivo phagocytosis in a cohort of critically ill patients.14 The mean rate of 
'neutrophils ingesting ≥ 2 zymosan particles' in ICU patients was 39% (standard deviation 
(SD) 13%) and was associated with a high rate of subsequent ICUAI. Therefore we believe 
an effect size incorporating an absolute increase of at least 15% (i.e. from 39% to 54% mean 
phagocytosis) is clinically important. To place this in context, in our hands ex-vivo treatment 
of patients' neutrophils with GM-CSF resulted in 68% of neutrophils ingesting ≥ 2 zymosan 
particles i.e. an absolute increase of 29%. We therefore have considerable confidence in the 
ability to achieve this effect size. On the basis of these data our power calculation estimates 
that a sample size of 17 in each group gives power of 90% to detect such a difference 
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(absolute difference in mean phagocytosis of 15% between the groups at 2 days) with a 
significance level of 0.05 using the 2-sample t-test. To allow for an attrition rate of 
approximately 10% we would intend to recruit 38 patients (19 per group). This is equivalent 
to an effect size of 1.15. 
 
This sample size would provide 90% power to detect an effect size of 1.15 at a significance 
level of 0.05 (e.g. with respect to a comparison of change from baseline between the 2 
groups, where an estimate of the change in SD is not available from the literature).  
 
 
 
12.2 Data Analysis 
 
 
12.2.1 Dose finding study 
 
The dose finding study, incorporating a small number of patients is designed to assess 
safety, feasibility and tolerability. It is not designed to enable, or powered for, comparative 
hypothesis testing and therefore only basic descriptive statistics (including frequencies, 
means, medians, standard deviations, interquartile ranges and proportions/rates as 
appropriate) together with associated confidence intervals will be presented to summarise 
the outcome data. These summaries will be presented by dose level, with safety data being 
reviewed prior to dose escalation. 
 
 
12.2.2 RCT  
 
As this is a phase 2 clinical study, with relatively small numbers of participants, we intend to 
report descriptive statistics (such as rate estimates for any dichotomous or categorical 
variables and means, medians, standard deviations and inter-quartile ranges for continuous 
measures) with appropriate confidence intervals in order to inform future study design. 
Summaries of demographic data will also be reported. 
 
We will also explore comparative analysis of the primary endpoint (neutrophil phagocytic 
capacity at 2 days after administration of GM-CSF/placebo) between the treatment groups 
although, due to the sample size, this will be exploratory in nature rather than definitive. 
Analysis will be performed using Analysis of Covariance (ANCOVA) or similar methods in 
order to allow for the effects of covariates, including any stratification factors. We shall also 
examine change from baseline and other time periods for this outcome variable in a similar 
manner. 
 
Several outcomes will be evaluated to determine whether treatment with GM-CSF shows 
efficacy for surrogate biological and clinical outcomes. Secondary endpoints will be 
examined using broadly similar methods. However, dichotomous variables will be analysed 
in an exploratory fashion using techniques such as logistic regression. Although the 
incidence of ICUAIs and 30-day mortality will be documented, these important clinical 
endpoints are not included as major outcome variables as this proof of concept study is not 
adequately powered to assess these (they are expected to be the focus of trials leading on 
directly from this work). 
 
Data analysis will be on an intention to treat basis, although other exploratory analyses (such 
as on a per-protocol basis) may also be considered. Data with missing observations (other 
than due to mortality) will be examined to determine both the extent of and reason for such 
omissions. Multiple imputation techniques will be used as appropriate to allow for this in the 
analysis. 
Protocol'number:'AJSEB001''''''''''''''''Version'8.0:'''09/10/2013' Page'39'
 
 
13. REGULATIONS, ETHICS AND GOVERNANCE 
 
 
13.1 Sponsorship 
 
The study will be sponsored by Newcastle upon Tyne Hospitals NHS Foundation Trust. 
 
 
13.2 Regulatory and Ethical Approvals 
 
The study will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki.  A favourable ethical opinion from a Research Ethics Committee 
and R&D approval via the NIHR Coordinated System for gaining NHS Permissions is a 
prerequisite prior to commencement of the study. MHRA approval is also a prerequisite prior 
to commencement of the study. Local R&D approval will be secured before recruitment may 
commence at each site. The NCTU will require a written copy of local approval 
documentation, before sites recruit patients into the study. The study will be registered with 
the UK National Institute for Health Research (NIHR) Clinical Research Portfolio.  In order 
that the study remains on the NIHR Portfolio and receives the appropriate level of support 
through the relevant Local Research Network, accrual data on patient recruitment will be 
forwarded to the UK Clinical Research Network (UKCRN) Co-ordinating Centre on a monthly 
basis by the NCTU. The study will be registered on the European Clinical Trials Database 
(EudraCT) and other public databases. 
 
 
13.3 Ethical Considerations 
 
The vulnerability of this study group is fully appreciated and every effort will be undertaken to 
protect patients’ safety and well-being. 
 
 
13.4 Protocol Compliance 
 
The investigators will conduct the study in compliance with the protocol given favourable 
opinion by the REC and the MHRA. Amendments to the protocol will require favourable 
opinions from the relevant ethics committee, R&D and MHRA prior to implementation, except 
when modification is needed to eliminate an immediate hazard(s) to patients.  The NCTU in 
collaboration with the Sponsor will submit all protocol modifications to the REC and MHRA 
for review in accordance with the governing regulations.  Protocol compliance will be 
monitored by the trial manager who will ensure that the trial protocol is adhered to and that 
necessary paperwork (CRF’s, patient consent) are being completed appropriately.  Any 
deviations from the protocol will be fully documented in source documentation and in the 
CRF. 
 
 
13.5 Patient Confidentiality 
 
In order to maintain confidentiality, all CRFs, stored samples and study reports will identify 
patients by the assigned unique study identifier number only.  The only link between the 
patient’s identity and the unique study identifier number will be held at the relevant study site, 
in a locked drawer with restricted access.  
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13.6 Good Clinical Practice (GCP) 
 
The study will be carried out in accordance with the principles of the International Conference 
on Harmonisation Good Clinical Practice (ICH-GCP) guidelines (www.ich.org).  The CI, site 
PIs, clinical research associate and study nurse must have completed GCP training and 
have up to date certification before recruitment begins. 
 
 
 
13.6 Study Monitoring 
 
 
13.6.1 Direct Access to Data 
 
The agreement with each PI will include permission for study-related monitoring, audits, 
ethics committee review and regulatory inspections, by providing direct access to source 
data and study-related documentation.  Consent from patients/legal representatives for direct 
access to data will also be obtained. Patient confidentiality will be maintained and will not be 
made publicly available to the extent permitted by the applicable laws and regulations. 
 
13.6.2 Monitoring Arrangements 
 
The NCTU will be responsible for study monitoring.  On-site monitoring visits will be 
conducted in accordance with the study’s monitoring plan. Before the study starts at either 
participating site, an initiation visit will take place to ensure that essential documents and trial 
supplies are in place and that site staff are fully aware of the study protocol and SOPs.  On-
site monitoring visits during the study will check the completeness of patient records, the 
accuracy of entries on CRFs, the adherence to the protocol, SOPs and GCP, and the 
progress of patient recruitment.  
 
Site PIs should ensure that access to all study related documents including source 
documents (to confirm their consistency with CRF entries) are available during monitoring 
visits.  The extent of source data verification will be documented in the monitoring plan.   
 
 
 
 
13.7 Indemnity 
 
The participating NHS Trusts have liability for clinical negligence that harms individuals 
toward whom they have a duty of care. Indemnity in respect of negligent harm arising from 
study management is provided via NHS schemes by the Newcastle Upon Tyne NHS 
Foundation Trust in its role as sponsor.  Indemnity in respect of negligent harm arising from 
study conduct is provided by NHS schemes, via the participating NHS Trusts, covering NHS-
employed staff and medical academic staff with honorary NHS contracts, who are conducting 
the trial. Indemnity in respect of negligent harm arising from study design or protocol 
authorship is provided by NHS schemes, for those protocol authors whose substantive 
contract of employment lies with the NHS, and via University insurance schemes for protocol 
authors who have their substantive contract with a University.  This is a non-commercial 
study and there are no arrangements for non-negligent compensation. 
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13.8 Finance 
 
The study is funded by the Medical Research Council through the Developmental Clinical 
Studies scheme (study funding reference number G1100233). 
 
 
13.9 Record Retention 
 
Each site PI will be provided with an ISF by the NCTU and will maintain all study records 
according to GCP and the applicable regulatory requirements. The study master file (SMF) 
will be held by the NCTU and the essential documents that make up the file will be listed in a 
SOP. On completion of the trial the SMF and study data will be archived by the NCTU 
according to the applicable regulatory requirements and for up to 15 years. The ISFs and all 
study record files held by the PIs will be transferred to the custody of the CI. Following 
confirmation from the Sponsor the NCTU will notify the CI when they are no longer required 
to maintain the files.  If the CI withdraws from the responsibility of keeping the study records, 
custody must be transferred to a person willing to accept responsibility and this must be 
conveyed in writing to NCTU. 
 
 
 
 
14. STUDY COMMITTEES 
 
14.1 Study Management Arrangements 
 
The CI will have overall responsibility for the conduct of the study. The NCTU will be the 
Study Co-ordinating Centre. The NCTU will provide study management and coordination, 
data management and monitoring. The study manager will be responsible on a day-to-day 
basis for overseeing and co-ordinating the work of the multi-disciplinary study team.  
 
 
14.2 Project Management Group (PMG) 
 
The PMG will be considered quorate if it contains at least  
• the CI,  
• the Project Manager,  
• one of the site PIs,  
though all members of the study group will be welcome to attend. Members of the DMSC will 
also be invited. 
 
The PMG will meet at approximately 3 monthly intervals. Additional meetings can be called if 
risks, important changes or unexpected costs are identified. Management responsibility 
between meetings rests with the CI, assisted by the Project Manager.  
The PMG will report to the DMSC, and to public/patient groups (for example CritPal).  
 
 
14.3 Data Monitoring and Safety Committee 
 
A DMSC will be appointed comprising at least two independent clinicians with experience in 
undertaking clinical studies and caring for patients with haematological and critical illness, 
and a statistician, all of whom are independent of the study. The DMSC will convene 1 week 
after completion of each dosing schedule within the dose-finding study and thereafter 
approximately every 3 months. The DMSC’s responsibility is to safeguard the interests of the 
study participants, in particular with regard to safety, and to assist and advise the PMG so as 
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to protect the validity and credibility of the study. The DMSC will receive reports allowing 
them to monitor recruitment, adverse events and outcome data. Where the DMSC members 
consider that cessation of the study should be considered or mandated, the Sponsor will be 
promptly informed. 
 
 
14.4 User Involvement 
 
The study will be registered with the INVOLVE open-access database 
(http://www.involve.org.uk). The PMG will also report to the Chairman of the Patient Liaison 
Committee of the Intensive Care Society (CritPaL). CritPaL will be invited to comment on 
elements of the study including Participant Information Sheets and dissemination of results. 
 
 
 
15. PROPOSED STUDY MILESTONES 
 
Formal milestones are in place for this study and have been agreed with the funders 
(Medical Research Council). Timely recruitment to the study requires entry of approximately 
1 patient per week between the 4 ICUs. An interim analysis at 2 months will assess whether 
recruitment is proceeding to target. The PMG will assess whether recruitment is satisfactory.  
 
 
 
16. DISSEMINATION 
 
The data generated from the trial will be the property of the Chief Investigator and the Co-
investigators. Publication will be the responsibility of the Chief Investigator. The findings will 
be presented at national and international meetings and we aim to publish the findings in 
high quality peer-reviewed open access journals.  
 
A lay person’s summary of the principal findings of the results will be sent to all patients 
involved in the study at their request.  In addition a lay person’s summary will be sent to 
CritPaL. A report of the study findings will be sent to the INVOLVE registry.  
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17. LIST OF APPENDICES 
 
Appendix 1 – Criteria for the diagnosis of SIRS 
 
Appendix 2 – Product Information Leaflet for Leukine (Sargramostim, rhu GM-CSF). 
 
Appendix 3 – Product Monograph  
 
Appendix 4 – HELICS Criteria for the diagnosis of ICUAI : Hospitals in Europe Link for 
Infection Control through Surveillance: Surveillance of Nosocomial Infections in Intensive 
Care Units: Protocol version 6.1, September 2004.  Case definitions of ICU-acquired 
infections, pages 7-11. 
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APPENDIX 1 
 
Criteria for the diagnosis of SIRS 
 
Two of the following must be present 
 
• Temperature < 36 or >38 C 
• Heart rate > 90 bpm 
• Tachypnoea with respiratory rate > 20 breaths per minute or PaCO2 < 4.3kPa 
• White blood cell count <4x109/L (<4000/mm³) or >12x109/L (>12,000/mm³), or 10% 
bands 
American College of Chest Physicians /Society of Critical Care Medicine Consensus 
Conference  1992.
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